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Gold nanoparticles exhibit a combination of physical, chemical, optical, and electronic 
properties unique from all other nanotechnologies. These structures can provide a highly 
multifunctional platform with which to diagnose and treat diseases and can dramatically enhance a 
variety of photonic and electronic processes and devices. The work herein highlights some newly 
emerging applications of these phenomena as they relate to the targeted diagnosis and treatment of 
cancer, improved charge carrier generation in photovoltaic device materials, and strategies for 
enhanced spectrochemical analysis and detection. Chapter 1 introduces the reader to the design, 
synthesis, and molecular functionalization of gold nanotechnologies, and provides a framework from 
which to discuss the unique photophysical properties and applications of these nanoscale materials 
and their physiological interactions in Chapter 2. Chapter 3 discusses ongoing preclinical research in 
our lab investigating the use of near-infrared absorbing gold nanorods as photothermal contrast 
agents for laser ablation therapy of solid tumors. In Chapter 4, we present recent work developing a 
novel strategy for the targeted treatment of hormone-dependent breast and prostate tumors using 
multivalent gold nanoparticles that function as highly selective and potent endocrine receptor 
antagonist chemotherapeutics. In Chapter 5, we discuss a newly-emerging tumor-targeting strategy 
for nanoscale drug carriers which relies on their selective delivery to immune cells that exhibit high 
accumulation and infiltration into breast and brain tumors. Using this platform, we further 
investigate the interactions of nanoscale drug carriers and imaging agents to a transmembrane protein 
considered to be the single most prevalent and single most important contributor to drug resistance 
and the failure of chemotherapy. Chapter 6 presents work from a series of studies exploring enhanced 
charge carrier generation and relaxation in a hybrid electronic system exhibiting resonant interactions 
 xxviii
between photovoltaic device materials and plasmonic gold nanoparticles. Chapter 7 concludes by 
presenting studies investigating the contributions from so-called “dark” plasmon modes to the 





INTRODUCTION TO GOLD NANOTECHNOLOGIES 
 
1.1 Synthesis of Gold Nanoparticles: Bottom-Up Methods 
 While the first syntheses of colloidal gold pre-date much of the peer-reviewed literature, the 
first scientific report describing the production of gold nanoparticles came in 1857 when Michael 
Faraday found that the “fine particles” formed from the aqueous reduction of gold chloride by 
phosphorus could be stabilized by the addition of carbon disulfide, resulting in a “beautiful ruby 
fluid”.[1] Today, most colloidal synthetic methods for obtaining gold nanoparticles (Figure 1.1) 
follow a similar strategy (Table 1.1), whereby solvated gold salt is reduced in the presence of surface 
capping ligands which prevent aggregation of the particles by electrostatic and/or physical repulsion. 
Particle size is adjusted by varying the gold ion:reducing agent and/or gold ion:stabilizer ratio, with 




Figure 1.1. Gold nanoparticles commonly applied in biomedical applications. A) Gold nanorods, 
(B) silica-gold core-shell nanoparticles, and (C) gold nanocages. The intense colors of these 
nanoparticles (middle panel) arises from the collective excitation of their conduction electrons, or 
surface plasmon resonance (SPR) modes, which results in photon absorption/scattering (right panel) 
at wavelengths that vary with (A) aspect ratio, (B) shell thickness, and/or (C) galvanic displacement 
by gold. Adapted from Dreaden et al. [2,3]. 
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Table 1.1. Summary of synthetic approaches to obtain various gold nanostructures.a Adapted from 
Dreaden et al. [3]. 
 
a CTAB, cetyl trimethylammonium bromide; PVP, poly(vinylpyrrolidone); CPC, cetylpyridium 
chloride; CTAC, cetyl trimethylammonium chloride; AFM, atomic force microscopy; SAM, self-
assembled monolayer; STEPS, structural transformation by electrodeposition on patterned substrates. 
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Using theoretical electrodynamics set forth by Maxwell in 1865,[4] Mie showed in 1908 that 
the intense colors from Faraday’s gold sols arose from the absorption and scattering of light by 
spherical gold nanoparticles which they contained.[5] Following the advent of the electron 
microscope by Knoll and Ruska in 1932,[6] Turkevich provided the first structural studies of gold 
nanoparticles formed under varying synthetic conditions in 1951;[7] later in 1973, Frens performed 
systematic studies of Turkevich’s citrate-mediated growth method, producing monodisperse spherical 
gold nanoparticles 16 – 150 nm in diameter (Figure 1.2A).[8] Mechanistically, citrate-mediated gold 
reduction occurs through a concerted redox reaction whereby citrate is both chemically oxidized by 
chloroauric acid and thermally oxidized by heating to form dicarboxyacetone (DCA; Figure 1.3A) 
and CO2.[9-11] Electrons from DCA serve to reduce Au(III)Cl3 to Au(I)Cl, which is believed to 
form a bidentate (COO-) complex with DCA. Particle nuclei form via a disproportionation reaction, 
where (3) AuCl complexes combine to form (2) zero-valent Au atoms and (1) AuCl3 complex. 
Particle size is generally adjusted by varying the Au salt:citrate ratio or reaction pH.[9,12] Until 
recently, the formation of these particles was presumed to proceed via spontaneous nucleation and 
isotropic growth (i.e. LaMer growth[13]). Recent studies by Pong et al. however, indicate that the 
small (ca. 5 nm diameter) nuclei formed from the citrate-mediated thermal reduction of chloroauric 
acid initially self-assemble into a network of interconnected chains that grow in diameter with 
increasing Au deposition.[14] Spherical particles are believed to break off from these structures 
forming the nanosphere product typically observed from the Turkevich method. This “necklace-
breaking” mechanism is fundamentally distinct from other multiparticle mechanisms such as classic 
Ostwald ripening or oriented attachment (in which small crystalline particles fuse with one another 
along a crystalline face). In contrast, more recent studies by Polte et al., directly contradict these 
results, indicating that particle formation proceeds via four overlapping steps: i) nucleation, ii) 
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aggregation of nuclei, iii) slow isotropic growth via reduction and/or coalescence/Ostwald ripening 
[15], and iv) rapid consumption of the gold precursor.[16] Finer points of mechanistic detail 
notwithstanding, related approaches have been used to obtain monodisperse gold nanospheres as 




Figure 1.2. Gold nanoparticles of various size and shape with potential applications in biomedicine.  
A) Small and (B) large  nanospheres,  (C) nanorods, (D) sharpened nanorods, (E) nanoshells, (F) 
nanocages/frames, (G) hollow nanospheres, (H) tetrahedra/octahedra/cubes/icosahedra, (I) rhombic 
dodecahedra, (J)  octahedra, (K) concave nanocubes, (L) tetrahexahedra, (M) rhombic dodecahedra, 
(N) obtuse triangular  bipyramids, (O) trisoctahedra, and (P) nanoprisms. Adapted from Dreaden et 
al. [3]. 
 In 1981, Schmid et al. showed that much smaller (1.4 ± 0.4 nm diameter) phosphine-
stabilized gold particles  could be produced from the reduction of PPh3AuCl by diborane in benzene, 
yielding Au55(PPh3)12Cl6.[18] This cluster is a true molecule with a well-defined formula weight, 
unlike the colloidal gold solutions discussed in the previous paragraph. Hutchison later reported that 
gold clusters 1.4 – 10 nm in diameter could be obtained via ligand exchange and that these particles 
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could be similarly produced under ambient conditions and without the need for diborane gas.[19] In 
1994, Brust and Schiffrin investigated the synthesis of thiol-stabilized gold clusters using a two-phase 
system in which gold chloride was solvated in toluene by way of a phase-transfer reagent 
(tetraoctylammouium bromide).[20] Here, dodecanethiol was used as a stabilizer for gold clusters 
formed in the organic phase as reducing sodium borohydride was added to the aqueous phase. These 
and similar clusters [21] have attracted much attention due to their molecule-like properties and 
facile conjugation, however due to their reported toxicity,[22,23] biomedical applications are 
somewhat limited, including uses in immunolabeling,[24,25] and as contrast agents for x-ray imaging 




Figure 1.3. Turkevich/Frens Synthesis of Gold Nanoparticles and Seed-Mediated Growth of Gold 
Nanorods. A) Au(III) is reduced to Au(I) when citrate is oxidized to dicarboxyacetone (DCA) in the 
presence of chloroauric acid and/or heating. Au(I) chloride is believed to form a bidentate complex 
with DCA which undergoes a disproportination reaction to form (2) zero-valent Au atoms and (1) 
Au(III) chloride. B.i) Au(III) chloride quantitatively displaces Br- counterions in micelles of 
cetyltrimethylammonium bromide (CTAB) and subsequent borohydride reduction produces small 
(ca. 1.5 nm diameter) seed nanoparticles surface-stabilized by a CTAB-bilayer. B.ii) Au(III) bound to 
CTAB-micelles is reduced to Au(I) by ascorbic acid. Directional growth of Au nanorods occurs via 
crystallographically-preferential reduction of Au(I) onto the seed nanoparticles. For simplicity, note 
that (B) omits shape-directing contributions from adsorbed halide ions and/or Ag(I) ions. Adapted 
from Dreaden et al. [28]. 
 
 Interest in the shape-controlled synthesis of gold nanostructures began to take hold in the 
early 1990’s, when Masuda [29] and Martin [30] developed techniques to prepare gold nanorods by 
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electrochemical reduction into nanoporous aluminum oxide membranes. These methods produced 
relatively monodisperse structures, but due to the low yield and somewhat large diameter (>100 nm), 
the optical response from these nanorods was, at the time, difficult to discern and largely dominated 
by multipolar plasmon resonance modes due to phase retardation of the incident field, resulting in 
non-symmetric plasmon field density distribution.[31,32] Wang and coworkers later demonstrated 
the synthesis of much smaller gold nanorods (ca. 10 nm in diameter) by electrochemical oxidation of 
a gold plate electrode in the presence of cationic, quaternary ammonium surfactants 
(cetyltrimethylammonium bromide, or CTAB, and tetraoctylammonium bromide, or TOAB) and 
under ultrasonication.[33] The resulting nanorods solutions exhibited plasmon resonance modes for 
their short (transverse) and long (longitudinal) axis polarizations, verifying for the first time with gold 
nanorods the optical theory proposed by Gans 1912 for the scattering and absorption of spheroidal 
plasmonic nanoparticles.[34] 
 Murphy [35] and El-Sayed [36] later demonstrated a colloidal growth method to produce 
monodisperse gold nanorods in high yield based on seeded growth (Figure 1.2C; Figure 1.3B). In 
this method, small (ca. 1.5 nm diameter) single-crystal Au seed particles, produced from the 
reduction of chloroauric acid by borohydride in the presence of CTAB, are aliquoted into a growth 
solution containing additional surfactant and gold salt that has been mildly reduced by ascorbic acid, 
forming dehydroascorbic acid and resulting in an AuCl2- surfactant complex.[37] Collisions between 
the Au(I) complex and the seed particles, together with contributions from surface-adsorbed halide 
ions, silver ions, and crystallographically-preferential surfactant adsorption, results in the anisotropic 
growth of gold nanorods ca. 10-20 nm in width and up to 300 nm in length, depending on the 
specific synthetic conditions employed.[38] Readers may wish to note that the bonding interaction 
between Au and CTAB is atypical of most all chemical conjugation schemes involving AuNPs. Br- 
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anions are known to form atomic surface layers on gold and other metals/semiconductors (i.e. 
adlayers) and also form electrostatically coordinate CTA+ cations and their micelles. The general 
consensus for AuNR-CTAB bonding involves the formation of a Br- adlayer on the AuNR surface 
which coordinates N headgroups on CTA+. The aliphatic tail of surface-bound CTA+ then associates 
with another CTA+ cation oriented with its N+Br- headgroup facing outwards [39-41]. Due to the 
relatively weak association between aliphatic CTA+ tails, repeated centrifugal purification and or 
exposure to organic solvents can result in nanoparticle destabilization that can be mitigated by 
redispersion of the particles in aqueous CTAB (ca. 1 mM). Using this method, gold nanorods ca. 10 
– 20 nm in diameter and up to  300 nm in length can be obtained in relatively high yield, allowing 
for their subsequent use in a number of biomedical applications (See Chapter 2).[41] Nanorod 
aspect ratio can be controlled by the seed/gold salt ratio or by the relative concentration of adsorbate 
ions. For some time, the precise mechanism and purported reproducibility of nanorod growth has 
remained a hotly debated topic, confounded by the fact that some nanorod preparations contained 
additive impurity ions such as silver while others did not.[42] Proposed contributions include 
underpotential deposition, halide adsorption, surface packing density, and alloy formation among 
others. Electron microscopy has indicated that the nanorods grow along the [001] direction with less 
stable crystalline facets along the sides of the rods and more stable crystalline facets at its tips,[43] 
although, a more recent re-analysis of these same gold nanorods suggest that the side faces are much 
higher-index facets than previously believed.[44] Pure gold nanorods made in the absence of silver 
ions show a pentatetrahedral twinned structure, again with the most stable bulk gold facets at the 
ends of the nanorods.[45] Recently, Mirkin and coworkers have shown that concentration of iodine 
contaminants present in various commercially-available CTAB stocks play a critical role in 
determining subsequent morphology and explain the apparent lack of reproducibility reported among 
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nanorod preparations employed by various research groups. The authors posited that preferential 
iodine adsorption on {111} facets at the nanorod tips prevent CTAB binding and thus promote 
longitudinal growth. Surprisingly, the roles of silver and halide ion adsorption in directing 
anisotropic growth remains a point of contention.[38] Zubarev and coworkers have further studied 
the CTAB / gold nanorod system and shown that the length and width of these nanorods can be 
amplified by addition excess Au(I) and that their lengths can be selectively etched by the addition of 
Au(III), allowing the size and optical properties of these structures to bet tailored via the 
disproportionation reaction of Au(I) to produce Au(III) and Au(0).[46] Liz-Marzán and coworkers 
also showed that spherically-capped colloidal gold nanorods could be reshaped to form single-crystal 
octahedra, using poly(vinylpyrrolidone) (PVP) functionalized gold nanorods as seeds for the 
ultrasound-induced reduction of chloroauric acid by N,N-dimethylformamide (DMF) in the 
presence of PVP.[44] The authors showed that by increasing the ratio of gold salt to nanorod seeds, 
that subsequent morphology varies from sharpened (octagonal) rods to tetragons to octahedra 
(Figure 1.2D). The authors attribute this transformation to differing Au growth rates on various 
crystallographic facets of the nanorods (i.e. {111}<{110}<{100}) and variations in surface energy due 
to the adsorption of ions and/capping agent(s). 
 Silica-gold core-shell nanoparticles, or gold nanoshells (Figure 1.2E), have recently attracted 
much attention due to their interesting optical properties and numerous biomedical applications. 
Kerker and coworkers predicted in 1951[47] that concentric spherical particle could exhibit tunable 
plasmon resonance which varies as a function of the ratio of shell thickness to core radius. Halas and 
coworkers showed in 1998 that near-infrared absorbing gold nanoshells could be prepared by 
electrostatically adsorbing small gold nanoparticles to the surfaces of silica nanoparticles and 
subsequently reducing additional gold onto the structures to form a conformal shell.[48] In a typical 
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synthesis, silica nanoparticle cores are synthesized by the base-catalyzed condensation of orthosilicate 
[49] (i.e. Stöber hydrolysis) and functionalized with an amine-terminal silane. Small, anionic gold 
nanoparticles synthesized from the aqueous reduction of chloroauric acid by 
tetrakis(hydroxymethyl)phosphonium chloride (THPC) are electrostatically adsorbed onto the 
surfaces of the silica cores and added to a solution of mildly reduced chloroauric acid. When 
formaldehyde is added to the solution, the adsorbed gold particles serve as nucleation sites for the 
further reduction of gold around the silica core, subsequently forming a conformal nanoshell. In later 
reports, reduction via carbon monoxide (rather than formaldehyde) was shown to produce thinner 
and more uniform nanoshells.[50] Other related structures with novel optical properties such as 
asymmetric “nanoeggs” and quadruply concentric “nanomatryushkas” have also been developed.[51]  
 Gold nanocages and nanoframes recently developed by Xia and coworkers (Figure 1.2F) also 
show promise in a variety of biomedical applications due to their desirable optical properties and 
potentially cargo-holding hollow structures.[52,53] The synthesis of these nanoparticles is based on a 
phenomena known as galvanic replacement, whereby more noble metal ions (e.g Au, Pt) 
spontaneously oxidize the surface atoms of a less noble metal (e.g. Ag, Cu) with concomitant 
reduction of the more noble metal.[53] In this case, gold nanocages/frames are produced by reacting 
Au(III) with silver nanocubes produced from the polyol reduction of silver nitrate. Because the 
reduction of one Au(III) ion requires surface oxidation to three Ag(I) ions, the density of the resulting 
structure is significantly decreased: in the case a single-crystal cube, initially forming hollow Au/Ag 
alloy “nanoboxes”  which further react to form porous Au nanocages and eventually faceless Au 
“nanoframes”.[54] 
 Near-infrared absorbing (spherical) hollow gold nanoparticles (Figure 1.2G) have also been 
recently developed for use in drug loading/delivery and photothermal therapy applications. Caruso 
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and coworkers obtained hollow gold nanospheres by calcination or dissolution of polystyrene–gold 
core–shell nanoparticles.[55] Here, polystyrene nanospheres were coated in polyelectrolyte multilayer 
films and small, 4-(dimethylamino)pyridine (DMAP) stabilized gold nanospheres (6 nm diameter) 
were electrostatically adsorbed to the polyelectrolyte surface. Hydroxylamine was then used to further 
reduce chloroauric acid onto the seed-coated polystyrene spheres, forming a nearly conformal gold 
shell. The polystyrene cores were then removed by dissolution in tetrahydrofuran (THF) or 
calcination at 310 °C to obtain hollow gold spheres ca. 650 nm in diameter. Liang et al. later showed 
that similar structures could be obtained by galvanic replacement with citrate-stabilized cobalt 
nanospheres synthesized from the reduction of CoCl2 by borohydride under anaerobic 
conditions.[56] Subsequent addition of the cobalt nanospheres to chloroauric acid gave hollow gold 
nanoshells (ca. 60 nm diameter) in high yield. Wall thicknesses could be tuned by adjusting the ratio 
of gold salt to Co nanoparticles.  
 In 2004, Yang and coworkers showed that more geometrically complex gold nanostructures 
(100–300 nm in size) could be synthesized by a modified polyol process (Figure 1.2H).[57] Using 
ethylene glycol as a solvent/reducing agent and PVP as a particle stabilizer, tetrahedra, cubes, 
octahedra, and icosahedra were obtained in high yield with good monodispersity. The authors found 
that subsequent nanoparticle morphology was highly dependent on the concentration of gold present 
in the reaction solution, with tetrahedra formed at high concentrations and icosahedra (as well as a 
small number of octahedra) at lower concentrations. By adding a small quantity of silver nitrate 
during the reaction process, gold nanocubes were also obtained. Here, the authors suggested that 
crystallographically preferential adsorption of PVP resulted in enhanced [100] growth and suppressed 
[111] growth, yielding {111}-dominant tetrahedra and icosahedra. They also hypothesized that 
preferential adsorption of silver ions to {111} facets could lead to the formation of {100}-dominant 
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cubes. Murphy and Sau later demonstrated the high-yield synthesis of similarly complex gold 
nanostructures via seed-mediated growth methods closely related to that used to produce colloidal 
nanorods.[58] By varying the concentrations of Au(III), ascorbic acid, and silver nitrate present in the 
growth solution, as well as the quantity of added seeds, rectangular, hexagonal, cubic, triangular, and 
star-like nanoparticles were obtained. In 2006, Song and coworkers developed an analogous seed-less, 
modified polyol synthesis.[59,60] Briefly, chloroauric acid was reduced in/by 1,5-pentanediol in the 
presence of PVP stabilizer. As the concentration of AgNO3 was increased during the reaction, 
subsequent morphology ranged from Au octahedra, truncated octahedra, cuboctahedra, cubes, to 
higher polygons. As previously hypothesized by Yang and coworkers, the authors attributed this 
control to the suppression of [100] growth and/or enhanced [111] growth. Niu et al. later showed 
that other complex gold nanostructures could be produced in high yield (>96%) by a related seeded 
growth method.[61] Here, CTAB-capped gold nanorods were amplified in a Au(III)/CTAB solution 
and functionalized with cetylpyridinium chloride (CPC) to serve a single-crystalline seeds (ca. 40 nm 
diameter) for the subsequent growth of rhombic dodecahedral, octahedral, and cubic gold 
nanocrystals from Au(I). Interestingly, the authors found that the CPC surfactant preferentially 
stabilized {100} > {110} > {111} facets, in contrast to their typically observed surface free energies (i.e. 
{110} > {100} > {111}). Rhombic dodecahedral morphology (Figure 1.2I) was observed when CPC-
Au{100} (and to a lesser extent, -Au{110}) association was dominant and octahedral geometries 
(Figure 1.2J) were observed when CPC-Au{111} association was found to dominate. Cubic gold 
nanoparticles were found to form upon the addition of Br- ions which the authors attributed to 
increasing stabilization of {100} facets by Br- adsorption and subsequent electrostatic association of 
CP+. 
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 Recently, Mirkin and coworkers have also developed a method to produce monodisperse 
gold nanocubes in high yield (Figure 1.2K) by a seeded growth technique analogous to that used to 
produce nanorods, except in this case, using the chloride analog of CTAB: cetyltrimethylammonium 
chloride, CTAC.[62] The authors found that nanocube size could be adjusted by simply varying the 
amount of seeds added to the growth solution, obtaining cubes with edge lengths ranging from 38 ± 
7 nm to 269 ± 18 nm with and as high as 95% yield. Due to the concavity of their faces, the 
nanocubes exhibited a surface plasmon resonance ca. 80 nm red-shifted from their {100}-faced 
counterparts and are expected to exhibit novel catalytic properties. The authors hypothesized that the 
formation of high-index {720} facets could be due to surface-bound Ag formed by underpotential 
deposition (UPD) and its increasing stabilization by a Cl- adlayer. Ming et al. previously obtained 
structurally-related, near-infrared absorbing tetrahexahedral gold nanoparticles enclosed by 24 {037} 
facets using a similar synthetic approach involving CTAB (>95% yield) (Figure 1.2L).[63] Personick 
et al. showed that rhombic dodecahedra (Figure 1.2M) and obtuse triangluar bipyramids (Figure 
1.2N) could be obtained by a seeded (7 nm diameter) growth involving CTAC and dilute Ag+ 
concentrations, obtaining the only {110}-faceted bipyrimidal gold nanostructures reported to date 
(31 ± 5 nm and 270 ± 26 nm edge length, respectively).[64] Crystallographic analysis found that the 
rhombic dodecahedra contained 12 identical {110} facets while the near-infrared absorbing triangular 
bipyrimads contained 2 triangular prisms separated by bridging (111) planes. Further analysis 
indicated that these structural differences arose from the use of a mixture of seeds containing both 
single-crystals and twin-defected particles and that their product particles could be easily isolated by 
size-selective filtration. Interestingly, they also found that as the Au(III):seed ratio was increased that 
deposition increasingly favored growth on twinned bipyramidal particles, an effect they hypothesized 
resulted from the low(er) binding affinity of Cl- for Au which allowed Ag UPD growth-directing 
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effects to dominate. Even more exotic structures such as gold trisoctahedra have been obtained in by 
a simple aqueous reduction of chloroauric acid (Figure 1.2O).[65] Zheng and coworkers showed 
that these nanostructures, 100-200 nm in diameter and enclosed by 24 {221} facets, are formed by 
the ascorbic acid reduction of chloroauric acid in the presence of CTAC (ca. 85% yield). While the 
precise mechanism for their formation is yet to be fully determined, the authors also found that 
CTA+ and Cl- were necessary for the formation of trisoctahedra and suggested that ascorbic acid or its 
oxidation products may stabilize high-energy concave faces. 
 Triangular, or prismatic, nanoparticles have been obtained by a number of methods 
including photoreduction, seed-mediated growth, plasmon-driven synthesis, and biosynthesis. Sastry 
and coworkers first obtained gold nanoprismatic structures in fair yield (ca. 200–500 nm in size, 45% 
yield) from the aqueous reduction of chloroauric acid by lemongrass extract.[66] The authors 
attributed this transformation to the reducing capacity of aldose sugars present in the plant extract, 
with shape-directing formation due to the crystographically preferential adsorption of 
aldehydes/ketones present in the extract. Schatz and Mirkin later showed that similar gold 
nanoprisms (144 ± 30 nm edge length) could be synthesized in high yield using a seeded growth 
method (Figure 1.2P).[67] In a typical synthesis, borohydride-reduced, citrate-capped spherical seeds 
(5.2 ± 0.6 nm diameter) are synthesized from chloroauric acid and sequentially amplified in a 
solutions of chloroauric acid, sodium hydroxide, ascorbic acid, and CTAB. The nanoprisms were 
isolated by filtration using a commercially-available aluminum oxide membrane (100 nm nominal 
pore size) and analyzed using optical spectroscopic and computational methods. 
 To the novice nano-synthetic chemist, all of the above methods sound alarmingly similar. 
Most include gold seed particles bearing ionic groups, the addition of metal ions with a reducing 
agent, and other additives which promote the formation of one shape or another. This similarity 
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highlights both the power and frustration of colloidal nanoparticle synthesis: that small changes in 
reaction conditions can lead to very different reaction products, suggesting overall that these 
nanoparticles are the result of kinetic, as opposed to thermodynamic, stabilization effects. Viable 
thermodynamic arguments can also be made, usually with the idea that the additives bind to 
particular facets of the gold and lower the surface energy of that facet; however, because the stability 
of hydrated, nanoscale metal crystalline facets is difficult to predict and control in the presence of 
ions, many groups have adopted the use a “hard template” approach to control nanoparticle shape. 
 Since its first demonstration in the early 1990s, template-based electrochemical deposition of 
gold nanostructures has found subsequent use in a variety of biomedical and bioanalytical 
applications. Keating and Natan have shown that multisegmented, template-deposited nanorod 
structures can be employed in a multiplexed  bioanalytical detection scheme (i.e. nanobarcode, NBC, 
assay).[68] By electrodepositing metallic segments of varying length, surface chemistry, and 
composition (e.g. Au, Ag, Pt, Ni, Co, Cu), large nanorods (600 nm x ca. 10 microns or more) with 
striped features can be prepared. Subsequent chemistry to attach proteins and/or DNA to these 
multisegmented nanorods has led to detection of biomoecules with high sensitivity by fluorescence 
readout (e.g. sandwich-assay based configurations). Because the nanobarcodes and their segment 
patterns can be easily distinguished by optical microscopy, biomolecule detection schemes can be 
highly multiplexed:  that is, the detection of the unique optical signature corresponding to each type 
of nanorod can indicate the presence of a specific biomolecule which it recognizes. Mirkin and 
coworkers later showed that by incorporating short segments of a selectively-etchable material (e.g. 
Ag, Ni) that discrete structures separated by sub-diffraction limited distances could be synthesized in 
high yield with good monodispersity (on-wire lithography, OWL).[69]  In a typical synthesis, gold 
and silver segments are electrodeposited into the cylindrical pores of an aluminum oxide membrane 
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template by sequential addition and removal of metal salt solutions. The membrane template is then 
etched by hydroxide and the multisegmented nanorods are deposited onto a substrate. A thin layer of 
gold or glass is then deposited to cover one side of the nanorod, providing structural support across 
length of the multisegmented nanorod and allowing distances between gold segments to be 
maintained following removal and etching (e.g. nitric acid dissolution of Ag or Ni). The technique 
has been applied in a variety of applications including surface-enhanced Raman spectroscopic 
detection and molecular electronics. 
 Apart from colloidal nanostructures with well-defined geometry, branched gold nanostars 
[70-73] have also proven to be useful in a number of biomedical applications i) due to their intense 
scattering properties, amenable to microscopic labeling-based applications,[71] ii) their high spectral 
sensitivity to changes in the local dielectric  environment, useful in bimolecular sensing 
applications,[71,73] and iii)  their high near-infrared absorption which can be leveraged in laser 
photothermal therapy approaches or for electromagnetic enhancement of in vivo, in vitro,[74] and in 
situ [75] surface enhanced Raman spectroscopy (SERS).[76,77] Hafner and coworkers have obtained 
gold nanostars by replacing the small (1-2 nm diameter) gold seeds used in a typical gold nanorod 
synthesis with a commercially-available (10 nm diameter) gold nanospheres capped by citrate-
mediated chloroauric acid reduction.[71] Liz-Marzán and coworkers have developed a method to 
produce gold nanostars with high yield and reproducibility using a method similar to that used to 
produce gold decahedra and octahedra (vide infra).[78] Briefly, an aqueous solution of chloroauric 
acid (Au3+) is gently reduced (Au+) by DMF in the presence of PVP (10 kDa), followed by further 
reduction by borohydride. The seeds are aged for 24 h and an aliquot is added to solution of 
chloroauric acid which has also been mildly reduced by DMF in the presence of PVP. 
Monodispersity was found to be improved upon pre-reduction of Au3+ to Au+ by DMF and 
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morphology/resonance wavelength was found to be controlled by the gold salt:seed ratio. Final 
nanostar dimensions were determined from the size of the seeds and increasingly sharp structures 
relevant to SERS- and sensing-based applications were formed at ambient temperatures. For a 
comprehensive survey of the synthesis, properties, and applications of gold nanostars, interested 
readers are directed to Ref. [72]. 
 1.2 Synthesis of Gold Nanoparticles: Top-Down Methods 
While biomedical applications of gold nanoparticles typically involve so-called “bottom-up” 
synthetic approaches, a number of diagnostic and bioanalytical applications can make use of the high 
uniformity and precise spatial arrangement(s) afforded by top-down fabrication methods. For 
example, in the late 1990’s Van Duyne and coworkers developed a template-based synthesis in which 
gold nanoparticle arrays could be deposited using a shadow-mask approach (Figure 1.4A).[79,80] 
Here, two-dimensional close-packed arrays of polymer nanospheres were self-assembled onto flat 
substrates and gold was vapor deposited into the pyramidal voids formed at their intersections 
(termed nanosphere lithography, NSL). Following removal of the polymer spheres (e.g. in organic 
solvent), ordered arrays of plasmon resonant nanoparticles were obtained over large areas in high 
yield.[80] Moerner [81] and El-Sayed [82] have employed electron-beam lithographic methods to 
obtain arrays of gold nanostructures with precise control over structural morphology and interparticle 
spacing (Figure 1.4Bb). Whitesides and coworkers have shown that gold nanostructures (ca. ≥ 30 
nm) can be fabricated by a so-called “nanoskiving” method whereby gold deposited onto flat or 
structured polymeric substrates (typically epoxy) are sectioned via ultramicrotome and released (e.g. 
by oxygen plasma etching) (Figures 1.4C-E).[83] Mirkin and coworkers have developed a 
lithographic method based on atomic force microscopy (AFM) in which chemical resists consisting of 
self-assembled monolayers are patterned onto gold thin films which are subsequently etched to reveal 
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precise, large-area patterned arrays of gold nanostructures (dip-pen lithography, DPL) (Figures 1.4F-
I).[84,85] In a more recent report, Aizenberg and coworkers show that directional vapor deposition 
of gold and combined electrochemical deposition of conducting polymers onto PDMS-molded 
substrates can be used to fabricate gold nanostructured particle arrays with tapered, anisotropic, and 





Figure 1.4. Exemplary gold nanostructures obtained by various “top-down” synthetic approaches. A) 
Nanosphere lithography (NSL), (B) electron-beam lithography (EBL), (C-E) nanoskiving, (F-I) dip-
pen lithography (DPL) , (J-L) structural transformation by electrodeposition on patterned substrates 
(STEPS), (M-O) nanocrescent synthesis, and (P-S) nanopyramid synthesis. Adapted from Dreaden et 
al. [3]. 
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 Although many of the aforementioned “top-down” synthetic approaches often yield 
substrate-supported/bound gold nanostructures, these methods can also be used to produce free-
standing gold nanoparticles amenable to colloidal dispersion and a variety of biomedical applications. 
Lee and coworkers have recently explored the use of three-dimensional, crescent-shaped hollow gold 
nanostructures (nanocrescent moons) obtained via shadow mask Au vapor deposition onto sacrificial 
template nanoparticles (Figures 1.4M-O).[87,88] In a typical synthesis, commercially-available 
polystyrene nanospheres are deposited onto a glass substrate coated with an acetone-soluble polymer 
(photoresist). The planar sample is then rotated as gold is directionally (i.e. electron-beam) deposited 
onto the polystyrene spheres, leaving a shadow-masked cavity at the sphere-substrate interface. 
Depending on the angle between the substrate and the incident flux of gold, as well as the size of the 
sacrificial templates, the geometry and thus, the optical properties of the nanocrescent structures can 
be easily tuned throughout the visible and near-infrared spectral regions. The template-bound 
nanocrescents are subsequently released from the substrate via acetone lift-off and the polystyrene 
templates are then removed via dissolution in toluene. The free nanocrescents can be functionalized 
with a variety of colloidal stabilizers and linker molecules for a range of biomedical diagnostic and 
therapeutic applications. Because of their sharp surface features and intraparticle plasmon coupling 
effects, these particles have proven to be highly useful as substrates for surface enhanced Raman 
scattering (SERS) [87,88] and can be synthesized in a hierarchical manner to incorporate other 
functional materials such as magnetic segments [88] which can facilitate ex vivo manipulation or 
enhanced contrast in magnetic resonance imaging (MRI). 
 Odom and coworkers have shown that free-standing, hollow, pyramidal gold nanostructures 
of varying geometry can be obtained in a related approach utilizing nanopatterned silicon and vapor-
phase metal deposition (Figures 1.4P-S).[89,90] Here, the authors first fabricate an array of 
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cylindrical posts (ca. 250nm diameter) on a Si substrate via phase-shift photolithography using a 
positive-tone photoresist. A thin (ca. 20 nm) cladding film of Cr is next deposited onto the array and 
the photoresist is removed by lift-off in acetone. The exposed array of Si nanofeatures is then 
chemically etched by KOH/isopropyl alcohol (IPA) to yield an array of negative nanopyramidal pits. 
A thin (ca. 20-60 nm) film of gold (or another type/combination of metal/material) is then vapor 
deposited onto the array and the Cr template layer is removed using a commercial chemical etchant 
to reveal an array of substrate-bound, hollow gold nanopyramids. The nanopyramids are 
subsequently released via KOH/IPA Si etching and can be similarly functionalized with a variety of 
colloidal stabilizers or linker groups for the attachment of biomolecules. Like the hollow gold 
nanocrescents, because gold nanopyramids exhibit sharp surface features and intense intraparticle 
near-field coupling, these structures exhibit both near-infrared absorption for photothermal contrast 
and high electromagnetic SERS enhancement.[91] One particularly attractive feature of these 
structures is the ability to differentially functionalize the inner and outer surfaces of the 
nanopyramids by doing so before/after release from the Si support.[92] Tipless, or truncated, 
nanopyramidal structures can also be fabricated [93] by rotating the planar template array at some 
angle with respect to incident flux of collimated (electron-beam deposited) gold vapor, allowing for 
further SERS enhancement and an increase in multipolar plasmon contributions which can 
contribute to novel nonlinear optical phenomena such as Fano [94,95] resonance.  Photothermal 
conversion from these structures in solution [96] (∆T≤18 °C) has been shown to be comparable to 
those obtainable with more conventional nanorod, nanoshell, nanocage, and hollow gold 
nanostcutures in vivo, well above those minimally required for therapeutic hyperthermia [97] (∆T~3-
6 °C). 
1.3. Functionalization of Gold Nanoparticles 
 24
Chemical functionalization of the nanoparticle surface is necessary to impart biological 
compatibility and specificity to gold nanoparticles.  The synthetic reagent CTAB, for example, which 
is so crucial in a number of preparations of gold nanorods and other shapes, is toxic to cells at 
micromolar concentrations on its own.[98] We do note, however, that in terms of delivery of 
nanoparticles to tumors, the “leaky vasculature” of tumor tissue itself favors (passive) nanoparticle 
localization there, without the need for (active) chemical functionalization.[99-102] We also note 
that the binding of a “toxic” agent such as CTAB to a nanoparticle surface makes it far less 
bioavailable than it would be if it were free in solution, and therefore the tolerable dose of a 
nanoparticle bearing a given molecule might be quite different than that of the molecule alone.[98] 
 Functionalization of gold nanoparticles for biomedical applications follows largely on work 
initially conducted by Nuzzo and Whitesides on the formation of self-assembled monolayers (SAMs) 
of molecules on planar gold [103,104] and later by Bard [105,106] and Murray [107-109] in 
studying the dynamics and conformations of these assemblies by electrochemical, scanning probe, 
and mass spectrometric methods. A rich variety of functional molecular linkers and passivating agents 
are currently employed in the conjugation of gold nanoparticles used in biomedical applications; 
however, the anchoring groups utilized for attachment of these molecules to the gold surface 
generally include: thiolate,[20,110,111] dithiolate, [112] dithiocarbamate,[113] amine,[114] 
carboxylate,[114] selenide,[115] isothiocyanate,[110,114] or phosphine[18,111] moieties. Recent 
evidence suggests that direct Au-C bond formation may be achieved by way of a trimethyl tin leaving 
group; however its use in biomedical- or nanoparticle- based applications has yet to be tested.[116] 
The choice of particular molecular anchor typically varies depending on the desired lability of the 
molecule for a specific application. Non-labile applications most often employ thiol-based anchoring 
groups while labile applications often make use of amine or carboxylate surface anchors (Table 1.2). 
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Burda and coworkers, for example have shown that therapeutic outcomes following gold 
nanoparticle-mediated delivery of photodynamic therapy agents drastically benefits from the use of 
more labile amino linkers versus stronger thiol groups due to vesicular sequestration of particle-bound 
drug molecules.[117,118] 
 
Table 1.2. Useful Physiochemical Parameters for Gold Nanoparticles and Surfaces. 
Physiochemical parameter Value Reference 
Au-S bond 40 to 45 kcal mol-1 [119,120] 
Au-NH2 bond 8 kcal mol-1 [121] 
Au-COO- bond 2 kcal mol-1 [121] 
Maximum (111) Au surface 
density 
1.5 × 1015 atoms cm-2 [105] 
Typical Au Adsorbate densities 10-10 to 10-9 mol cm-2; 
10 to 100 µC cm-2 
[105] 
Au Fermi energy -5.1 eV (v EFVAC) [122] 
CTAB-AuNR longitudinal 
molar extinction cross section 
λ(nm) * 12.3 × 106 - 5.02 × 109 Interpolated 
from [123] 
Citrate-AuNP molar 
extinction cross section 
ε(15)528nm = 3.6 × 108 cm-1 M-1 
ε(30)530nm = 3.0 × 109 cm-1 M-1 
ε(40)533nm = 6.7 × 109 cm-1 M-1 
ε(50)535nm = 1.5 × 1010 cm-1 M-1 
ε(60)540nm = 2.9 × 1010 cm-1 M-1 
ε(80)550nm = 6.9 × 1010 cm-1 M-1 
[124] 
 
 In the case of common alkanethiols, room temperature surface adsorption is spontaneous, 
occurring over milliseconds to minutes.[104] Packing/reordering of the monolayer can occur over 
several hours, however in practice, overnight particle-ligand incubation with additional sonication or 
gentle heating is often sufficient to achieve optimal results. Murray place exchange [107-109] of the 
nanoparticle-bound SAMs can also be performed to functionalize gold nanoparticles with mixed or 
fully exchanged monolayers with coverages as high as 1.5 × 1015 molecules cm-2, although, obtaining 
precise ratios of mixed self-assembled monolayers can be challenging if not performed 
simultaneously. Alkanethiol coverages are typically on the order of 1.5 × 1014 molecules cm-2.[105] 
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While bond strength between anchoring groups and the gold surface play a critical role in 
determining subsequent functionality, packing density and surface energetics make equally important 
contributions. Although dithiolates are often viewed as preferable to their mono-thiolate counterparts 
due to multivalent binding avidity, these molecules are actually more prone to oxidative desorption 
due to inefficient packing.[112] In contrast, oxidative desorption of dithiolates from ZnS-passivated 
CdSe quantum dots has been shown to be significantly lower than that of mono-thiolates, due 
presumably to increasingly efficient surface packing/chemistry.[125] Cima and Langer have found 
that thiolates, most commonly employed for attachment to gold nanoparticles in non-labile 
biomedical applications, can remain stably adsorbed for up to 35 days under physiologic 
conditions.[126] 
 Common among most applications of gold nanoparticles in biomedicine is the need for 
adequate stabilization in biological environments containing high serum concentrations and high 
ionic strengths. Thiolated poly(ethylene glycol), PEG-SH, is by far the most commonly employed 
surface ligand used with biomedical gold nanoparticles. Its well-documented hydrophilicity permits 
the aqueous dispersion of gold nanoparticles conjugated with a wide range of lipophilic molecules 
[127] and increases circulatory half life [128] by blocking adsorption of serum proteins and opsonins 
which facilitate uptake and clearance by the mononuclear phagocyte system (MPS), less frequently 
referred to as the reticuloendothelial system (RES).[129-132] Recent studies by Dai and coworkers 
indicate that carbon nanotubes (far more hydrophobic than gold nanoparticles) functionalized with 
branched PEG ligands exhibit superior pharmacokinetics and minimal RES uptake compared with 
PEG ligands of the same molecular weight.[133] Circulating gold nanoparticles can be expected to 
benefit from similar functionalization strategies. Recent evidence from Jordan and coworkers also 
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suggest that polyoxazoline (POx) stabilizers may serve as suitable alternatives and/or superior ligands 
to PEG.[134-136] 
 Gold nanoparticles can be conjugated with a variety of biofunctional molecules by simple 
physical methods such as hydrophobic-hydrophobic interaction (Figure 1.5A) and charge-pairing 
(Figure 1.5B). Rotello and coworkers have shown that highly hydrophobic molecules (e.g. 
chemotherapeutics such as  paclitaxel and doxorubicin) can be labily bound to biomedical gold 
nanoparticle conjugates via the use of amphiphilic ligands.[137] By creating a hydrophobic corona 
inside of a hydrophilic ligand shell, they were able to demonstrate the entrapment and efficient 
release of hydrophobic fluorescent molecules via “membrane-mediated diffusion”.[137] Classical 
cross coupling reagents can also be employed for the non-labile conjugation of a wide range of 
biofunctional targeting, therapeutic, and imaging contrast agents (Figure 1.5C). Most applications 
involving amine-containing molecules/proteins employ classical carbodiimide cross coupling 
(carboxylate + amine → amide) with a number of commercial chemical manufacturers producing 
ready-made N-hydroxysuccinimide (NHS) -activated heterobifunctional polymers and 
ligands.[138,139] Linkage to sulfhydryl groups can be similarly achieved by way of maleimide-
terminal ligands, also widely commercially available.[140] Huisgen cycloaddition (click, or azide-





Figure 1.5. Schematics illustrating various methods by which gold nanoparticles can be conjugated 
with biofunctional molecules. A) hydrophobic entrapment, (B) electrostatic adsorption, and (C) 
covalent cross coupling by carbodiimide, maleimide, and click chemistry. Adapted from Dreaden et 
al. [3]. 
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Functionalization of gold nanoparticles can be qualitatively verified by a number of means 
including vibrational spectroscopy (e.g. IR or Raman), plasmon resonance shift, thermogravimetric 
analysis (TGA),[138] and/or hydrodynamic diameter or zeta potential change (via dynamic light 
scattering, DLS). In practice however, quantitative measures such as absorption/fluorescence 
assay,[127,141] mass spectrometry (inductively-coupled plasma, ICP,[123,142] or matrix-assisted 
laser desorption ionization, MALDI[143]), x-ray photoelectron spectroscopy (XPS),[144,145] and/or 
cyclic voltammetry is often preferred. 
 Inorganic complexes such as cisplatin or its prodrug forms can also be datively bound to gold 
nanoparticle ligands by way of appropriate ligands (Figure 1.6A).[146] Lippard and coworkers have 
shown that a Pt(IV) prodrug form of cisplatin can be coordinated by carboxylate-terminal ligands on 
gold nanoparticles which facilitate intracellular transport and subsequent activation of the prodrug. 
Mirkin and coworkers have pioneered the use oligonucleotide-functionalized gold nanoparticles, 
employing thiolated ssDNA as surface linkers to which targeting ligand-, biomolecule-, and/or 
imaging contrast agent-tethered complementary ssDNA can be hybridized (Figure 1.6B).[147,148] 
Recently, Rotello and coworkers have demonstrated the synthesis, gold nanoparticle conjugation, and 
photo-triggered release of the cytotoxic thymidylate synthase inhibitor 5-fluorouracil (5-FU) by way 
of a photocleavable, o-nitrobenzyl PEG-SH linker, demonstrating significant toxicity following UV 
exposure and dramatically diminished cytotoxicity in its absence (Figure 1.6C).[149] 
 Other strategies for the functionalization of gold nanoparticle conjugates employ core-shell 
type geometries where the nanoparticle or other molecules are entrapped within a polymer or 
dielectric shell which can be further conjugated. Caruso and coworkers showed that gold nanospheres 
could be encapsulated via consecutive adsorption of charge-paired polyelectrolyte films, also known 
as layer-by-layer (LbL) assemblies.[150] Gold nanospheres were coated with alternating layers of 
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anionic sodium poly(styrenesulfonate) (PSS) (15.2 kDa) and cationic 
poly(diallyldimethylammonium chloride) (PDADMAC) (20 kDa) with the adsorption of each layer 
following centrifugal purification. The resulting nanoparticles exhibited tunable surface charge and 
allowed for the electrostatic adsorption of proteins (see Figure 1.5B) over a wide range of isoelectric 
points and solvent pH values. The same LbL concept works for coating gold nanorods, enabling 
switching of the effective surface charge from positive to negative, and overcoating the surfactant 
bilayer to present ammonium, sulfate, or other charged groups to the solvent.[151,152] Stable, 
hollow polymeric nanocapsules can be obtained by CN- etching of both polymer-coated gold  
nanospheres[150,153] and nanorods.[154] Due to their hierarchical assembly and controllable 
interlayer diffusion, Hammond and coworkers have found LbL assemblies useful in a number of 
multidrug and gene delivery applications.[155-159]  
 In the mid 1990’s, Liz-Marzán and Mulvaney[160] showed that gold nanoparticles could be 
fully encapsulated by silica (glass) shells [161] (Figure 1.7A) by vitreophobic surface conjugation and 
facile silane chemistry (Figure 1.7B).[162] This prospect is particularly attractive for use with gold 
nanorods, where compelling evidence showing complete removal/displacement of CTAB molecules 
from the sides of the rods has yet to be demonstrated. Natan[163] and Nie[164] have further 
explored this concept, fabricating gold-silica core-shell nanoconjugates containing entrapped Raman 
reporter molecules. Because the enhanced optical properties afforded by resonant excitation of the 
gold core’s surface plasmon resonance (surface enhanced Raman scattering, SERS), highly 




Figure 1.6. Schematics illustrating additional methods by which gold nanoparticles can be 
conjugated with biofunctional molecules. A) dative covalent bonding, (B) oligonucleotide 
hybridization, and (C) and photolabile linkage. Adapted from Dreaden et al. [3]. 
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Figure 1.7. Silane conjugation chemistry for biomedical gold nanoparticle conjugates. Silica shell 
(Stöber) functionalized (A) gold nanospheres and (B) gold nanoprisms. C) Reaction schemes for 
conjugation to (i) hydroxyl- and (ii) silane-functionalized gold nanoparticles. D) Reaction scheme for 
the encapsulation of bioanalytically- and/or therapeutically-relevant molecules about gold 
nanoparticles. Adapted from Dreaden et al. [3]. 
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1.4 Outlook and Conclusions 
The aforementioned synthetic approaches can produce an incredibly diverse array of gold 
nanostructures with a cadre of varying chemical, photophysical, pharmacokinetic, and 
pharmacodynamic properties. The sections to follow will discuss novel biomolecular and photonic 
interactions of these functionalized nanomaterials and their applications in oncology, surface-
enhanced spectroscopic detection, and photovoltaics. 
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GOLD NANOPARTICLES IN BIOMEDICINE 
 
While advances in the detection and treatment of cancer has resulted in dramatic 
improvements to human health in the US, reductions in cancer mortality rates have not kept pace 
with the large increase in incidence.[3] Today, 1 in 2 males and 1 in 3 females in the US will develop 
cancer at some point during their lifetime.[4] 1 in 4 males and 1 in 5 females in the US will die from 
the disease. There is a clear and urgent need for increasingly potent and selective methods with which 
to detect and treat cancers in their earliest stages. 
 Nanoparticles – materials with dimensions between 10-9 and 10-8 meters – have been 
systemically administered in humans since clinical approval of the first micellar drug Sandimmune® 
by the US Food and Drug Administration (FDA) in 1983 and the first polymer-drug nanoconjugate 
Adagen® later in 1990.[5] Since then, an explosion of research in nanoscale diagnostic and 
therapeutic agents has given rise to a range of biomedical nanotechnologies and platforms,[2,6-12] 
including protein-drug nanoconjugates,[13] micelles,[14-17] liposomes,[18,19] dendrimers,[20-22] 
inorganic nanoparticles,[12,23-30] and other polymer-drug nanoconjugates [6,31-34] (Table 2.1). 
More than two dozen biodiagnostic or therapeutic nanotechnologies have been approved for clinical 
use with roughly 250 others in clinical development. The global market share for biomedical 
nanotechnologies is expected to grow to $70-160 billion by 2015, rivaling the current worldwide 
market for biologics.[35] These nanoscale constructs provide a range of multiple, fundamentally new 
properties which can be exploited in ways that can improve our ability to detect, treat, and monitor 
disease states. Further, the unique interactions between these nanoscale materials and comparably 
sized physiological structures, proteins, organelles, DNA, etc. can also be leveraged to compliment 
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existing medical diagnostic/treatment strategies and to foster the development of new and potentially 
more efficacious approaches. 
Gold nanoparticles exhibit a combination of physical, chemical, optical, and electronic 
properties unique from other biomedical nanotechnologies and provide a highly multifunctional 
platform with which to image and diagnose diseases,[36-40] to selectively deliver therapeutic agents, 
[37,41-43] to sensitize cells and tissues to treatment regimens,[44,45] to monitor and guide surgical 
procedures,[26,46,47] and to preferentially administer electromagnetic radiation [46-49] to disease 
sites (Figure 2.1). Because of their large size, circulating nanoparticles preferentially accumulate at 
tumor sites and in inflamed tissues due to the characteristically defective architecture of the vessels 
which supply oxygen and nutrients to these tissues (Section 2.2) [50,51]. Once circulating 
nanoparticles extravasate through the large vascular pores at these disease sites, they remain lodged 
due characteristically diminished lymphatic drainage and low diffusivity.[52] First termed by Maeda 
in 1986,[53,54] the enhanced permeability and retention (EPR) effect provides a basis for the 
selective accumulation of many high molecular weight drugs currently in clinical use. Gold 
nanoparticles can be used to deliver drugs or imaging contrast agents that otherwise exhibit poor 
solubility or pharmacokinetic profiles,[55,56] or to deliver agents which are intrinsically susceptible 
to enzymatic degradation and/or exhibit poor intracellular penetration such as small interfering RNA 
(siRNA).[42,57-59] Nanogold can be routinely surface functionalized at active ligand densities 102 − 
103 fold higher than that achievable using liposomal or polymeric nanoparticles, respectively, 
allowing their binding affinity [60] to be optimized for a particular disease, type, stage, or patient. 
Because of their comparability in size to the distances between cell-surface targets, gold 
nanostructures can simultaneously engage multiple, adjacent receptor sites, achieving increased 


















































Figure 2.1. Applications of colloidal gold nanoparticles in drug delivery and laser photothermal 
therapy. A) Gold nanospheres, B) gold nanorods, C) gold nanoshells, and D) gold nanocages. 
Adapted from Dreaden et al. [1]. 
 
2.1 Photophysical Properties and Biomedical Applications of Gold Nanoparticles 
Gold nanoparticles (Table 2.2) are particularly attractive platforms for targeted diagnostics 
and therapeutics (Figure 2.2) due to their unique optical and electronic properties. These structures 
can be conjugated at ligand densities [62] (1.0 × 106 µm-2) that are 100- and 1000-fold higher than 
that achievable with conventional liposomes [63] or PLGA (poly(lactic-co-glycolic acid)) 
nanoparticles,[64] respectively, and the selective accumulation of gold nanoparticles at solid tumors 
can facilitate highly efficient photothermal ablation via non-invasive near-infrared (NIR) laser 
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exposure [2,12,65-67] (Figure 2.3A), high-Z enhanced X-ray computed 
tomography/radiotherapy,[44,48] non-invasive photoacoustic imaging/cytometry [67-70] (Figure 
2.3B), contrast-enhanced optical coherence tomographic imaging [71] (OCT, Figure 2.3C), and 
electromagnetic enhancement in non-invasive spectroscopic biomarker detection schemes both in 
vitro [72] and in vivo [73] (Figure 2.3D). 
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Table 2.2. Selected reviews on gold nanotechnology and its use in biomedicine. Adapted from 






Figure 2.2. Exponential growth in the number of publications on gold nanotechnology and 
nanomedicine over the past two decades.[74] A) Annual publications in nanomedicine dramatically 
increased following award of the 1996 Nobel Prize in Chemistry to Kroto, Curl, and Smalley for 
their discovery of fullerenes. Medicinal applications of gold nanotechnologies further added to this 
growth following US President Bill Clinton’s formation of the National Nanotechnology 
Infrastructure Network (NNIN) in 2000 and US President George H.W. Bush’s expansion of the 
program in 2003 with the 21st Century Nanotechnology Research and Development Act. B) 
Contributions from various countries to publications on gold nanomedicine in 2000 and 2010. 
Publications in 2000 were limited to just 5 countries while those in 2010 included more than 50. 
aOther countries represent those with <2.9%. C) Overlap between publications on gold 
nanotechnology and nanomedicine in 2010 and comparison of their corresponding average number 
of citations and h-indices. Note that publication data in (A) is not cumulative. Adapted from 
Dreaden et al. [2]. 
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Figure 2.3. Properties of gold nanotechnologies that can be used to enhance therapeutic treatment 
and diagnostic imaging of cancer. A) Photothermal therapy: gold nanoparticles can serve as contrast 
agents for the selective laser photothermal ablation of tumor cells. Arrow indicates laser focus. Image 
obtained in collaboration with Prof. X. Huang (U of Memphis) and Prof. C.K. Payne (Georgia 
Tech). B) Photoacoustic cytometry/tomography: pulsed laser excitation of cells/tissues labeled with 
gold nanoparticles can be used to detect or sequester circulating tumor cells (CTCs, upper panel) or 
to non-invasively image/diagnose/stage tumors and guide surgical procedures (lower panel). C) 
Optical coherence tomography (OCT): the backscattering and photothermal properties of gold 
nanotechnologies can be used to enhance OCT contrast for monitoring disease metastasis to the 
lymphatic system. D) Surface enhanced Raman scattering (SERS): Electromagnetic near-field 
enhancements generated by gold nanoparticles can improve non-invasive in vitro (upper panel) and 
in vivo (lower panel) spectral cancer diagnostics. Adapted from Dreaden et al. [75]. 
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The novel optical and electronic properties of gold nanoparticles are particularly attractive 
for use in multimodal drug delivery applications where these structures can afford enhanced drug 
pharmacokinetics/biodistribution (Section 2.2) and simultaneous hyperthermia,[12,25,47,48,66,76] 
and radiation therapy contrast,[44,71,77-80] as well as photo-imaging contrast,[36,38,70,71,77,81-
87] spectrochemical diagnostic contrast,[37,40,46,89-91] and, when molecularly directed to specific 
sub-cellular sites, intrinsic pharmacodynamic [2,12,88] properties. The ability of these structures to 
act as photothermal therapeutic agents arises due to the delocalized nature of their free (conduction) 
electrons and the increasing polarizability of these charge carriers at the surfaces of these materials. 
These surface electrons exhibit collective modes of oscillation (surface plasmon modes) which vary in 
frequency depending on the size/shape of the nanoparticle and its dielectric environment.[89] 
Plasmon modes which result in a dipolar charge density distribution can couple with and resonantly 
absorb optical photons of the same frequency, resulting in a transient increase in the energy of these 
electrons equivalent to that of the photon (EFermi(Au) ca. -5.1 eV v. EFVAC) (Table 2.3) [90]. 
Plasmonic photothermal heat generation [91] can thus be simplified as a three step process: i) 
electron-electron coupling, ii) electron-phonon coupling, and iii) phonon-phonon coupling. 
Electron-electron coupling follows the energy absorption process, whereby the average (Fermi) energy 
of electrons in the nanoparticle is transiently increased for a few hundred femtoseconds. This 
increased electron energy decays via the coupled electronic and lattice heat capacities of the material 
(i.e. energy per unit temperature), resulting in a transient (ca. 1 ps) increase in the material’s lattice 
temperature and thus, an increase in the volume of the nanoparticle. Volume expansion equilibrates 
through phonon “breathing” modes (phonon-phonon coupling) whereby coherent oscillations of the 
atomic lattice (phonon vibrations) dissipate energy, resulting in heat transfer to the surrounding 
media over several picoseconds. The extent of macroscopic heat generation depends on the incident 
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excitation power and the particle, but in most biomedical applications, photothermal heat generation 
often exceeds ∆T~20 °C [2,12,46-49,67,76]. 
 
Table 2.3. Useful physical parameters/relationships for plasmonic nanoparticles. 
Photophysical parameter Value Reference 
Bulk plasma (plasmon) frequency (ωb) Au: 1.30 × 1016 s-1; Ag: 1.40 × 1016 s-1 [92] 
Spherical surface plasmon frequency (ωNP) ωb[ℓ/(2ℓ+1)]1/2 [93] 
Cavity surface plasmon frequency 
(spherical, ωC) 
ωb[(ℓ+1)/(2ℓ+1)]1/2 [93] 
a ℓ = 1(dipole), 2(quadrupole),…; n.b. ℓ  sometimes referred to as surface plasmon mode, order, 
symmetry, and/or angular momentum. 
 
By changing the size/shape/surface of the gold nanoparticle, one can tune the wavelength of 
its plasmon absorption to coincide with spectral regions where the attenuation of photons by tissues 
and physiological fluids (i.e. water, oxy/deoxyhemoglobin, etc.) is minimal.[12,94] For example, in 
the near-infrared (NIR) window (ca. 650 – 900 nm; Figure 2.4), one can achieve upwards of 10 cm 
penetration depth through breast tissue even at low (µW/cm2) laser power densities.[2,12,95] The 
local temperature increases attainable using plasmonic laser photothermal therapy (Table 2.4) are 
well sufficient to induce rapid tumor cell death (necrosis) with minimal damage to surrounding 
tissues. In milder, hyperthermic cases (∆T~3-5 °C),[96] deleterious physiological responses such as 
cell membrane disruption, protein denaturation, metabolic signaling disruption, thrombosis, tumor 
ischemia, the induction of heat-shock proteins, signaling disruption, diminished membrane 
transport, and impaired DNA synthesis/repair can also lead to pro-apoptotoic responses in particle-
labeled cells.[97,98] Other plasmonic metals include Li, Na, K, Mg, Al, Fe, Cu, Ag, and Pt.[99] Of 
these, gold is the only nanoscale metal which exhibits both inert reactivity and plasmon resonance 





Figure 2.4. Wavelength range of the near-infrared (NIR) tissue transmission window. A) In the 650-
900 nm spectral range, absorption from physiologic fluids such as oxy/deoxyhemoglobin and water is 
minimal, allowing (B) maximum penetration depths for external laser radiation. Photothermal 
therapy, photoacoustic tomography, and optical diagnostic imaging are most efficient in this range. 
Gold nanoparticle contrast agents are designed to optimally absorb in these regions. Adapted from 





Gold nanoparticles are also highly useful probes for microscopic imaging-based applications. 

























































equivalent to the emission intensity of 500,000 of the most efficient Alexa Fluor® dyes or 2,000 of the 
most efficient Qdot® 800 quantum dots.[101] While gold nanoparticles have been used for decades as 
labels in immunohistochemical and electron microscopic analysis of tissue sections,[102] Sokolov et 
al. first demonstrated in 2003 that the resonant scattering from gold nanoparticles could be used to 
image subcellular cancer biomarkers (EGFR) in vitro using confocal reflectance microscopy of 
immunolabeled gold nanoparticles (ca. 12 nm core diameter) for potential cancer diagnostics, 
staging, and treatment monitoring. Our labs have shown that simpler, less expensive, higher 
sensitivity cardioid dark-field optics can also be used to obtain high-contrast scattering images from 
immunolabeled gold nanoparticles in vitro, in this case in true-color, to achieve the identification and 
selective (photothermal) labeling of malignant cells.[103,104] Lin and coworkers first demonstrated 
the use of plasmonic nanoparticles (gold nanoparticles) for in vitro photothermal therapy in 2003, 
using 30 nm gold nanospheres conjugated with IgG antibodies for CD8 to label lymphocyte cells. 
Following exposure to a nanosecond pulse visible laser, 95% of cells treated with the gold 
nanospheres were killed.[105] Hirsch et al. first demonstrated the use of plasmonic nanoparticles for 
in vivo laser photothermal therapy in the same year, showing that interstitially-injected PEGylated 
gold nanoshells could selectively and efficiently ablate xenograft tumors in mice locally irradiated 
with a near-infrared laser.[49] Dickerson et al. were the first to demonstrate the use of increasingly 
efficient PEGylated gold nanorods in analogous therapeutic in vivo applications (See Chapter 
3).[46] Bahatia and coworkers later showed that the intrinsic x-ray absorbing properties of gold 
nanorods (doubly greater than that of clinical iodine standards) can be used to guide NIR PTT and 
increase treatment efficacy.[48] Using x-ray computed tomography (CT) and contrast from tumor-
accumulated gold nanorods, they were able to non-invasively image and three-dimensionally 
reconstruct tumor xenograft margins in mice models. Subsequent NIR PTT achieved complete 
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tumor resorption and 100% survival of the nanoparticle treated group, while tumors in sham-treated 
and control groups grew uncontrolled with ≤ 1 month survival (0.75 W cm-2, 1 min, 1 cm spot dia). 
 In 2007, Xia and co-workers first demonstrated the use of gold nanocages for contrast in in 
vitro NIR PTT.[106] Nanocages conjugated to antibodies to human epidermal growth factor 
receptor 2 (anti-HER2) were used to selectively target breast cancer cells overexpressing cell surface 
HER2. Cell destruction using NIR laser exposure was observed at a minimum power density of 1.5 
W cm-2 (5 min, 2 mm spot dia). The group later showed that intravenous (iv) administration of 
PEGylated gold nanocages and subsequent NIR laser exposure (λ~808 nm; 0.7 W cm-2, 10 min) 
could significantly decreased (-70%) tumor metabolic activity as measured by 18F-fluorodeoxyglucose 
positron emission tomography (18F-FDG PET).[47] The nanocages exhibited ca. 5.7 % 
accumulation of the initial dose (g-1 tissue) at the tumor site with histologically verified tumor 
necrosis following laser exposure. Using similarly synthesized hollow-core, spherical gold 
nanoparticles, Li and coworkers have studied in vitro NIR PTT using anti-EGFR conjugates of the 
hollow gold nanoparticles, as well as their in vivo biodistribution following iv administration.[107] 
EGFR-overexpressing squamous cell carcinoma cells were found to be selectively labeled and 
photothermally destroyed following cw NIR laser exposure (40 W cm-2, 5 min, 2 mm spot dia). 
Intravenous administration in tumor bearing nude mice resulted in predominant RES organ (i.e. 
liver, spleen, and kidney) accumulation. Tumor accumulation was found to be as high as 6.5% of the 
initial dose with predominant perivascular localization. Targeted NIR PTT of melanoma tumors 
using hollow gold nanoparticles was further studied in animal models by the same group using an 
agonist ligand of melanocortin type-1 receptor, overexpressed by melanoma cells.[108] 
Biodistribution studies following 24 h of intravenous circulation found significantly enhanced tumor 
accumulation by the active targeting strategy (13 v. 5 % initial dose g-1 tissue). Histological analysis 
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following NIR laser exposure determined significantly enhanced necrotic response from nanoparticle 
treated tumors (66% v. 8% sham, 0.5 W cm-2, 1 min, 1 cm spot dia). PET imaging also indicated 
dramatically decreased (-89%) metabolic activity in nanoparticle treated tissues, but not in sham or 
control tumors. Xia and Wang have further demonstrated that the NIR absorption properties of 
nanocages and other plasmonic gold nanoparticles can be used to non-invasively image tumors for 
surgical or PTT guidance, as well as to assess the stage and location of primary melanoma tumors in 
vivo by photoacoustic tomographic imaging (Figure 2.3B).[68] Also using a ligand of melanocortin 
type-1 receptor, they showed that systemically administered nanocages can be preferentially targeted 
to melanoma tumors, allowing ca. 40% increased imaging contrast and actively-targeted tumor 
accumulation. 
Determining the optimal gold nanostructure for NIR photothermal therapy (PTT) can be 
highly subjective due to the numerous ways in which such analyses can be performed. Structures can 
be compared based on their absorption cross sections, absorption efficiencies, or thermal transduction 
efficiencies on a per particle, per unit gold, per unit mass, or per unit extinction basis. Gold nanorods 
have been shown to exhibit much larger and narrower NIR absorption cross sections and efficiencies 
than either nanoshells or nanocages.[109,110] Experiments comparing NIR thermal transduction 
from solutions of equivalent optical density (i.e. extinction) found gold nanorods and AuS2-Au 
nanoshells to be much more efficient photothermal contrast agents than SiO2-Au nanoshells.[110] 
Per unit mass gold, nanorods have exhibited 1/3 the spectral bandwidth, ca. 3-fold higher extinction 
cross section, and 6 times greater heating capability than SiO2-Au nanoshells in NIR laser 
photothermal experiments.[48] 
One notable advantage for the use of PEGylated gold nanotechnologies in the clinic is their 
classification by the US FDA as a “medical device” in photothermal therapy applications, allowing for 
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substantially accelerated and less costly approval processes. Human pilot studies exploring the use of 
iv-administered PEGylated silica-gold core-shell nanoparticles for NIR laser photothermal ablation of 
recurrent and/or refractory head and neck tumors are currently ongoing in the US (NCT00848042; 
Nanospectra Biosciences, Inc.), with ongoing human pilot studies investigating the use of this 
technology for the treatment of primary prostate cancer in Mexico. Both studies are scheduled to be 
completed in the middle of this year. Because gold nanoparticles are comprised of a high atomic 
number (i.e. high-Z) element, they have also been shown to substantially to improve the efficacy of 
radiotherapy treatments via tumor-localized photoelectron and Auger electron ejection, which can 
damage the DNA of tumor cells in the local surrounding tissue.[44] Although hyperthermia is 
known to synergize with radiotherapy treatments, [111] reports of multimodal plasmonic laser 
photothermal therapy and high-Z enhanced radiotherapy using gold (and other plasmonic) 
nanoparticles has yet to be explored. 
2.2 Pharmacokinetics, Biodistribution, and Cellular Uptake of Gold Nanoparticles 
 One of the earliest reports involving the use of gold nanoparticles in drug delivery 
applications came in 1954, when Root et al. investigated the clinical use of colloidal Au198 particles 
for radiotherapy treatment of liver cancer and leukemia, both with minimal success.[112] For the 
next 47 years, examples of peer-reviewed scientific studies involving biomedical applications of 
colloidal gold were scant at best. In 2001, Paciotti and Tamarkin began research studying the use of 
gold nanoparticles as a platform for the delivery of tumor necrosis factor  α (TNFα) to solid tumor 
models in mice.[113,114] Subsequent Phase I clinical trials found that the PEGylated 27 nm (TEM 
diameter) gold nanoparticles were well tolerated in patients and able to safely deliver TNFα at 
dosages 3-fold higher than the previously reported maximum tolerable dose for the lone drug with no 
serious adverse side effects; Phase II trials are currently pending.[115] 
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Malignant cells require increasing amounts of nutrients in order to sustain their accelerated 
growth and division. To meet this demand, solid tumors stimulate the production of new 
vasculatures through which increasing amounts of blood can be supplied (i.e. angiogenesis). In 
contrast to normal vessels, the angiogenic neovasculature is characterized by a highly disordered 
endothelium with large gaps that permit the preferential penetration of nanosized conjugates (Figure 
2.5,6A). Characteristically diminished lymphatic drainage from the tumor interstitium also serves to 
increase retention of such compounds at the tumor site, resulting in both augmented penetration and 
decreased clearance of circulating nanoconjugates. The EPR effect has been demonstrated using a 
variety of protein/DNA/polymer complexes, as well as nanoparticles including micelles, liposomes, 
metal nanostructures, and quantum dots.[11] As one would expect, the optimal size for EPR of a 
gold nanoparticle conjugate varies depending on the stage, location, and type of cancer, however 
non-deformable particles with a hydrodynamic diameter (HD) greater than the renal clearance 
threshold (ca. 6 nm HD, anionic; 6-8 nm, cationic [116]) and up to the 200 nm HD splenic 
clearance threshold [116] can be expected to exhibit preferential tumor accumulation. Although 
efficient renal (urinary) clearance is sometimes desirable, readers may note that polycationic 
nanoparticles can exhibit poor circulatory half lives due to electrostatic attraction with the negatively 
charged laminar surfaces of the blood vessels. Polyanionic nanoparticles, on the other hand, often 
exhibit decreased cell penetration due to electrostatic cell-surface repulsion. Nanoparticle 
opsonization and phagocytic uptake is typically lowest when particles are neutral in zeta potential and 
contain hydrophilic polymers which shield hydrophobic-hydrophobic and/or electrostatic 
interactions with IgG and serum proteins.[117] In contrast to orally administered drugs which 
optimally exhibit high lipophilicity (Log P ~ 3-5), optimal lipophilicity of a therapeutic nanoparticle 
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Figure 2.5. Graphic illustrating the size-selective preferential accumulation of circulating gold 
nanoparticle conjugates at tumor sites by the enhanced permeability and retention (EPR) effect. 
Large gold nanoparticle conjugates preferentially penetrate through blood vessels at tumor sites due 
to their disordered endothelial cells, while smaller molecules continue to circulate. Diminished 
lymphatic drainage at the tumor site also serves to reduce the clearance of these gold nanoparticle 




Figure 2.6. Properties of nanoscale technologies that can be leveraged to enhance the diagnosis and 
treatment of solid tumors. A) The EPR effect: Polymer cast replicas of blood vessels in normal (left) 
and malignant tissues (right) illustrate why high molecular weight compounds (i.e. nanoparticles) can 
preferentially accumulate at tumor sites supplied by disordered vasculatures. B) Multivalent avidity: 
unlike monovalent ligands, nanoscale constructs can simultaneously bind multiple adjacent receptors 
to augment uptake/selectivity. C,D) Enhanced stability: nanoscale carriers can enhance the solubility, 
circulatory half lives, biodistribution, and intracellular penetration of water-insoluble 
chemotherapeutics and proteins/nucleic acids (e.g. siRNA) which are susceptible to enzymatic 
degradation and subject to poor intracellular penetration rates. Scale bars represent 100 µm. Adapted 
from Dreaden et al. [75]. 
 
Numerous size-dependent blood half-lives and biodistribution profiles for spherical and rod-
shaped gold nanoparticles have been reported. De Jong and coworkers detected gold nanoparticles, 
by inductively coupled plasma mass spectrometry (ICP-MS) in the blood, liver, spleen, lungs, 
kidneys, testis, thymus, heart and brain after iv administration in male rats with 10, 50, 100 and 250 
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nm spherical citrate-gold nanoparticles.[119] The highest amount of gold was detected in the blood, 
liver and spleen (24 h post-injection) with lower amounts in the lungs, kidneys, testis, thymus, heart 
and brain. 10 nm gold nanoparticles were the most widespread through different organs, with the 
highest gold content in the liver, and to a lesser extent, in the spleen. After 24 h, liver accumulation 
(%ID g-1 tissue) was found to be 46%, 21%, 44%, and 31% for 10, 50, 100 and 250 nm gold 
nanoparticles, respectively and 2.2%, 1.3%, 1.4%, and 1.2%., respectively, in the spleen. In contrast, 
Terentyuk et al. observed opposing trends using gold nanoparticles functionalized with poly(ethylene 
glycol) (PEG).[120] Following tail vein injection in white rats, the accumulation of gold in the liver 
and spleen was found to decrease with decreasing nanoparticle size from (50 to 15 nm), with 15 nm 
PEG-gold nanoparticles exhibiting the greatest blood residence times. Passively- (EPR-) targeted gold 
nanospheres have exhibited as much as 2 %ID g-1 and 5 %ID tumor accumulation in murine 
xenograft models (%ID g-1, % initial dose per gram tissue);[108,121] actively-targeted gold 
nanoparticles have likewise exhibited upwards of 6-13 %ID g-1 tumor accumulation following 
systemic administration.[107,108,121] 
It is apparent from the conflicting trends reported in the literature that systematic 
examinations of pharmacokinetic and biodistribution profiles for different nanoparticle sizes and 
surface chemistries is warranted. Chan and coworkers have performed a comprehensive examination 
of blood pharmacokinetics and biodistribution profiles for gold nanoparticles 25-119 nm in 
hydrodynamic diameter (HD), coated with varying molecular weights of PEG.[122] Decreasing 
nanoparticle size and increasing PEG molecular weight was found to increase the blood half-life of 
these nanoparticles following iv administration in CD1 mice (Figure 2.7). All nanoparticles 
exhibited increasing accumulation in the liver and spleen over time with greater apparent filtering 
capacity demonstrated by the spleen (%ID g-1 tissue). Passive tumor accumulation at subcutaneous 
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MDA-MB-435 xenografts following iv injection of the PEGylated gold nanospheres was found to be 
greatest for 61 nm HD PEGylated (5 kDa) gold nanoparticles with trends following: 61 > 83 > 99 > 
40 > 22 nm HD at 24 h. Accumulation in the spleen and liver (24 h, %ID g-1) likewise peaked for 61 
nm HD particles. Size-dependent permeation of the tumor interstitium was evaluated after 8 h 
circulation of PEGylated nanoparticles, revealing decreasing intratumoral penetration with increasing 
nanoparticle size. 61 nm HD PEGylated gold nanoparticles (ca. 32-45 nm physical diameter with 5 
kDa PEG) exhibited optimal blood half-life and tumor accumulation profiles with tumor 
accumulation, MPS biodistribution, and blood half life comparable for increasing PEG molecular 
weight. Due to their less optimal intratumoral penetration characteristics and relatively high 
MPS/RES organ uptake, administration of a combination of 61 nm HD PEGylated gold 




Figure 2.7. Pharmacokinetics of PEGylated gold nanoparticles. A) Relationship between circulatory 
half live, hydrodynamic diameter, and tumor accumulation for spherical gold nanoparticles of 
varying size and thiolated poly(ethylene glycol) (PEG) surface stabilizer molecular weight. B) Graph 
illustrating that circulatory half lives of PEGylated gold nanospheres is inversely proportional to 
particle size and PEG molecular weight (for particles >16 nm physical diameter). C) Graph 
illustrating similar pharmacokinetics of PEGylated gold nanoparticles in tumor-bearing and non-
tumor-bearing mouse models. Adapted from Dreaden et al. [1]. 
 
The biodistribution profiles of rod-shaped gold nanoparticles are also of current interest as 
these structures have shown potential in drug and/or gene delivery applications [123-126] and 
photothermal therapy [2,12,46-49,67,76]. Systemically-administered, gold nanorods (55 x 13 nm) 
with no polymer functionalization have exhibited sustained circulation in the blood of Sprague-
Dawley rats over periods as long as 14 days.[127] Accumulation in RES organs was observed with a 
plateau in gold nanorod accumulation in the liver at 1 d circulation. Retention in the liver over 28 d 
was also found, suggesting diminished capacity for hepatobiliary clearance/excretion of CTAB-
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capped gold nanorods. Splenic accumulation exhibited a gradual increase over this time period, with 
lung, kidney, heart, brain, bone, and muscle accumulation likewise decreasing. CTAB-gold nanorods 
were observed by transmission electron microscopy (TEM) in the lysosomes of both the spleen and 
liver. Fecal excretion suggested some capacity for hepatobiliary clearance of these size gold nanorods, 
however due to their lack of adequate polymer stabilization, these results may not reflect those 
observable with PEGylated gold nanorods. Upon coating 65 x 11 nm gold nanorods with PEG, 
Niidome and coworkers observed no accumulation in major organs, with the exception of the liver, 
72 h post injection. Here, PEGylation imparted dramatic improvements to both the 
pharmacokinetics and biodistribution profiles of systemically administered gold nanorods. Bhatia and 
coworkers found that PEGylated gold nanorods (5 kDa PEG-SH) can exhibit up to 17 h blood half 
life in nude mice with ca. 7 %ID g-1 tumor accumulation after 72 h.[48] Huang et al. have explored 
the active targeting of PEGylated gold nanorods by i) a single-chain variable fragment (ScFv) peptide 
that recognizes the epidermal growth factor receptor (EGFR), ii) an amino terminal fragment (ATF) 
peptide that recognizes the urokinase plasminogen activator receptor (uPAR), and iii) a cyclic RGD 
peptide that recognizes the avb3 integrin receptor were also performed (hydrodynamic diameter 68-81 
nm, zeta potential -5 to -25 mV).[128] As anticipated, active targeting was found to significantly 
improve the cellular accumulation of these nanoconjugates in vitro (A549 lung cancer cells); the 
blood half life of the PEGylated gold nanorods however, was reduced by 25 - 48% upon co-
conjugation with these active targeting ligands and the tumor accumulation (24 h) of ATF- and 
ScFV anti-EGFR-targeted gold nanorods was enhanced ca. 67 and 46% relative to passively targeted 
PEGylated gold nanorods administered in mice models. Surprisingly, the tumor accumulation of 
cyclic RGD-targeted gold nanorods was significantly diminished (ca. -57 % relative to PEGylated 
gold nanorods), suggesting that laser photothermal therapy using this specific formulation may be 
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best suited to intratumoral injection schemes. Like other nanoparticles, the blood half life of 
PEGylated gold nanorods generally increases with PEG grafting density [129] and/or PEG molecular 
weight, both of which can augment subsequent passive tumor accumulation. 
 Although most gold nanoparticle conjugates are capable of exhibiting some degree of passive 
biodistribution, particle size, charge, and lipohilicity also play critical roles in determining the extent 
of cellular uptake once accumulated at a particular location. Chan and coworkers have studied the 
size-dependent cellular uptake of citrate-capped gold nanoparticles into cervical cancer cells (HeLa) 
and found that size-dependent internalization peaked at 50 nm (TEM diameter).[130] In another 
study using immunoglobulin G (IgG) antibody-gold nanoparticle conjugates, they found that ca. 40 
nm (TEM diameter) particles conjugated to antibodies to human epidermal growth factor receptor 2 
(anti-HER2; Herceptin) exhibited the greatest uptake into breast cancer cells (SK-BR-3) and 
elicited the greatest therapeutic response (Figure 2.8).[131] Multivalent functionalization of smaller 
gold nanoparticles (ca. 2 nm TEM diameter) resulted in inefficient uptake due to the decreased 
ability of these small particles to occupy multiple receptor binding sites. Larger nanoparticles (ca. 70 
nm TEM diameter), although capable of avid receptor binding, were too large to allow efficient 
membrane wrapping necessary for endocytotic uptake. Although the optimal particle size for 
intracellular penetration obviously varies depending on the cell size, type, receptor density, metabolic 
activity, etc., as well as the specific targeting strategy employed (i.e. IgG, fragments thereof, etc.), this 
study nonetheless highlights the importance of therapeutic nanoconjugate size in determining 
subsequent intracellular transport kinetics and anticipated treatment efficacy. Cationic zeta potential 
(i.e. positive surface charge) can also promote the uptake of nanoconjugates due to electrostatic 
attraction with anionic cell-surface proteoglycans. In some cases however, this attraction can result in 
significant cytotoxicity due to membrane disruption. Lipophilicity, as measured by octanol:water 
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partition coefficient (Log P) further promotes nanoparticle-cellular interaction and uptake by 
association with hydrophobic cell-surface and extracellular matrix domains. Due to poor aqueous 
stability and low circulatory half life however, highly lipophilic gold nanoparticles are typically co-
conjugated with hydrophilic polymer stabilizers such as PEG. 
 
 
Figure 2.8. Size-dependent receptor-mediated endocytosis of antibody-gold nanoparticle conjugates. 
A) Schematic illustrating how nanoconjugate size and receptor density affect HER2-mediated uptake 
of herceptin-labeled gold nanoparticles into SK-BR-3 breast cancer cells. 2 nm gold nanoparticles 
were not efficiently internalized because multiple receptors could not be simultaneously bound. 70 
nm particles exhibited multivalent binding; however they were too large for efficient membrane 
wrapping (i.e. endocytosis). B) Increased relative fluorescence intensity associated with nanoparticle 
uptake was found to correlate well with (C) subsequent therapeutic response. Nuclei are stained blue, 
scale bar = 10 µm, *p < 0.05, error bars ± SD, n = 4. Adapted from Dreaden et al. [12]. 
 
Given their utility in drug delivery and photothermal therapy, one might reasonably 
question whether gold nanospheres or nanorods are preferable for biomedical targeting/delivery. 
Although rod-shaped nanoparticles exhibit greater in vivo transvascular flux relative to spherical 
particles of equivalent hydrodynamic diameter [132], these particles have also exhibited diminished 
cellular uptake in vitro.[132] Fukumura, Bawendi, and Jain have examined the transmembrane 
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permeability, gel diffusivity, and transvascular flux of PEGylated semiconductor nanoparticles and 
nanorods of equivalent (33-35 nm) HD. They found that in all cases, nanorods exhibited optimal 
(per particle) transport properties and 4.1 times more rapid transvascular penetration, the latter 
presumed to be due to reduced steric hindrance from and viscous drag near vessel pore walls. Chan 
and coworkers have found that citrate-gold nanospheres (14 and 74 nm TEM diameter) exhibit 
higher intracellular accumulation (per particle) in HeLa cervical carcinoma cells than either 14 × 40 
or 14 × 74 nm gold nanorods, with 50 nm spheres exhibiting the highest accumulation among a 
range of sizes/shapes. Readers may note however, that direct comparison between non-PEGylated 
gold nanospheres and nanorods can be difficult given the surface ligands present during their 
synthesis and the extent to which they can be exchanged and/or conjugated to match one another’s 
physiochemical properties. 
2.3 Challenges, Outlook, and Conclusions 
While tremendous advances in the clinical translation of therapeutic gold nanotechnologies 
have been forged over the past decade, there remains a substantial body of work yet to be performed 
in order to realize broad acceptance of these platforms as first-line treatment modalities. One area of 
particularly pressing concern is the potential toxicity of these constructs and their unintended impacts 
on human health. In order to meet this urgent need, the National Institute of Standards and 
Technology (NIST), the U.S. Food and Drug Administration (FDA), the National Cancer Institute 
(NCI) have established the Nanotechnology Characterization Laboratory (NCL) to aid researchers in 
the regulatory review, preclinical testing/evaluation, and eventual translation of nanotechnologies 
intended for cancer therapies and diagnostics. While critically important in the near-term, clinical 
translation would also benefit from longer-term studies investigating potential deleterious effects 
from chronic inflammation [133] associated with diminished clearance of these particle constructs, 
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potential mutagenicity, and effects on reproductive health. Researchers in the field may also be better 
served to dispel many common misconceptions about gold nanoparticles, such as i) their presumed 
high cost of production, ii) the notion that humans have not been exposed to these materials until 
recent years, and iii) the perception that the avidity or efficacy of multivalent gold nanoparticles 
should not be directly compared with their monovalent molecular counterparts. As just three 
examples: i) the gold content present in a full-course dosage of TNF α-gold nanoparticles recently 
administered in a Phase I clinical trial (NCT00356980; CytImmune Sciences, Inc.) [115] currently 
costs less than 12¢ per patient and the quantity of gold salt used to produce the nanorods 
administered in Dickerson et al. [46] currently costs less than 23¢ per mouse.[134] In comparison, 
CHO cell–based manufacturing of biologics costs roughly $150 per gram (e.g. Amgen, Genentech 
[135]), while the price of gold and ionic its salts is roughly $50 per gram Au. ii) Contrary to popular 
belief, recent studies indicate that nanoscale silver particles can readily leach from both Ag 
nanoparticles and bulk Ag earrings over the course of just weeks,[136] suggesting that human 
exposure to noble metal nanoparticles may date as far back as the advent of modern currency. iii) 
While it is understandable that some may argue that binding affinity and/or drug potency of a 
multivalent nanoparticle should be compared on a per-ligand or per-drug molecule basis, such 
contentions appear to ignore efficacy. It would seem illogical for an oncologist to discount the 
effectiveness of cisplatin or Avastin simply because they bear two distinct binding sites. Areas of 
research, such as high-throughput gold nanoconjugate synthesis/screening, low-cost models to predict 
excretion, and larger-scale in vivo characterization to allow direct side-by-side comparison of these 
constructs are currently underexplored and greatly needed. Going forward, one of the biggest 
challenges to systemically-deliverable gold nanotechnologies will be mass balance – that is – the 
demonstration of efficient clearance/excretion and accounting for the subsequent 
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accumulation/excretion of every µg of these drugs that are administered. Some areas of particular 
optimism include laser photothermal therapy for tumors in poorly accessible regions or those near 
vital organs/tissues (e.g. vocal cords, nerves, etc.), high-Z enhanced radiation therapy, isolated limb 
perfusion techniques, and intraoperative ablation of tumor margins. Given these challenges, those in 
the field should be mindful that although therapeutic gold nanotechnologies may have advanced 
quite rapidly into the clinic since their first proposed viable applications in biomedicine just 11 years 
ago,[114] compared with liposomal and monoclonal antibody technologies which took nearly 30 
years since their first description as potential therapeutic agents to receive FDA approval (See Table 
2.1), the field still has tremendous room for growth and further exploration of the new and exciting 
properties/functionality yet to be discovered and clinically applied. 
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LASER PHOTOTHERMAL CANCER THERAPY 
 
 The application of nanotechnology in medicine has been a rapidly growing field in recent 
years.[1-8] A variety of structures with unique structural,[9,10] optical,[11,12] electronic,[13] 
magnetic,[14] and catalytic [15] properties have been exploited in the areas of cancer imaging,[2,16-
19] diagnostics,[6,20,21] and treatment.[22-30] Noble metal nanoparticles provide remarkable 
opportunities in these applications due to their inherently low toxicity [31-33] and strongly enhanced 
optical properties associated with localized surface plasmon resonance.[34-36] The enhanced 
electromagnetic field surrounding such particles gives rise to large absorption, Rayleigh (Mie) 
scattering, raman scattering, and two-photon luminescence cross-sections, properties which have been 
utilized in photothermal cancer therapy (PTT),[24-30] surface enhanced Raman detection (SERS), 
[37-39] and diagnostic imaging [17-20] applications. 
While surgical excision of tumors is a highly effective method of cancer treatment, curative 
strategies for primary tumors located in vital or poorly accessible tissues remain a challenge. In cases 
of recurrent tumors or those with ill-defined margins, alternative and multimodal oncological 
approaches are employed. The primary [40-42] and adjunctive [43-46] treatment of cancers by 
induced hyperthermia is a well established but burgeoning field of medical research. Here, 
temperatures in tumor-loaded tissues are elevated to 40-43°C [47] and above by selective or non-
selective application of microwave, radio, ultrasound, alternating magnetic, infrared, or visible 
radiation. At temperatures greater than 43°C, protein denaturation and disruption of the cellular 
membrane is known to occur and ablation of tumor tissues has been shown in numerous 
cases.[42,48,49] Under mild temperature increases, clinical studies indicate an acceleration of both 
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perfusion and reoxygenation [50,51] of tumor tissues, thereby increasing the efficacy of cytostatic 
drug delivery (chemosensitization) and radiotherapy (radiosensitization), respectively. In all cases, 
clinical studies indicate statistically significant benefits to local tumor control and overall survival 
rates for primary [40-42] and conjunctive hyperthermia.[52-56] Although promising, conventional 
non-invasive hyperthermic strategies are often less selective than those based-on or used in 
combination with thermal contrast agents, in many cases, causing damage to surrounding healthy 
tissues, as well as significant discomfort. Moreover, hyperthermic treatments using commercially 
available instruments are often limited to shallow penetration depths [46] (<3 cm), lower treatment 
temperatures, and regions of the body with regular surface composition. Invasive approaches using 
microwave antennas are highly susceptible to interference, while magnetic particle treatments require 
large doses. 
Photothermal therapy [49,57-59] is a minimally-invasive treatment method in which photon 
energy is converted to thermal energy sufficient to induce cellular hyperthermia. Selectivity is 
achieved by focused directional control or invasive [40-42] (fiber optic) positioning of the incident 
radiation, often pulsed [28-30] or continuous wave [24-28,30,48] (cw) laser, and is typically 
accompanied by preferential administration of photoactive molecules [60-62] or nano-scale particles. 
Photoexcitation of the latter two results in non-radiative relaxation by local heat transfer to the 
surrounding tumor environment. In contrast, photodynamic therapy (PDT),[63-65] relies on non-
radiative relaxation through local formation of cytotoxic singlet oxygen species. While PTT and PDT 
treatments have garnered significant attention, such methods are inherently limited by 
photobleaching effects and absorption cross sections several times weaker than those of noble metal 
nanoparticles. 
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Recent advances in the field of plasmonics present new opportunities for both primary and 
multimodal PTT strategies using noble metal nanoparticles. By photo-exciting conduction electrons 
which oscillate at the surfaces of such structures (surface plasmons), highly efficient local heating can 
be achieved by non-radiative relaxation through electron-phonon and subsequent phonon-phonon 
coupling processes.[35] While several materials and spherical nanoparticles exhibit surface plasmon 
resonance in the visible region, opportunities for in vivo plasmonic photothermal therapy [8] (PPTT) 
are restricted due to a high degree of absorption by tissues at visible wavelengths. Such ablative 
treatments are therefore limited to shallow depths.[66] In contrast, PPTT of deep tissue malignancies 
may be accomplished by laser exposure and plasmon absorption in the near-infrared region (NIR). 
Due to minimal attenuation by water and hemoglobin at these wavelengths, NIR transmission [7] in 
soft tissues may be achieved at depths exceeding 10 cm. By chemically varying the shape or 
composition of noble metal nanoparticles,[9,21,24,67-69] surface plasmon absorption can be tuned 
from ultraviolet (UV) to infrared (IR) wavelengths. The enhanced nonlinear optical properties of 
spherical metal nanoparticles have also been used by our group in in vitro near-infrared pulsed laser 
PPTT by second harmonic generation.[29,70,71] 
 The potential uses of gold nanoparticles in near-infrared PPTT have been published using a 
variety of noble metal nanostructures, including gold nanoshells,[26,48] gold nanorods,[8,27,72] and 
recently, gold nanocages.[73] Studies using nanoshell-mediated PPTT indicate significantly 
improved local tumor control and survival times in animal models, while surface plasmon absorption 
of gold nanocages have been used in diagnostic imaging and in vitro therapy.[24] 
One of the simplest and widely used methods to obtain plasmonic nanoparticles involves the 
seed-mediated growth of colloidal gold nanorods.[68] The use of such particles in near-infrared 
PPTT is highly attractive due to their rapid synthesis, facile bioconjugation, strong absorption cross-
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section, and tunable optical extinction. Recent calculations by discrete dipole approximation (DDA) 
show the absorption cross section of nanorod structures to be nominally larger than that of nanocages 
and more than twice that of nanoshell structures at their NIR plasmon resonance.[73] By 
synthetically varying the aspect ratio of the nanorods, longitudinal plasmon absorption can be shifted 
throughout the visible, NIR, and IR regions.[68,74-76] 
Our previous work [27] showed that gold nanorods conjugated to epithelial growth factor 
receptor antibodies (anti-EGFR) can serve as contrast agents for in vitro biodiagnostics. Moreover, 
due to overexpression of the EGF receptor on cancer cell surfaces and the specificity of antibody 
binding, malignant cells were found to require half the energy necessary to destroy normal cells when 
both were incubated with the same concentration of nanorod bioconjugates, a key feature of selective 
PPTT.  
In the present work, the feasibility of in vivo near-infrared PPTT is demonstrated using 
colloidal gold nanorods in an animal model. Subcutaneous squamous cell carcinoma xenografts were 
grown in nude (nu/nu) mice and gold nanoparticles were selectively delivered to tumors by both 
direct and intravenous injection. Thiolated poly (ethylene) glycol (5 kDa) was covalently bound to 
the gold nanorod surface to increase biocompatibility,[77-80] suppress immunogenic responses, and 
to decrease adsorption to the negatively charge luminal surface of blood vessels. Near-infrared PPTT 
was performed extracorporally using a small, portable, inexpensive, continuous wave diode laser. 
Making use of the enhanced permeability and retention (EPR) effect,[81,82] preferential 
accumulation of PEGylated gold nanorods in tumor tissues was achieved due to the high density, 
extensive extravasation, and inherently defective architecture of the tumor vasculature, as well as the 
diminished lymphatic clearance from associated interstitial spaces. Significant decreases in tumor 
growth were observed for both direct tumor injection (P<0.0001) and intravenous (P<0.0008) 
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treatments. Inhibition of average tumor growth for both delivery methods was observed over a 13-
day period, with resorption of >57% of the directly-injected tumors and 25% of the intravenously-
treated tumors. 
3.1 Design and Development of Plasmonic Photothermal Cancer Therapy 
Synthesis and PEGylation of gold nanorods.  Seed-mediated growth was performed at 25 ºC 
from freshly prepared aqueous solutions (18 MΩ) following methods of Nikoobakht and El-
Sayed.[68] Briefly, 2.50 mL of 1.00 mM HAuCl4 (Aldrich, 24459-7) was added to 5.00 mL of 0.200 
M cetyltrimethylammonium bromide (CTAB, Aldrich). 600 µL of ice-cold 10 mM NaBH4 (Aldrich, 
480886) was added to the stirred solution and allowed to react for several minutes, forming the pale 
brown gold seed solution. Next, 100.0 mL of 1.00 mM HAuCl4 was added to 100.0 mL of 0.200 M 
CTAB and 4.50 mL of 4.00 mM AgNO3 (Fischer). 1.40 mL of 78.8 mM ascorbic acid (Aldrich, A-
7506) was added, followed by gentle mixing to form the transparent growth solution. 160 µL of the 
seed solution was added to the unstirred growth solution and allowed to react for 2 hours. Nanorods 
synthesized by this method are approximately 12 nm in width and 50 nm length (4.0 aspect ratio), 
with a longitudinal plasmon absorption maximum at 800 nm. 
Gold nanorod solutions were centrifuged twice at 20,000 x g for 15 min and re-dispersed in 
deionized water to remove excess CTAB molecules. mPEG-SH (Nektar Therapeutics, 5 kDa) was 
added to the ~1 nM colloidal nanorod solution at a final concentration of 10 mM. Rods were 
sonicated overnight and centrifuged at 20,000 x g for 15 min and redispersed in deionized water to 
remove excess PEG molecules. The PEGylated gold nanorods were again centrifuged at 20,000 x g 
for 15 min, sterile filtered, and re-dispersed in 10 mM phosphate-buffered saline (PBS, Mediatech) to 
the desired optical density at 800 nm. Extinction spectra of the PEGylated nanorod saline 
suspensions showed no peak shift, broadening, or reduction over a 1 week period prior to injection. 
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Cell culture and inoculation of mice with tumor cells. HSC-3 human squamous carcinoma cells 
(courtesy of Dr. Ivan H. El-Sayed - UCSF Dept of Otolaryngology) were cultured in DMEM 
(Mediatech) supplemented with 10% v/v heat-inactivated fetal bovine serum (Invitrogen), 2 mM L-
glutamine (Sigma), penicillin (100 U/ml) (Sigma), and streptomycin (100 µg/ml) (Sigma) in a 5% 
CO2 humidified atmosphere. Female nu/nu mice, 7-8 weeks of age, were obtained from Taconic 
(Hudson, NY). Mice were injected subcutaneously in the flank with 100 µL (3 x 106) HSC-3 cells 
suspended in 10 mM PBS. Near-infrared PPTT began once tumor burden reached 3 mm in 
diameter (7-9 days). All experiments were conducted with the approval of the Institutional Animal 
Care and Use Committee (IACUC) of the Georgia Institute of Technology (Atlanta, GA). 
Intratumoral nanoparticle accumulation, temperature, and imaging. Tumor bearing mice were 
injected with gold nanorods (ODλ=800 = 120, 100 µl) via the tail vein, and euthanized at specified 
time points. Tumor tissues was excised, fixed in 10% formalin for 24 hours, and embedded in 
paraffin blocks. Blocks were sectioned (5 microns) and stained using the Silver Enhancer Kit SE-100 
(Sigma-Aldrich) according to the manufacturer’s instructions. Incubation time for optimal 
visualization was determined to be 10 minutes. Silver staining of the tissue sections were examined 
using a BX60 Olympus microscope, and photographed using an Olympus Camedia digital camera.  
Thermal transient measurements of HSC-3 tumor interstitia were obtained using a 33 gauge 
hypodermic thermocouple (Omega). The tip of the thermistor was positioned at the tumor center-of-
mass and temperatures were recorded in 15 second intervals prior to, during, and following NIR 
exposure for direct (15 µL, ODλ=800=40, 10 min, 0.9-1.1 W/cm2, 6 mm dia) and intravenously (100 
µL, ODλ=800=120, 10 min, 1.7-1.9 W/cm2, 6 mm dia) administered gold nanorods, as well as for 
comparably exposed sham/NIR treatments (15 µL direct intratumoral injection of 10 mM PBS).  
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 In vivo imaging of PEGylated gold nanorod accumulation was monitored by attenuation of 
near-infrared transmission (808 nm diode laser, Power Technologies) using a custom-built CCD 
device array. Control measurements were taken from images obtained by 15 µL direct intratumoral 
injection of 10 mM PBS, while directly and intravenously administered measurements were obtained 
using previously mentioned dosages. 
In vivo near-infrared PPTT. Mice were anesthetized with ketamine/xylazine/acepromazine. 
15 µL of PEGylated gold nanorods (ODλ=800 = 40) were directly injected into the tumor interstitium 
or 100 µL of PEGylated gold nanorods (ODλ=800 = 120) were intravenously (tail) injected. Control 
tumor sites were injected with 15 µL of 10 mM PBS with no NIR exposure. For direct 
administration, mouse tumors were extracorporeally exposed to NIR radiation (0.9-1.1 W/cm2, 6 
mm dia, 10 min) within 2 minutes of injection to limit particle diffusion beyond the tumor 
boundaries. For intravenous administration, nanorods were allowed 24 hour circulation to maximize 
intratumoral particle accumulation prior to NIR exposure (1.7-1.9 W/cm2, 6 mm dia,10 min). 
Ellipsoidal tumor volume was calculated as V = (d)2(D)(π/6). Statistical hypothesis testing was 
performed using Welch’s t test and non-parametric analysis of variance was performed by the 
Kruskal-Wallis test. Due to the unusually rapid growth rates observed in the HSC-3 xenograft model, 
tumors and vital organs were harvested at day 14 for use in separate, ongoing toxicological 
investigations. 
3.2 Gold Nanorods as Highly Efficient Near-Infrared Photothermal Contrast Agents 
Intratumoral particle accumulation. PEGylated gold nanorods were intravenously injected 
(tail vein) to assess optimal intratumoral particle accumulation. Following injection, HSC-3 tumors 
were excised at varying time intervals, fixed, sectioned, and stained with silver to visualize the extent 
of particle loading. Nanorods directly injected into tumors were used as a positive control (data not 
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shown). Figure 3.1A shows a typical histological section from a HSC-3 tumor injected with 15 µL of 
10 mM PBS (control). Figures 3.1B,C illustrate representative tumor sections following 2 and 6 
hours of accumulation, respectively. At these time points, no appreciable accumulation of particles 
was observed. In contrast, high particle loading was observed following 24 hours of circulation 
(Figure 3.1D). Because the highest accumulation, and therefore PPTT selectivity, was observed at 24 
hours, this time point was used for subsequent intravenous near-infrared PPTT treatments. 
 
 
Figure 3.1. Histological sections of silver stained HSC-3 tumor xenografts from female nu/nu mice 
intravenously (tail) injected with (A) 100 µL of 10 mM PBS following 24 hr circulation and 
PEGylated gold nanorods (100 µL, ODλ=800=120) following (B) 2 hr (C), 6 hr, and (D) 24 hr 
accumulation. Direct injection of particles to the tumor interstitium was used as a positive staining 
control (data not shown). Arrow indicates staining of red blood cells (observed in all tumors). 
Adapted from Dickerson et al. [83]. 
 
 Transient particle accumulation following direct and intravenous administration was 
monitored by NIR transmission imaging (Figure 3.2). Intensity line-scans of NIR extinction showed 
marginal diffusion of directly injected particles over 3 min, with no subsequent change observed over 
several hours. Intensity line-scans from NIR transmission images of HSC-3 tumor sites directly 
injected with 15 µL of 10 mM PBS show nominal extinction due to increased tissue density, while 
line-scans obtained following intravenous nanorod delivery at 24 hr accumulation showed extinction 
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2.00 times that observed for control sites. Directly injected tumor sites showed NIR extinction (2 
min) more than 2.18 times greater than that observed by intravenous administration and 4.35 times 
that observed at control sites. 
 
 
Figure 3.2. NIR transmission images of mice prior to PPTT treatments. Inset shows intensity line-
scans of NIR extinction at tumor sites for control (■), intravenous (▲), and direct (●) administration 
of PEGylated gold nanorods. Control mice were interstitially injected with 15 µL 10 mM PBS alone, 
while directly administered mice received interstitial injections of 15 µL PEGylated gold nanorods 
(ODλ=800=40, 2 min accumulation), and intravenously administered mice recieved 100 µL PEGylated 
gold nanorod (ODλ=800=120, 24 hr accumulation) injections. Adapted from Dickerson et al. [83]. 
 
Thermal response measurements and nanorod accumulation. Thermal transient measurements 
for direct (Figure 3.3A) and intravenous (Figure 3.3B) near-infrared PPTT treatments show 
thermal equilibrium conditions prior to NIR irradiation. Rapid heating was observed upon exposure, 
followed by steady-state equilibrium. Note that >90% of the observed temperature increase occurred 
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within the first 3 minutes. Upon removal of NIR exposure, tissues displayed expected Newtonian 
cooling behavior. 
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Figure 3.3. Thermal transient measurements of HSC-3 tumor interstitia during (A) direct and (B) 
intravenous near-infrared PPTT (■) and sham/NIR (●) treatments using PEGylated gold nanorods. 
Direct PPTT treatments were performed by administration of 15 µL PEGylated gold nanorods 
(ODλ=800=40, 2 min accumulation) followed by 10 min of 0.9-1.1 W/cm2 NIR laser exposure. 
Intravenous PPTT treatments were performed by administration of 100 µL PEGylated gold 
nanorods (ODλ=800=120, 24 hr accumulation) followed by 10 min of 1.7-1.9 W/cm2 NIR laser 
exposure. Sham/NIR treatments were performed by administration of 15  µL 10 mM PBS and NIR 
laser exposure of comparable time and power density. Errors reported as SD. Adapted from 
Dickerson et al. [83]. 
 
Heating efficiencies of PPTT treatments (the ratio of steady-state temperature change in the 
presence of plasmonic particles to that in their absence) were found to be 3.59+0.5 for direct-
injection and 1.90+0.4 for intravenous injection of PEGylated gold nanorods. The former value is 
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remarkably similar to that observed during in vivo near-infrared PPTT treatments reported by Hirsch 
et al. [26] by direct injection of gold nanoshells. Observed increases in temperature change for 
sham/NIR treatments using comparable exposure times and power densities as direct and intravenous 
administration conditions correlate well with increases in power density. Disparity of direct and 
intravenous PPTT heating efficiency scales proportionately with observed increases in NIR extinction 
(4.35 and 2.00 times greater than control extinction, respectively) and is attributed to decreased 
particle loading by intravenous delivery. Although particle volume and concentration was 
significantly higher for intravenous injections, accumulation is likely limited by the extent of tumor 
angiogenesis and uptake by the reticuloendothelial system (RES). Treatment selectivity and efficacy 
was most apparent for direct injections; however, both methods showed significantly improved local 
tumor control. 
Tumor growth suppression: direct versus intravenous injection. Groups of four to six mice were 
initially used to establish optimal conditions for near-infrared PPTT treatment of HSC-3 tumor 
xenografts. 15 µl of PEGylated gold nanorods (ODλ=800=40) were directly administered at three sites 
within the tumor interstitium or 100 µL (ODλ=800=120) were intravenously injected (tail). After two 
minutes, tumors directly injected with nanorods were subjected to extracorporeal NIR exposure (808 
nm, 6 mm dia) and it was determined that 10-15 minutes of irradiation at 0.9-1.1 W/cm2 was 
necessary for significant tumor response and minimal damage to surrounding tissues. After 24 hours, 
tumors intravenously administered with nanorods were also subjected to extracorporeal NIR exposure 
(808 nm, 6 mm dia) and it was determined that 10-15 minutes of irradiation at 1.7-1.9 W/cm2 was 
necessary for significant tumor response and minimal damage to surrounding tissues. In addition, no 
statistically significant differences in tumor growth were observed for direct nanorod injections 
without NIR exposure, sham/NIR exposure alone, and PBS intratumoral injections alone (P=0.427 
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at day 9) (Figure 3.4). Figure 3.5 illustrates typically observed tumor resorption and growth 
inhibition following direct injection of PEGylated gold nanorods and near-infrared PPTT versus 
sham/NIR treatments. 
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Figure 3.4. Observed changes in HSC-3 xenograft growth for 15 µL ODλ=800=40 intratumoral 
PEGylated gold nanorod injections in female nu/nu mice without NIR exposure (■), 15 min 1.7-1.9 
W/cm2 NIR exposure alone (●), and 15 µL 10 mM PBS intratumoral injections (▲) alone (P=0.427 




Figure 3.5. Representative HSC-3 tumor resorption and growth inhibition in female nu/nu mice at 
day 13 following direct injection of EPGylated gold nanorods (15 µL, ODλ=800=40) and a single near-
infrared PPTT treatment (10 min, 0.9-1.1 W/cm2, 6 mm dia) versus sham/NIR treatment (15 µL, 
10 mM PBS) at the same NIR laser exposure power density and duration. Adapted from Dickerson 
et al. [83]. 
 
Using previously established treatment conditions, change in tumor volume was recorded 
over a 13 day period for control mice, as well as those treated by intravenous and direct nanorod 
injections followed by PPTT (Figure 3.6). Here, control mice were subjected to 15 µL direct 
injection of 10 mM PBS to the tumor interstitium, with no NIR exposure. Average change in tumor 
volume for each group was plotted (Figure 3.7) and statistical hypothesis testing for differences in 
average tumor growth was performed (Table 3.1). Figure 3.7 shows a >96% decrease in average 
tumor growth for directly treated HSC-3 xenografts and a >74% decrease in average tumor growth 
for intravenously treated HSC-3 xenografts at day 13 (relative to control tumors). Moreover, 
resorption of >57% of the directly treated tumors and 25% of the intravenously treated tumors was 
observed over the monitoring period. 
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Figure 3.6. Change in tumor volume following near-infrared PPTT treatment of HSC-3 xenografts 
by (A) control, (B) intravenous, and (C) direct injections of PEGylated gold nanorods. Control mice 
were treated by interstitial injection of 15 µL 10 mM PBS alone, while direct PPTT treatments were 
performed by administration of 15 µL PEGylated gold nanorods (ODλ=800=40, 2 min accumulation) 
followed by 10 min of 0.9-1.1 W/cm2 NIR laser exposure. Intravenous PPTT treatments were 
performed by administration of 100 µL PEGylated gold nanorods (ODλ=800=120, 24 hr 
accumulation) followed by 10 min of 1.7-1.9 W/cm2 NIR laser exposure. Adapted from Dickerson et 
al. [83]. 
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Figure 3.7. Average change in tumor volume for HSC-3 xenografts following near-infrared PPTT 
treatment by control (♦), intravenous (■), and direct (●) injection of PEGylated gold nanorods. 
Errors for control (n=10), direct injection (n=8), and intravenous injection (n=7) groups reported as 
standard error of the means. Control mice were treated by interstitial injection of 15 µL 10 mM PBS 
alone, while intravenous PPTT treatments were performed by administration of 100 µL PEGylated 
gold nanorods (ODλ=800=120, 24 hr accumulation) followed by 10 min of 1.7-1.9 W/cm2 NIR laser 
exposure. Direct PPTT treatments were performed by administration of 15 µL PEGylated gold 
nanorods (ODλ=800=40, 2 min accumulation) followed by 10 min of 0.9-1.1 W/cm2 NIR laser 
exposure. Adapted from Dickerson et al. [83]. 
 
Table 3.1. P-values for average volume change in HSC-3 tumors following near-infrared PPTT by 
808 nm irradiation of PEGylated gold nanorods. Adapted from Dickerson et al. [83]. 
 day 0 day 3 day 6 day 9 day 11 day 13 
direct vs control - 0.0003 0.001 0.0002 0.0001 0.0001 
tail vein vs control - 0.0136 0.0037 0.0005 0.0004 0.0008 
direct vs tail - 0.3415 0.1896 0.1936 0.1205 0.084 
 
Average tumor growth at day 13 for directly and intravenously treated tumors was 
significantly less than that observed in untreated control groups (P<0.0001 and P<0.0008, 
respectively). Differences in observed efficacy for direct and intravenous treatments gradually 
increased during the experiment, reaching statistical significance at the 8% level on day 13. Non-
parametric analysis of variance for the treated and untreated groups (Table 3.2) found statistically 
 100
significant differences at the 2% level and below for the duration of the experiment. These results 
clearly indicate both the selectivity and specificity of near-infrared PPTT. 
 
Table 3.2. Non-parametric analysis of variance for near-infrared PPTT treatment (2) and control 
groups. Adapted from Dickerson et al. [83]. 
day 0 day 3 day 6 day 9 day 11 day 13 
- 0.0024 0.0009 0.0008 0.0001 0.0005 
 
The dramatic changes in observed HSC-3 tumor growth are attributed to selective 
hyperthermia of malignant tissues treated with PEGylated gold nanorods by near-infrared PPTT. 
Preferential accumulation of PEGylated gold nanorods within the tumor interstitium occurs due to 
the EPR effect.[81] Because of their rapid metabolic rates, tumor cells are regarded as increasingly 
vulnerable to hyperthermic effects [44,72] such as disruption of metabolic signaling processes, 
protein denaturation, and the onset of acidosis or apoptosis caused by the production of heat-shock 
proteins [84] and other immunostimulants. Small increases in local temperature are known to result 
in disruption of nuclear and cytoskeletal assemblies and indeed, previous [44,85] and recent reports 
[29,72] indicate significant membrane blebbing [86-88] under hyperthermic conditions. Under 
severe conditions, hyperthermic damage can result in impaired vasculature supply, endothelial 
swelling,[44] and microthrombosis associated with homeostatic disruption.[89] In vitro, mild 
hyperthermia has been shown to impede the function of cell surface receptors, membrane transport, 
and RNA- and DNA-polymerization during protein synthesis. Repair of sublethal cell damage by 
DNA-polymerase-α and -β, such as that incurred during radiotherapy, has also been shown to be 
inhibited by hyperthermia. While tumor growth suppression and resorption is likely a cumulative 
result of the previously mentioned effects, it is presumed here that ablation of the tumor vasculature 
and localized membrane disruption predominates. 
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3.3 Outlook and Conclusions 
 Although the mechanism of cellular response in the present case is yet to be determined, the 
specificity of hyperthermic effects on tumor growth from both direct and intravenous near-infrared 
PPTT treatments is unmistakable (P<0.0001 and P<0.0008, respectively). Inhibition of average 
tumor growth and minimal damage to surrounding tissues is observed for both methods. Resorption 
of >57% of the directly-injected tumors and 25% of the intravenously-treated tumors clearly 
indicates the potential curative and adjunctive applications of NIR plasmonic photothermal therapy 
(PPTT) in pre-clinical settings. 
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GOLD NANOPARTICLES FOR THE TARGETED DIAGNOSIS/TREATMENT 
OF HORMONE-DEPENDENT TUMORS 
 
4.1 Antiestrogen Gold Nanoparticles 
4.1.1 Estrogen Receptor, Membrane Association, and Cancer 
Binding of the steroidal hormone 17β-estradiol (E2) to estrogen receptor (ER) is a process 
essential to normal cell proliferation and differentiation in women. E2 binding induces a 
conformational change in ER which allows it to recruit cofactors necessary for the transcription of 
various genes commonly upregulated in malignant cells [1] (e.g. transforming growth factor alpha,[2] 
c-myc,[3] and cathepsin D [4]. Accordingly, hormone receptors such as ER or progesterone receptor 
are overexpressed in 75–80% of all breast cancers.[5] Antiestrogen compounds, such as the small 
molecule breast cancer treatment drug tamoxifen (TAM) compete with E2 for binding to ER, 
conformationally preventing adoption of associated transcription cofactors and subsequently 
initiating programmed cell death.[6-9] 
Diagnostic and therapeutic applications of functionalized nanoparticles are highly attractive 
due to the inherently multivalent nature of their surface.[10-15] Like divalent antibodies, the binding 
affinity of a nanoparticle conjugate is enhanced proportional to the density of its binding sites. 
Receptor-mediated therapeutic response (i.e. potency) is similarly increased as a function of local 
ligand concentration and in cases where intracellular drug transport relies on passive diffusion, uptake 
of nanoparticle conjugates can greatly increase delivery rates.[16,17] Enhanced permeability and 
retention (EPR) of nano-sized drug conjugates can also lead to augmented and preferential 
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accumulation at tumor sites in vivo.[18,19] Due to their biocompatibility,[20,21] stability,[22] and 
potential use in photothermal laser treatments,[19,23-27] gold nanoparticles are excellent candidates 
for such ligand-receptor targeting strategies of cancer treatment. 
Selective targeting and delivery of gold nanoparticles functionalized with ligands of cell 
surface receptors overexpressed by malignant cells has been well documented. Huang et al. have 
shown that oral cancer cells that upregulate human epidermal growth factor receptor (EGFR, HER1, 
ErbB1) can be selectively labeled and photothermally destroyed by gold nanospheres and nanorods 
targeted with IgG antibodies.[25,28] ScFv fragments of anti-EGFR have also been used to selectively 
target and accumulate gold nanoparticles at tumor sites in vivo.[29] The folate receptor has been 
employed to selectively deliver gold nanospheres to malignant cells in vitro,[30] while Wei and 
coworkers have similarly demonstrated selective uptake and photothermal therapy of cancer cells 
using gold nanorods functionalized with a thiol-polyethylene glycol folate derivative.[26,31] 
Like several members of the hormone receptor family, ER isoforms are located both 
intracellularly and on the cell membrane.[11,32,33] Gold nanoparticle analogs of the commercial 
pharmaceutical tamoxifen could therefore act not only as, selective targeting agents, but also as 
increasingly potent endocrine treatments for malignancies which overexpress ER (e.g. breast cancer). 
To this aim, a thiol-polyethylene glycol (PEG-SH) tamoxifen derivative was synthesized for 
subsequent gold nanoparticle (AuNP) conjugation (Figure 4.1). A biocompatible [19,34] PEG-SH 
linker was employed (i) to enable covalent attachment to the AuNP surface (Au-S 126 kJ mol-1), 
[35,36] (ii) to minimize opsonin binding and reticulo-endothelial system uptake,[37] (iii) to suppress 
non-specific cell binding/uptake [38] and protein adsorption,[19,22] and (iv) to afford stability [22] 




Figure 4.1. A) Synthesis of thiol-PEGylated tamoxifen (TAM-PEG-SH) and (B) covalent 
attachment to 25 nm gold nanoparticles (AuNPs). Adapted from Dreaden et al. [39]. 
 
Our results have shown enhanced potency and selective intracellular delivery of tamoxifen-
targeted gold nanoparticles to ER(+) breast cancer cells in vitro. Particle uptake was observed in both 
a receptor- and ligand- dependent fashion with up to 2.7 −fold enhanced drug potency versus the free 
drug. Both delivery and therapeutic response were shown to be suppressed by estrogen competition. 
Optical microscopy/spectroscopy and cell viability indicate that augmented growth inhibition versus 
the free drug can be attributed to increased rates of intracellular TAM transport by cellular uptake of 
the nanoparticle conjugate. Receptor- and ligand- dependent nanoparticle delivery suggests that the 
plasma membrane localized estrogen receptor alpha may facilitate selective particle uptake and 
presents future opportunities for co-administration of laser photothermal therapy.[19,23-27] 
4.1.2 Design and Development of Antiestrogen and Antiangrogen Gold Nanoparticles 
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Synthesis of thiol-pegylated tamoxifen (TAM-PEG-SH). Octaethylene glycol (OEG), 
Tamoxifen, and all chemicals used in the synthesis were purchased from Sigma Aldrich. Anhydrous 
solvents and other reagents were purchased and used without further purification. Analtech silica gel 
plates (60 F254) were used for analytical TLC, and Analtech preparative TLC plates (UV 254, 2000 
µm) were used for purification. UV light was used to examine the spots. 200-400 Mesh silica gel was 
used in column chromatography. NMR spectra were recorded on a Varian-Gemini 400 magnetic 
resonance spectrometer. 1H and 13C NMR spectra were recorded in parts per million (ppm) relative 
to the peaks of CDCl3, (7.24 and 77.0 ppm, respectively). Mass spectra were recorded at the Georgia 
Institute of Technology mass spectrometry facility in Atlanta, GA. 
Synthesis of N-Desmethyl tamoxifen (1). The synthetic procedure was adapted from Olofson et 
al.;[40] briefly, tamoxifen (0.53 g, 1.43 mmol) was dissolved in anhydrous CH2Cl2 (15 ml) at 0 oC 
followed by addition of α-chloroethyl chloroformate (0.17 ml, 1.49 mmol). After 15 min at 0 oC, the 
reaction was refluxed for 24 h. The solvent was evaporated off to obtain a yellowish oil, to which 
methanol (10 ml) was added and refluxed for approximately 3 h. The solvent was evaporated off, and 
purification performed by gel filtration using CH2Cl2, then 10:1 CH2Cl2/CH3OH to obtain 0.52 g 
(91 %) of N-desmethyl tamoxifen 2. 1H NMR (DMSO, 400 MHz) δ 0.89 (3H, t, J = 7.2 Hz), 2.43 
(2H, q, J = 14.8, 7.6 Hz), 2.56 (3H, s), 3.12 (2H, t, J = 4.0 Hz), 4.08 (2H, t, J = 4.8 Hz), 6.57 (2H, 
d, J = 8.8 Hz), 6.76 (2H, d, J = 8.8 Hz), 7.03 – 7.31 (10H, m), 9.56 (1H, br); HRMS [FAB, mnba] 
(C25H27NO)+ calcd, 358.2171; found, 358.2198. 
Synthesis of Tosyl octaethylene glycol (2). The synthetic procedure was adapted from Bouzide 
and Sauvé.[41] Briefly, octaethylene glycol (0.50 g, 1.35 mmol) was dissolved in anhydrous CH2Cl2 
(7 ml) at 0 oC, followed by addition of freshly prepared Ag2O (0.47 g, 2.02 mmol), KI (0.09 g, 0.50 
mmol), and then TsCl (0.26 g, 1.35 mmol). The reaction mixture was left to stir at 0 oC, under 
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argon for 30 min, after which TLC deemed the reaction complete. Ag2O was filtered off over a pad 
of celite cake washing with 12:1 CH2Cl2/CH3OH. The filtrate was concentrated and purified on a 
silica column using 3:2, then gradually 1:4 CH2Cl2/acetone to yield the title compound as a colorless 
oil (0.55 g, 78 %). 1H NMR (CDCl3, 400 MHz) δ 2.44 (3H, s), 2.81 (1H, br), 3.58 – 3.70 (30H, 
m), 4.15 (2H, t, J = 4.8 Hz), 7.35 (2H, d, J = 8.4 Hz), 7.80 (2H, d, J = 8.4 Hz); HRMS [ESI] 
(C23H40O11S + H)+ calcd, 525.2364; found, 525.2377. 
Synthesis of Tamoxifen-OEG-OH (3). N-Desmethyl tamoxifen (1) (0.27 g, 0.68 mmol) and 
tosyl octaethylene glycol (2) (0.54 g, 1.05 mmol) were dissolved in anhydrous DMF (10 ml), 
followed by addition of K2CO3 (0.95 g, 6.85 mmol), and stirred under argon at ~ 85 oC for 24 h. 
DMF was evaporated off. Ethyl acetate was added to the residue and the resulting suspension was 
filtered off to remove excess K2CO3. Solvent was evaporated from the filtrate and the crude was 
purified by preparatory TLC using 12:1:0.1 CH2Cl2/CH3OH/NH4OH to obtain 0.342 g (70 %) of 
compound 3 as an oil. 1H NMR (CDCl3, 400 MHz) δ 0.90 (3H, t, J = 7.2 Hz), 1.85 (1H, br), 2.31 
(3H, s), 2.44 (2H, q, J = 14.0, 7.2 Hz), 2.64 (2H, t, J = 6.0 Hz), 2.76 (2H, t, J = 6.0 Hz), 3.53 – 
3.72 (30H, m), 3.91 (2H, t, J = 6.4 Hz), 6.54 (2H, m), 6.76 (2H, m), 7.10 – 7.40 (10H, m); 13C 
NMR (CDCl3, 100 MHz) δ 13.8, 29.2, 43.3, 50.7, 56.6, 57.2, 61.7, 65.6, 69.1, 70.3, 70.5, 70.6, 
70.7, 70.8, 73.0, 113.6, 126.2, 126.7, 128.0, 128.3, 129.7, 129.9, 132.1, 135.8, 138.4, 141.5, 
142.6, 144.0, 156.8; HRMS [ESI] (C41H59NO9 + H)+ calcd, 710.4262; found, 710.4253. 
Synthesis of Tamoxifen-OEG-Tosylate (4). Tamoxifen-OEG-OH (3) (0.33 g, 0.46 mmol) was 
dissolved in anhydrous CH2Cl2 (10 ml) at 0 oC, followed by addition of Ag2O (0.16 g, 0.69 mmol), 
KI (0.03 g, 0.18 mmol), and then TsCl (0.096 g, 0.5 mmol). Stirring was continued for 2 h at 0 oC, 
then at room temperature, overnight. Ag2O was filtered off through a pad of celite cake washing with 
ethyl acetate. Purification was performed on silica column eluting with 12:1 CH2Cl2/CH3OH 
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yielding the title compound as oil (0.24 g, 60 %). 1H NMR (CDCl3, 400 MHz) δ 0.91 (3H, t, J = 
7.2 Hz), 2.31 – 2.46 (8H, m), 2.71 (2H, br), 2.83 (2H, br), 3.57 – 3.70 (28H, m), 3.95 (2H, br), 
4.15 (2H, t, J = 4.4 Hz), 6.53 (2H, d, J = 8.4 Hz), 6.76 (2H, d, J = 8.8 Hz), 7.10 – 7.34 (12H, m), 
7.80 (2H, d, J = 8.4 Hz); LRMS [ESI] (C48H65NO11S + H)+ calcd, 864.1; found, 864.5. 
Synthesis of Tamoxifen-OEG-SAc (5). KSAc (0.079 g, 0.69 mmol) was added to tamoxifen-
OEG-Tosylate (4) (0.12 g, 0.14 mmol) dissolved in anhydrous THF and refluxed under argon at ~ 
75 oC for 16 h. TLC analysis indicated a substantial consumption of the starting material. THF was 
evaporated off, and the crude product dissolved in ethyl acetate. Decolorizing carbon was added and 
then filtered. Solvent was evaporated from the filtrate and the crude was purified by preparatory TLC 
using 12:1 CH2Cl2/CH3OH to obtain 50 mg (48 %) of 5 as reddish oil. 1H NMR (CDCl3, 400 
MHz) δ 1.03 (3H, t, J = 7.2 Hz), 2.45 (3H, s), 2.47 (3H, s), 2.56 (2H, q, J = 15.2, 7.6 Hz), 2.80 
(2H, t, J = 6.0 Hz), 2.91 (2H, t, J = 5.6 Hz), 3.21 (2H, t, J = 6.0 Hz), 3.70 – 3.80 (28H, m), 4.05 
(2H, t, J = 6.0 Hz), 6.66 (2H, d, J = 8.0 Hz), 6.88 (2H, d, J = 8.0 Hz), 7.22 – 7.46 (10H, m); 
HRMS [ESI] (C43H61NO9S + H)+ calcd, 768.4139; found, 768.4118. 
Synthesis of Thiol-peglated tamoxifen (6). Tamoxifen-OEG-SAc (5) (0.05 g, 0.065 mmol) was 
dissolved in acetone (1.5 ml) at 0 oC, followed by addition of 1M NaOH (1.5 ml) and stirring 
continued at 0 oC for 7 h. The reaction mixture was quenched with water (20 ml), and then extracted 
with 20 % CH3OH in CH2Cl2 (4 × 15 mL). The organic layers were combined, dried under sodium 
sulfate, evaporated and purified on preparatory TLC using 11:1 CH2Cl2/CH3OH to give 10 mg (21 
%) of the title compound as reddish semi-solid. 1H NMR (CDCl3, 400 MHz) δ 0.90 (3H, t, J = 7.2 
Hz), 2.32 (3H, s), 2.44 (2H, q, J = 8.0,7.6 Hz), 2.65 (2H, t, J = 6.0 Hz), 2.76 (2H, t, J = 6.4 Hz), 
2.85 (2H, t, J = 6.8 Hz), 3.53 – 3.72 (28H, m), 3.91 (2H, t, J = 6.0 Hz), 6.52 (2H, d, J = 8.8 Hz), 
6.74 (2H, d, J = 8.8 Hz), 7.08 – 7.32 (10H, m); 13C NMR (CDCl3, 100 MHz) δ 13.5, 28.9, 29.6, 
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38.3, 43.3, 56.4, 57.0, 65.6, 69.2, 69.6, 70.3, 70.4, 70.5, 70.6, 113.3, 125.9, 126.4, 127.8, 128.0, 
129.4, 129.6, 131.8, 135.4, 138.1, 141.2, 142.3, 143.7, 156.6; HRMS [ESI] (C41H59NO8S]+ calcd, 
725.3961; found, 725.4011. 
Gold nanoparticle synthesis and TAM-PEG-SH conjugation. Gold nanoparticles (25 nm dia) 
were synthesized by Turkevich reduction of chloroauric acid.[42] Briefly, 20 mL of 3.5 mg/mL 
aqueous sodium citrate was added to 200 mL of 1.0 mM aqueous HAuCl4 under reflux, with 
stirring. The solution was refluxed for 15 min, then removed from the heat and stirred for an 
additional 30 min. Excess sodium citrate was removed from the crude AuNP solution by 
centrifugation (13,000 × g). 
TAM-PEG-SH (5 mg) was solubilized in 100 µL ethanol and diluted to 0.5 mM in 
deionized water. 0.5 mM PEG-SH (5 kDa, Lysan Bio) was solubilized in deioninized water and 
PEG-SH or a 1:1 ratio TAM-PEG-SH and PEG-SH were added at a 1.4 × 104 -fold molar excess to a 
concentrated solution of citrate-capped AuNPs followed by overnight sonication. Particle 
concentration was estimated using the molar extinction coefficient for 23 nm citrate-capped gold 
nanospheres determined by Orendorff and Murphy (1.3 × 109 M-1cm-1).[43] TAM-PEG-SH AuNP 
conjugates were dispersed in DMEM growth media supplanted with 10% v/v heat-inactivated fetal 
bovine serum, penicillin (100 U/ml), streptomycin (100 µg/ml), 4.5 g/L glucose, 4.5 g/L sodium 
pyruvate, without L-glutamine and phenol red to final ligand concentrations of 0.1, 0.5, 1, 2, 5, 10, 
and 20  µM and used immediately. 
Gold Nanoparticle and Bioconjugate Characterization. Gold nanoparticles were analyzed by 
diffraction-contrast Transmission Electron Microscopy (TEM, JEOL 100CX II) and UV-Vis 
absorption spectroscopy (Ocean Optics, HR4000CG-UV-NIR). Absorption of TAM-PEG-SH at 
280 nm was used to quantify the number of bound TAM-PEG-SH ligands per nanoparticle. An 
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aqueous solution of gold nanospheres was incubated with a 1.4 × 104 -fold molar excess of both 
TAM-PEG-SH and PEG-SH overnight with sonication. Nanoparticle-conjugates were removed 
from solution by centrifugation (45 min, 13,000 × g) and the observed change in UV absorption 
(280 nm) before and after nanoparticle conjugation was used to approximate the number of bound 
ligands.  No contribution to absorption by PEG-SH was observed at these wavelengths and it 
assumed to occupy the majority of the remaining surface sites. 
Zeta potential of the gold nanoparticles and conjugates was measured using a NanoZS 
Zetasizer particle analyzer (Malvern) equipped with a 633 nm laser. 
 Cell culture and nanoparticle incubation. ERα(-) MDA-MB-231 and ERα(+) MCF-7 breast 
cancer cells (human adenocarcinoma, ATCC) or ERα(+) human squamous cell carcinoma [44-46] 
(HSC-3) cells were cultured to 105 cells/cm2 in DMEM growth media supplanted with 10% v/v 
heat-inactivated fetal bovine serum, penicillin (100 U/ml), streptomycin (100 µg/ml), 4.5 g/L 
glucose, 4.5 g/L sodium pyruvate, without L-glutamine and phenol red at 37 °C in a 5% CO2 
humidified atmosphere. Growth media was removed from the cell cultures and replaced with 
identical media containing gold nanoparticle conjugates heated to 37 °C at time = 0 h. 
Cell viability assay. Following incubation, growth media containing gold nanoparticle 
conjugates was removed and cells were rinsed twice in sterile Dulbecco’s phosphate buffered saline 
(DPBS). Mitochondrial dehydrogenase activity was assessed by MTT or XTT spectrophotometric 
assay (Sigma TOX1, TOX2) following the manufacturer’s instructions. The assay was performed 
using a SpectraMax Plus 384 microplate reader and statistical analysis was performed by t-test. 
Selected-area absorption microspectrometry and dark-field scattering microscopy. Collagen-coated 
growth substrates were prepared by immersion of 18 mm dia glass coverslips in ethanol, followed by 
30 min UV sterilization. Coverslips were immersed in a 0.22  µm filtered 0.04 mg/mL collagen 
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(Roche) solution - prepared by solubilization in 5 mL 1% v/v aqueous acetic acid and dilution in 250 
mL sterile DPBS for 6 h at 37 °C in a 5% CO2 humidified atmosphere. The coated substrates were 
rinsed in sterile DPBS and placed in 12-well plates immediately prior to cell passage. Following 
incubation with gold nanoparticle conjugates, substrates were twice rinsed in sterile DPBS buffer and 
cells were fixed in cold 4 % wt/wt paraformaldehyde in DPBS buffer for 15 min. Coverslips were 
coated in glycerol, then mounted and sealed onto glass slides. 
Dark-field microscopy was performed using an inverted objective Olympus IX70 microscope 
fitted with a dark-field condenser (U-DCW), 100x/1.35 oil Iris objective (UPLANAPO), tungsten 
lamp, and a Nikon D200 digital SLR camera. Optical extinction spectra were obtained in a 
transmission configuration using a SEE110 absorption microspectrometer fitted with a pinhole 
aperture, fiber optic-coupled CCD array detector, 50 × objective, and tungsten lamp. Periodic 
oscillations observed in some spectra are the result of interference between adjacent surfaces of the 
glass slides. 
4.1.3 Preclinical Evaluation of Antiestrogen and Antiandrogen Gold Nanoparticles 
The crude AuNP colloid (ca. 3 nM) was found by TEM to be predominantly comprised of 
25 nm gold spheres exhibiting an extinction maximum at 530 nm (Figure 4.2). Based on the change 
in UV absorption (280 nm) of TAM solutions following nanoparticle conjugation and removal, we 
estimate 12,000 TAM-PEG-SH ligands per particle - 41 % of the maximum theoretical surface 
coverage for a 25 nm dia Au (111) surface. A change in zeta potential from -38.4 mV to -5.79 mV 
was also observed following TAM-PEG-SH functionalization. To preserve aqueous stability, TAM-
PEG-SH AuNPs were not centrifuged prior to in vitro experiments, leaving 13 % of free drug in 
solution. For comparison, concentrations for the nanoparticle conjugate are reported as effective ligand 
concentration (i.e. TAM-PEG-SH) throughout. 
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Figure 4.2. Transmission electron microscopy (left) and optical extinction (right) of gold 
nanoparticles used in tamoxifen-targeting experiments. Adapted from Dreaden et al. [39]. 
 
Dark-field scattering microscopy was performed to assess intracellular nanoparticle uptake. 
Figure 4.3 illustrates representative images of ERα(+) [MCF-7, top] and ERα(-) [MDA-MB-231, 
bottom] breast cancer cells incubated for 24 h with 1 µM TAM-PEG-SH AuNPs and PEG-SH 
AuNPs. ERα(+) breast cancer cells displayed a high degree of intracellular and perinuclear 
localization of TAM-PEG-SH AuNPs, while ER(-) breast cancer cells showed no such labeling. 
These findings are consistent with both reported expression levels and cellular localization [47] of 
ERα in MCF-7 [48-50] and MDA-MB-231 [49,51] cell lines. As anticipated,[38] AuNPs labeled 
only with PEG-SH exhibited no apparent cellular labeling or uptake for either ERα(+) or ERα(-) 
breast cancer cells. Uptake of TAM-PEG-SH AuNPs by ERα(+) breast cells was observed to be time-
dependent, with marginal cell surface labeling at 2-6 h and a high degree of perinuclear and 
cytoplasmic localization at 24 h (Figure 4.4). To further demonstrate ER expression-dependent 
targeting, ERα(+) human squamous [HSC-3] oral cancer cells were incubated for 24 h in the 
presence of 1 µM TAM-PEG-SH AuNPs and PEG-SH AuNPs. Dark-field scattering images from 
HSC-3 cells show selective uptake of the TAM-PEG-SH AuNPs in a manner similar to that obtained 
from MCF-7 breast cancer cells (Figure 4.5). Selected-area optical extinction spectra obtained from 
the ERα(+) and ERα(-) breast cells exhibited AuNP surface plasmon extinction exclusively from 
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perinuclear regions of ERα(+) cells incubated with TAM-PEG-SH AuNPs (s/n~10) (Figure 4.6). 
Extinction from PEG-SH AuNPs was not observed from either cell line. 
 
 
Figure 4.3. Dark-field scattering microscopy showing ligand- and receptor- dependent intracellular 
targeting of breast cancer cells by gold nanoparticle conjugates.  Representative dark-field scattering 
images of ERα(+) [MCF-7, top] and ERα(-) [MDA-MB-231, bottom] human adenocarcinoma cells 
incubated for 24 h with 1  µM TAM-PEG-SH AuNP (left) and PEG-SH AuNP (right) conjugates 




Figure 4.4. Dark-field scattering images of time- and ERα expression- dependent intracellular 
delivery of TAM-PEG-SH AuNPs (1 µM) to ERα(+) (MCF-7, left) and ERα(-) (MDA-MB-231, 
right) breast cancer cells. Adapted from Dreaden et al. [39]. 
 
 
Figure 4.5. Comparison of ligand-dependent intracellular targeting selectivity with estrogen receptor 
positive oral cancer cells.  Representative dark-field scattering images of human squamous cell 
carcinoma (HSC-3) cells incubated for 24 h with 1 µM TAM-PEG-SH AuNPs (left)  and PEG-SH 
AuNPs (right). Adapted from Dreaden et al. [39]. 
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Figure 4.6. Optical imaging and spectroscopy showing receptor- and ligand- dependent perinuclear 
localization of tamoxifen-gold nanoparticle conjugates in breast cancer cells (s/n~10).  Representative 
microscopic images and selected-area optical extinction spectra obtained from ERα(+) MCF-7 breast 
cancer cells incubated for 24 h with (A) 1 µM TAM-PEG-SH AuNPs  and (B) unfunctionalized 
(PEG-SH) AuNPs, as well as ERα(-) MDA-MB-231 breast cancer cells incubated for 24 h with (C) 1 
µM TAM-PEG-SH AuNPs  and (D) unfunctionalized (PEG-SH) AuNPs. Adapted from Dreaden et 
al. [39]. 
 
Figures 4.7A,B illustrate time-dependent dose-response curves for cell viability of ERα(+) 
MCF-7 breast cancer cells incubated with equivalent concentrations of TAM-PEG-SH as the free 
drug and the nanoparticle conjugate, respectively. A comparison of the time-dependent IC50 (50% 
inhibitory concentration) values obtained for the free drug and its AuNP conjugate indicate 1.3 - 2.7 
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fold enhanced potency (Figure 4.7C) for TAM-PEG-SH AuNPs. While IC50 values for TAM-PEG-
SH alone are comparable to or better than those previously reported for MCF-7 breast cancer cells 
treated with both tamoxifen [44] and its active metabolite,[52] a much more dramatic improvement 
is observed upon nanoparticle ligation, in contrast to the free drug, with significant growth inhibition 
observed for TAM-PEG-SH AuNPs at both 6 and 12 h incubation (6.4 and 2.4 µM IC50, 
respectively). In accordance with previous studies,[20] no cytotoxic effects were observed in MCF-7 
cells treated with PEG-SH AuNPs at the highest concentrations and incubation times used in the 
present study (P>0.75). Moreover, cytotoxic effects were not observed in ERα(-) MDA-MB-231 
breast cancer cells incubated with TAM-PEG-SH alone, PEG-SH AuNPs, or TAM-PEG-SH AuNPs 
at the highest concentrations and incubation times used in the present study (P>0.28, 0.33, and 0.11, 
respectively). Although differences in sensitivity to and rates of particle/drug uptake and metabolism 
for ERα(+) and (-) cell lines may contribute to variation in apparent cytotoxicity, the observed 
ligand-dependency correlates well with levels of cellular ER expression, particularly under the 
conditions of extended incubation time and excess concentration used. In addition, cell viability 
following incubation with TAM-PEG-SH AuNPs in the absence of free drug was found statistically 
insignificant in difference from that observed in its presence. Here, AuNPs functionalized with 
TAM-PEG-SH equivalent to that present at the 24 h IC50 of the conjugate in the presence of free 
drug subsequently exhibited 57 + 14 % cell viability (P>0.6). The lack of significant growth 
inhibition by the free drug at short incubation times, together with an observed decrease in the 
disparity between IC50 values of the free drug and the AuNP conjugate over time, and the apparent 

















































































Figure 4.7. Time-dependent dose-response curves for cell viability of estrogen receptor alpha positive 
[MCF-7] breast cancer cells incubated with equivalent concentrations of TAM-PEG-SH (A) as a free 
drug and (B) as a gold nanoparticle conjugate.  C) Time-dependent IC50 (50% inhibitory 
concentration) values showing 1.3 – 2.7 times enhanced potency from the nanoparticle conjugate 
versus the free drug. Error bars represent SD.  3.6, 1.4, 1.1 µM TAM-PEG-SH IC50 (24, 36, 48 h, 
respectively) versus 6.4, 2.4, 1.3, 1.0, 0.88 µM TAM-PEG-SH AuNP IC50 (6, 12, 24, 36, 48 h, 
respectively). Adapted from Dreaden et al. [39]. 
 
Although our results with the HSC-3 cell line, an ERα(+) oral cancer cell line, further 
attested to the role of ERα in nanoaprticle uptake, it is however conceivable that particle lipophilicity 
could also contribute to differences cellular uptake and cytotoxicity. In light of this possibility, 
blocking experiments were performed using ERα's endogenous ligand 17β-estradiol (estrogen) to 
further confirm receptor-dependent targeting and therapeutic response. ERα(+) MCF-7 breast cells 
were incubated overnight with increasing concentrations of estrogen, followed by 24 h incubation 
with 10 µM TAM-PEG-SH AuNPs. Image overlays from bright-field transmission and dark-field 
scattering microscopy of these cells (Figure 4.8,9) indicate near complete suppression of TAM-PEG-
SH AuNP intracellular localization at estrogen concentrations as low as 20 nM. Decreased cell 
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surface labeling was also observed with increasing estrogen concentration. Such competitive effects 
are in agreement with previous reports indicating 1-2 orders of magnitude greater ERα binding 
affinity for 17β-estradiol versus TAM.[53] Cell viability experiments with ERα(+) breast cells 
incubated for 24 h with 10 µM TAM-PEG-SH AuNPs and previously blocked overnight with 
equimolar concentrations of estrogen were also performed (Figure 4.10). As in previous studies with 
the free drug,[8] the cytotoxic activity of TAM-labeled AuNPs was near completely suppressed 
following pre-exposure of the cells to estrogen (P>0.87), while they retained optimal potency in the 
absence of estrogen (P<0.0001). These findings correlate ERα binding with both TAM-PEG-SH 
AuNP intracellular localization and subsequent cell death. 
 
 
Figure 4.8. Representative dark-field scattering (red) and bright-field transmission (green) image 
overlays of TAM-PEG-SH AuNP competitive binding following 24 h incubation with 17β-estradiol.  
ERα(+) breast cancer cells [MCF-7] were incubated overnight with increasing concentrations of 
estrogen, followed by 24 h incubation with 10 µM tamoxifen-gold nanoparticle conjugates. Adapted 




Figure 4.9. Representative dark-field scattering images of TAM-PEG-SH AuNP competitive binding 
following overnight incubation with estrogen.  ERα(+) breast cancer cells [MCF-7] were incubated 
overnight with increasing concentrations of 17β-estradiol, followed by 24 h incubation with 10 µM 
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Figure 4.10. Suppression of TAM-PEG-SH AuNP activity by estrogen competition in ERα(+) 
breast cancer cells.   Growth inhibition of MCF-7 cells incubated for 24 h with 10 µM TAM-PEG-
SH AuNPs when previously untreated (left) and treated overnight with 10 µM 17β-estradiol (right). 
Adapted from Dreaden et al. [39]. 
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The ERα expression-dependent uptake observed here also suggests that the cell membrane-
associated receptor may facilitate intracellular nanoparticle transport. Indeed, plasma membrane 
localized ERα is well documented, as is its recognition of both antibody epitopes for the nuclear 
receptor and 17β-estradiol in mammalian cells.[11,32] The functions of membrane ERα beyond 
classical gene transcription, and more recently membrane-initiated signaling, are however less 
understood.[54] Comprehensive studies by Levin and coworkers indicate intracellular transport and 
caveolar localization of ERα in the plasma membrane of MCF-7 cells in vitro (via caveolin-1 and -2 
association).[50] In order to determine whether plasma membrane localized ERα could contribute to 
receptor-mediated endocytosis of TAM-PEG-SH AuNP conjugates, cytotoxicity was examined under 
conditions of negligible endocytotic activity. MCF-7 cell viability was shown to increase by 87 + 2 % 
following incubation with 20 µM TAM-PEG-SH AuNPs for 6 h at 4 °C versus 37 °C (P<0.04), 
indicating that endocytosis – in addition to ERα binding and intracellular particle delivery – is 
required for therapeutic response from tamoxifen-labeled AuNP conjugates.  
4.1.4 Outlook and Conclusions 
In summary, tamoxifen-gold nanoparticle conjugates were shown to selectively target 
estrogen receptor alpha in human breast cancer cells with up to 2.7 times enhanced potency in vitro. 
Optical microscopy and spectroscopy indicate a high degree of perinuclear and cytoplasmic 
localization of the targeted particles, while neither localization nor cytotoxic effects were observed 
from the untargeted nanoparticles. Time-dependent dose-response studies show that augmented 
potency results from increased rates of drug transport by nanoparticle uptake versus passive diffusion 
of the free drug. Receptor-selective and estrogen-competitive cytotoxicity/uptake of the nanoparticle 
conjugates indicates no additive effects associated with the gold particles themselves and suggests that 
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plasma membrane-localized ERα may facilitate selective endocytotic transport of these and other 
therapeutic nanoparticle conjugates. Increased potency and selective intracellular delivery of 
tamoxifen-gold nanoparticle conjugates provides opportunities for further enhancement by co-
functionalization or adjunctive laser photothermal therapy. 
4.2 Antiandrogen Gold Nanoparticles 
4.2.1 Androgen Receptor, Membrane Association, and Cancer 
Prostate cancer is the most commonly diagnosed cancer among men in developed 
countries.[55] One in six males in the US [56] and one in nine males in the UK [57] will develop the 
disease at some point during their lifetime. Despite tremendous advances in prostate cancer 
screening, more than a quarter million men die from the disease every year [55] due primarily to 
treatment-resistance and metastasis. Colloidal nanotechnologies can provide tremendous 
enhancements to existing targeting/treatment strategies for prostate cancer to which malignant cells 
are less sensitive. Here, we show that antiandrogen gold nanoparticles – multivalent analogs of 
antiandrogens currently used in clinical therapy for prostate cancer – selectively engage two distinct 
receptors involved in treatment-resistant prostate cancer. These particles were found to preferentially 
accumulate in hormone-insensitive and chemotherapy-resistant prostate cancer cells and exhibited 
>104-fold enhanced drug potency versus antiandrogens currently in clinical use. These antiandrogen 
gold nanoparticles bound androgen receptor with the highest affinity reported to-date (to our 
knowledge) and showed for the first time that multivalent antiandrogens can act as agonists for a 
newly discovered G protein-coupled receptor involved in prostate cancer risk, progression, and 
survival. 
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Androgen deprivation therapy (ADT) is currently recommended for the treatment of 
advanced/metastatic prostate cancer.[58] Nonsteroidal antiandrogens such as flutamide (Eulexin®), 
bicalutamide (Casodex®), and nilutamide (Nilandron®) are some of the most commonly prescribed 
ADT drugs and diminish androgenic effects by competitively inhibiting androgen-androgen receptor 
binding associated with prostate cancer growth, division, and survival. While most advanced or 
metastatic prostate cancers initially respond well to ADT, malignant cells that survive 2–3 years will 
typically enter an antiandrogen-resistant [59] (i.e. castration-resistant) state and subsequently exhibit 
chemotherapy-resistance as well.[60] Without further intervention, median survival following this 
period is just 18–24 months. Increasingly selective and potent drugs are urgently needed to treat 
these prostate cancers. 
Nanoscale drug conjugates can provide improved targeting selectivity for prostate cancer 
treatments via multivalent ligand display (augmented affinity and avidity) and size-dependent passive 
accumulation; they can also realize increasing potency through high drug loading capacity and 
enhanced intracellular transport rates (endocytosis versus passive diffusion). Langer, Farokhzad, and 
Lippard have shown that PLGA nanoparticles targeted with aptamers towards prostate-specific 
membrane antigen can deliver platinum prodrug chemotherapeutics to prostate cancer cells with 
substantially greater drug potency than untargeted carriers or cisplatin alone.[61,62] Folate-targeted 
lipid nanoparticles have also been applied in gene therapy [63] and RNA interference [64] for 
prostate cancer in vivo. Katti and Kannan have shown that gold nanoparticles targeted with 
bombesin peptides directed towards gastrin-releasing peptide receptor (overexpressed on prostate 
cancer cells) selectively target prostate cancer cells in vitro/vivo with multivalent affinity and can 
provide enhanced contrast for x-ray computed tomography (CT) imaging.[65] Neoadjuvant 
administration of gold nanoparticles has been further shown to sensitize prostate cancer cells towards 
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external beam radiation therapy [66] and to facilitate in vivo laser photothermal ablation therapy in 
animal models of prostate cancer.[67] 
We hypothesized that derivatives of commercially-available antiandrogen chemotherapeutics 
could serve as combined targeting and therapeutic agents for tissue-selective drug delivery of 
nanoscale drug carriers to prostate cancers expressing membrane androgen receptor [68,69] and/or a 
recently deorphaned androgen-sensing G protein-coupled receptor, GPRC6A,[70] involved in 
increased prostate cancer risk, growth, and poor survival. We found that multivalent antiandrogen 
gold nanoparticles selectively target and engage both androgen receptor and GPRC6A and facilitate 
cell death in antiandrogen treatment-resistant prostate cancer cells at concentrations more than four 
orders of magnitude lower than their corresponding free drugs. Antiandrogen gold nanoparticles 
bound androgen receptor with the highest affinity reported to-date (to our knowledge). These 
platforms provide opportunities for further increased treatment efficacy via drug co-conjugation, laser 
photothermal ablation, radiotherapy sensitization, and imaging-based treatment 
guidance/monitoring.[71,72] 
4.2.2 Design and Development of Antiestrogen and Antiangrogen Gold Nanoparticles 
Nanoparticle Synthesis and Characterization. Gold nanoparticles were synthesized using the 
methods of Turkevich[42] and Frens.[73] Briefly, 10 mL of 16.6 mM trisodium citrate was rapidly 
added to 190 mL of 0.638 mM aqueous chloroauric acid solution under reflux with stir. The 
solution was allowed to react for 20 min and the crude nanoparticle product was centrifuged (4185 × 
g) for 20 min. Particle sizing was performed using transmission electron microscopy (TEM, JEOL 
100CX II) and image analysis software (ImageJ). Octanol/water partition coefficient (log P) was 
determined using the shake-flask method and experimentally determined particle molar extinction 
cross sections reported by Liu et al. for a 26 ± 6 nm diameter gold nanoparticle.[74] Hydrodynamic 
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diameter was measured using a NanoZS Zetasizer particle analyzer (Malvern, 633 nm). Optical 
extinction was characterized by UV-Vis absorption spectroscopy (Ocean Optics, HR4000CG-UV-
NIR). Particles used in these studies were 29 ± 4 nm in diameter (λmax~532 nm). 
Conjugation of the Nanoparticles. Thiol-PEGylated antiandrogen ligands were solubilized in 
DMSO and added to aqueous solutions of purified gold nanoparticles at varying molar excesses and 
allowed to react overnight under sonication, in dark, at 30 ºC. The conjugates were purified by 
centrifugation (30 min, 4185 × g) and stored at 4 ºC prior to use. Surface adsorbate coverages were 
determined by UV absorption assay (α-Bic, 280 nm; β-Bic, 262 nm) using experimentally 
determined cross sections for the particle [74] and ligand. α-Bic and β-Bic nanoconjugates used in 
these studies were functionalized with 95% PEG-thiol (5 kDa, Lysan Bio) and 5% antiangrogen 
ligand (2.25 ± 0.02 × 103 α-Bic particle-1; 1.56 ± 0.08 × 103 β-Bic particle-1) and were conjugated at a 
1.0378 × 104 and 1.5567 × 104 molar excess of thiolated ligands, respectively. Control particles were 
fully PEGylated. 
Cell Culture and In Vitro Analysis. DU-145 human prostate carcinoma cells (ATCC) were 
subcultured in Dulbecco's modified eagle's medium (DMEM) supplanted with 10% v/v fetal bovine 
serum (FBS), 20 I.U./mL penicillin, 100 ug/mL streptomycin, and 250 ng/mL amphotericin B at 37 
ºC in a 5% CO2 humidified atmosphere. Cell viability was determined from mitochondrial 
dehydrogenase activity by tetrazolium assay (XTT, Sigma). All experiments were performed on cells 
passaged 12 h prior. Unless otherwise noted, nanoparticle concentration indicates particle molarity. 
Radioligand Binding. Radioligand binding (Ricerca Biosciences) was performed using rat 
androgen receptor and [3H]mibolerone (PanVera) in triphosphate buffer (pH 7.4). 78 ng of AR was 
incubated with 1.5 nM [3H]mibolerone for 4 h at 4 ºC, then incubated with a hydroxyapatite slurry 
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over 15 minutes and filtered. The filters are washed 3 times and counted to determine 
[3H]mibolerone specifically bound. 
GPRC6A Expression and Stimulation. PC-3, 22Rv1, and LNCaP prostate carcinoma cells 
(ATCC) and non-malignant RWPE-1 prostate cells (ATCC) were subcultured in RPMI 1640 
supplemented with 10% v/v fetal bovine serum (Gibco). Cells (103 well-1) were cultured in triplicate 
in 96-well flat-bottomed microculture dishes in the presence and absence of various compounds for 
72 hr. Gprc6a expression levels were analyzed by total RNA levels isolated using a quantitative real-
time polymerase chain reaction RT-PCR protocol (Perkin-Elmer), as described previously.[70] 
Briefly, PCR reactions contained 100 ng of template (cDNA or RNA), 300 nM each of forward and 
reverse primer, and 1× iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) in 50 µL. Samples 
were amplified for 40 cycles in an iCycler iQ Real-Time PCR Detection System (Bio-Rad) with an 
initial melt at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute. PCR product accumulation was monitored at multiple points during each cycle by 
measuring the increase in fluorescence caused by the binding of SybrGreen I to dsDNA. The 
threshold cycle (Ct) of tested-gene product from the indicated genotype was normalized to the Ct for 
cyclophilin A. The primers for human Gprc6a consisted of hGPRC6A.F130: cataattggaggtttgtttgc 
and hGPRC6A.R346: cactgtgacttctgtacaagtgtc. Dissociation analysis was used to confirm the 
presence of a single transcript and lack of primer-dimer amplification in all PCR reactions. 
Cyclic adenosine monophosphate (cAMP) accumulation in response to GPRC6A 
stimulation was determined via spectrophotometric enzyme-linked immunosorbent assay (EIA kit, 
Cayman Chemical) of GPRC6A-/AR- HEK-293 (ATCC) and transfected [75] GPRC6A+/AR- HEK-
293.mGPRC6A cell extracts according to the manufacturer’s instructions. HEK-293 (ATCC) and 
HEK-293.mGPRC6A cells (105 well-1) were subcultured in triplicate in DMEM containing 10% v/v 
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fetal calf serum and 1% v/v penicillin/streptomycin (Gibco). Quiescent cells were treated overnight 
with stimulators as indicated, then100 nM forskolin for 30 minutes at 37 °C. Treatment was stopped 
and the cells were lysed by replacing media with 0.5 ml 0.1 N HCl. cAMP levels were measured 
following the manufactory’s protocol. 
Imaging. Nanoconjugate localization was determined by optical dark-field scattering microscopy. 
Sterile glass coverslips (18 mm dia) were incubated with 0.04 mg/mL rat tail collagen/DPBS for 6 h 
at 37 °C in a 5% CO2 humidified atmosphere and rinsed in DPBS. Cells were passaged onto the 
coverslips and after 12 h, growth solutions were replaced with fresh media containing 0.2 nM gold 
nanoparticle conjugates. After incubation (24 h), cell monolayers were rinsed in DPBS and fixed in 4 
% paraformaldehyde/DPBS at 4 ºC for 15 min. The fixed coverslips were coated with glycerol, 
mounted, and sealed onto glass slides. Optical dark-field scattering microscopy was performed using 
an inverted objective Olympus IX70 microscope fitted with a dark-field condenser (U-DCW), 
100x/1.35 oil Iris objective (UPLANAPO), (white light) tungsten lamp, and a Nikon D200 digital 
SLR camera. Please note that dark-field scattering optics are distinct from confocal optics and that 
fluorescence images were obtained on a separate instrument. 
Fluorescence microscopy was performed on a Zeiss NLO META confocal microscope. 
Antiandrogen nanoparticles were labeled with a carboxyfluorescein-terminal PEG-SH (5 kDa). 5-
(and-6)-carboxyfluorescein succinimidyl ester (Molecular Probes) was reacted with amine-terminal 
PEG-SH (5 kDa, Lysan Bio) in pH 7.4 DPBS buffer for 24 h in dark, with sonication. 
Fluorescently-labeled PEG-SH was dialyzed twice (5 Da MWCO, Spectra/Por) at a 103 volume 
excess for 24 h with three solvent exchanges. Carboxyfluorescein-terminal PEG-SH was incubated 
with the antiandrogen nanoparticles for 12 h with sonication at RT and purified by centrifugation 
(6000 rpm, 15 min). Cell cultures were incubated with 5.0 µM Alexa Fluor 647-dextran (10 kDa) to 
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label endo/lysosomal compartments and 0.33 nM of the fluorescently-labeled nanoconjugates. After 
12 h, DAPI was added to 300 nM and allowed to incubate for 15 min. The cell monolayers were 
then twice rinsed with DPBS and fixed in 4 % paraformaldehyde/DPBS at 4 ºC for 30 min. The 
microscopy samples were again twice rinsed with DPBS and incubated with 1 mg/mL NaBH4 at 4 
ºC to minimize fixative-induced fluorescence. After 5 min, the borohydride solution was replaced 
with fresh solution and allowed to incubate for another 5 min at 4 ºC. The samples were then rinsed 
three times with DPBS and imaged. 
4.2.3 Preclinical Evaluation of Antiestrogen and Antiandrogen Gold Nanoparticles 
Gold nanoparticles (AuNPs, 29 ± 4 nm diameter, Figure 4.11A) were synthesized by 
Turkevich/Frens reduction of chloroauric acid and conjugated with a mixed self-assembled 
monolayer of 5% thiol PEGylated antiandrogen and 95% thiolated poly(ethylene glycol) stabilizer 
(PEG-SH, 5 kDa). Antiandrogen ligands used in these studies were employed to reflect structural 
homology between antiandrogens in clinical use with α- and β-Bicalutamide (α-Bic, β-Bic; Figure 
4.11A) both bearing an aromatic α-anilide ring characteristic of flutamide, bicalutamide, and 
nilutamide, as well as a five-membered imidazolidinedione ring characteristic of nilutamide and the 
H-bonded structure of bicalutamide and/or the active metabolite of flutamide. β-Bic contains an 
additional β-aromatic ring characteristic of bicalutamide which binds the hydrophobic pocket formed 
by helix 12 residues on androgen receptor and confers it enhanced potency [76] (Figure 4.11B). 
Antiandrogen ligands were synthesized by Cu(I)-catalyzed Huisgen cycloaddition (i.e. click, azide-
alkyne coupling) with PEGylated lipoic acid. Thiol anchoring groups were used to enable stable Au 
surface bond formation and PEG stabilizer/spacer groups were employed to sterically stabilize the 
subsequent nanoparticle constructs in physiological media and to resist protein adsorption and/or 
 134
immunogenic response. α-Bic- and β-Bic-AuNPs contained 2.25 ± 0.02 × 103 and 1.56 ± 0.08 × 103 
antiandrogen ligands per particle, respectively (Figure 4.12). 
 
 
Figure 4.11. Multivalent antiandrogen gold nanoparticles for the treatment of castration-resistant 
prostate cancer. A) Electron micrographs of the as-synthesized 29 ± 4 nm diameter gold 
nanoparticles. B) Illustration of the antiandrogen nanoconjugates with receptor binding groups 
shown groups in grey/red. C) Molecular docking of the antiandrogen ligands with androgen receptor 
showing outward orientation of the thiol PEGylated nanoparticle linker groups and maintenance of 
contact points within the androgen receptor binding pocket by the bicalutamide ligand (β-Bic, red) 
and its β ring-deficient analog (α-Bic, blue), as compared to their precursor drugs bicalutamide 
(magenta) and its nilutamide analog (yellow). D) Physiochemical properties of the antiandrogen gold 




Figure 4.12. Conjugation of the antiandrogen gold nanoparticles. UV absorption calibration curves 
for (A) α-Bicalutamide and (B) β-bicalutamide antiandrogen ligands in water. C) Antiandrogen 
ligand coverages on 29 ± 4 nm diameter gold nanoparticles as a function of ligand excess present 
during conjugation.  D) Normalized optical extinction spectra of the purified antiandrogen and 
PEGylated gold nanoparticles in water. Error bars represent SD. Adapted from Dreaden et al. [77]. 
 
α-Bic and β-Bic AuNPs were found to be  50 ± 1 nm in hydrodynamic diameter, which 
recent studies by Chan and coworkers indicate to the be within the optimal size range for both tumor 
accumulation and cellular internalization of AuNPs [78,79] (Figure 4.11D). PEGylated control 
nanoparticles were found to be 49 ± 1 nm. The octanol:water partition coefficient of α-Bic- and β-
Bic-AuNPs was found to be -1.4 ± 0.2 and -0.27 ± 0.03, respectively, both below that expected from 
an intravenously administered drug (1.92) with acceptable pharmacokinetics.[80] 
Molecular docking of the antiandrogen ligands with androgen receptor (AR) show that the 
contact points of their parent drugs within the AR binding pocket are maintained by the ligands and 
that their thiol PEGylated linker groups face outwards to enable accessibility by nanoparticle-bound 
ligands (Figure 4.11C). Receptor binding competition with radiolabeled androgen (Figure 4.13A) 
shows that the AR binding affinities (Ki) of α-Bic and β-Bic are enhanced 25,000- and 8,400-fold, 
respectively, when displayed as a multivalent nanoparticle construct (Figure 4.13B), binding AR 
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with greater affinity than its endogenous hormone dihydroxytestosterone (DHT, 0.28 – 2 nM) 
[76,81] and yielding, to our knowledge, the highest reported Ki for a non-steroidal antiandrogen. α-
Bic- and β-Bic bound AR with affinities comparable to those previously reported for 
bicalutamide,[82] while their nanoparticle conjugates did so at concentrations 11- and 5.4-fold less 
than a nanoparticle-equivalent quantity of free antiandrogen ligands, respectively (Figure 4.13A, 
inset; Figure 4.13B). Because membrane AR (mAR) binds antibodies [68] and endogenous 
androgens [83] for intracellular AR, and because antiandrogens can diminish the effects of 
androgenic mAR stimulation,[84] these data suggest that antiandrogen gold nanoparticles can 
selectively target mAR which is preferentially overexpressed by human prostate cancer cells and whose 
expression levels correlate with  poor prognosis (Gleason score) [85] and total AR levels [68] found in 




Figure 4.13. Antiandrogen gold nanoparticles selectively engage androgen receptor (AR) and G 
protein-coupled receptor GPRC6A targets. A) AR binding competition between radiolabeled 
androgen and antiandrogen nanoparticles (solid) or antiandrogen ligands (dashed) showing 
multivalency-enhanced AR binding affinity (Ki) from the nanoparticle constructs. Antiandrogen 
nanoparticles displaced [3H]androgen from AR with 8,400–25,000 fold greater affinity than free 
antiandrogens (main panel, a) and did so at concentrations lower than expected from an equivalent 
number of nanoparticle ligands (inset, A). Grey hash marks denote lower and upper limits reported 
for AR’s endogenous high affinity ligand, dihydrotestosterone (DHT). B) Half maximal inhibitory 
concentration (IC50) and binding affinity (Ki) for antiandrogen nanoparticles and ligands with their 
corresponding multivalency-enhanced values. C) Upregulated GPRC6A mRNA expression levels 
measured from various prostate cancer cell lines relative to non-malignant RWPE-1 prostate cells. D) 
Androgen-competitive downstream production of cyclic adenosine monophosphate (cAMP) 
accumulated in response to overnight GPRC6A stimulation by α-Bic- and β-Bic-AuNPs in an AR-
/GPRC6A- and AR-/GPRC6A+ transfected cell line. DHT, dihydrotestosterone. Error bars represent 
SEM. P for individual values relative to untreated controls or as indicated; *P<0.05, **P<0.01. 
Adapted from Dreaden et al. [77]. 
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GPRC6A is a membrane-associated C family G protein-coupled receptor recently discovered 
through genomic homology search.[87] GPRC6A senses androgens and is a positive regulator of 
testosterone and a negative regulator of estrogen; its expression has been shown to contribute to 
prostate cancer growth, malignancy (Figure 4.13C), and poor survival in animal models of prostate 
cancer.[70] Polymorphism at its GPRC6A gene was recently associated with significantly altered 
susceptibility to prostate cancer in a genome-wide association study among Japanese men (P=1.6 × 
10−12).[70,88] Downstream production of cyclic adenosine monophosphate (cAMP) in response to 
GPRC6A stimulation was assessed using an established AR-/GPRC6A- and AR-/GPRC6A+ 
transfected cell line.[75] α-Bic- and β-Bic-AuNPs significantly stimulated GPRC6A in an androgen-
competitive manner (Figure 4.13D), eliciting cAMP production at sub-nM concentrations. 
GPRC6A stimulation by α-Bic- and β-Bic-AuNPs was 2.0- and 1.9-fold greater than that by an 
equivalent or greater concentration of PEGylated-AuNPs (P=0.06 & 0.15, respectively) and was 2.3- 
and 3.5-fold greater than their nanoparticle-equivalent concentrations of free ligands (P=0.003 & 
0.03, respectively) (Figure 4.14). These data show that antiandrogen gold nanoparticles can 




Figure 4.14. Nanoparticle-equivalent concentrations of antiandrogen ligands and PEGylated control 
nanoparticles engage GPRC6A significantly less than antiandrogen gold nanoparticles. Downstream 
cyclic adenosine monophosphate (cAMP) accumulated in response to GPRC6A stimulation by α-
Bic/β-Bic ligands and PEGylated control nanoparticles showing significantly lower GPRC6A 
engagement/stimulation by α-Bic (2.3-fold, P=0.003), β-Bic (3.5-fold, P=0.03), and PEGylated gold 
nanoparticles (2.0-fold v. α-Bic-AuNPs, P=0.06; 1.9-fold v. β-Bic-AuNPs, P=0.15). Error bars 
represent SEM. P for individual values relative to untreated controls or as indicated; *P<0.05. 
Adapted from Dreaden et al. [77]. 
 
Binding/uptake selectivity of the antiandrogen gold nanoparticles was assessed in a 
membrane-AR+ and GPRC6A+ prostate carcinoma cell line [83] whose response to chemotherapy 
and antiandrogen therapy reflects that of castration-resistant prostate cancer,[60] DU-145 (Figure 
4.15A). Fluorescently-labeled antiandrogen gold nanoparticles exhibited high intracellular 
accumulation in DU-145 cells and localized in a manner similar to that reported for AR,[89] while 
PEGylated nanoparticles exhibited no significant accumulation. Uptake and localization patterns of 
both targeted and untargeted nanoparticles in an AR null [90] squamous cell carcinoma cell line 
showed only non-specific cell surface binding (Figure 4.16). We hypothesized that androgen-
stimulated upregulation of AR in DU-145,[91] and correspondingly increased mAR expression,[68] 
may augment antiandrogen nanoparticle accumulation in prostate cancer cells. Particle 
uptake/localization was imaged using a technique termed optical dark-field scattering microscopy 
which can achieve sensitivity orders of magnitude higher than conventional fluorescence-based 
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methods.[71,72] Testosterone (T, 10-6 M) stimulation of DU-145 had no effect on PEGylated 
nanoparticle accumulation (Figure 4.17), but significantly increased α-Bic- and β-Bic-AuNP 
accumulation, consistent with previous reports of 1.5–2 fold testosterone-induced receptor 
upregulation in DU-145 [91] (Figure 4.15B). These imaging data show that antiandrogen gold 
nanoparticles selectively accumulate in antiandrogen treatment-resistant AR+/GPRC6A+ prostate 




Figure 4.15. Antiandrogen gold nanoparticles selectively accumulate in chemotherapy- and 
antiandrogen-resistant prostate cancer cells expressing membrane-androgen receptor (mAR) and G 
protein-coupled receptor GPRC6A and induce cell death with 104-fold increased drug potency. A) 
Confocal fluorescence images of selective antiandrogen nanoparticle intracellular localization (green) 
in mAR+/GPRC6A+ DU-145 prostate cancer cells. Endo/lysosomes were labeled with dextran (red) 
and nuclei were stained with DAPI (blue). B) Optical dark-field scattering microscopy of DU-145 
cells showing augmented antiandrogen gold nanoparticle accumulation in response to androgen-
stimulated mAR-upregulation by testosterone (T, 10-6 M). Note that images in (A) and (B) were 
obtained using different instruments. C) Dose-dependent cell viability (%) of antiandrogen 
treatment-resistant DU-145 prostate cancer cells incubated with antiandrogen gold nanoparticles and 
(D) antiandrogen ligands (24 h). Nanoparticle equivalent ligand concentrations are plotted in (D) for 
comparison, showing (E) 1.5×104- and 2.0×104-fold enhanced drug potency. Scale bars represent 10 




Figure 4.16. Nonspecific cell surface binding of antiandrogen gold nanoparticles with an androgen 
receptor null cancer cell line. Confocal fluorescence microscopy of androgen receptor negative human 
squamous cell carcinoma (SCC) cells illustrating non-specific membrane binding antiandrogen gold 
nanoparticle conjugates. HSC-3 cells were incubated with antiandrogen- or control-gold 
nanoparticles (green) and a dextran endo/lysosomal marker (red) for 12 h. Nuclei were stained with 




Figure 4.17. PEGylated gold nanoparticles exhibit low, androgen stimulation-independent 
accumulation in antiandrogen treatment-resistant prostate cancer cells expressing membrane-
androgen receptor (mAR) and G protein-coupled receptor GPRC6A. Optical dark-field scattering 
microscopy of DU-145 prostate cancer cells showing baseline accumulation levels of PEGylated 
control gold nanoparticles both in the presence and absence of androgen-stimulated mAR-
upregulation by testosterone (T, 10-6 M). Scale bars represent 10 µm. Adapted from Dreaden et al. 
[77]. 
 
Cytotoxicity of the antiandrogen nanoparticles and their ligands to chemotherapy- and 
antiandrogen-resistant [60] mAR+/GPRC6A+ DU-145 prostate carcinoma cells was investigated by 
tetrazolium assay (24 h). α-Bic- and β-Bic-AuNPs induced half maximal cytotoxicity (IC50) at 9.5 
and 1.5 nM, respectively, exhibiting potency 1.5×104- and 2.0×104-fold greater than their 
corresponding free drugs, respectively (6- and 13-fold greater than expected from a nanoparticle-
equivalent concentration of free ligands, respectively) (Figure 4.15C-E). Free α-Bic- and β-Bic 
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cytotoxicity was comparable to that previously reported for bicalutamide and OH-flutamide with 
DU-145,[92] while PEGylated gold nanoparticles exhibited no significant toxicity over the 
therapeutically-relevant AuNP concentration ranges. Together, these data correlate selective AR and 
GPRC6A engagement (vide infra) with enhanced drug potency and cell death by antiandrogen gold 
nanoparticles. 
4.2.4 Outlook and Conclusions 
In summary, we found that antiandrogen gold nanoparticles selectively engaged two distinct 
receptors involved in prostate cancer growth and progression. These particles selectively accumulated 
in castration- and chemotherapy-resistant prostate cancer cells and induced cell death at nanomolar 
concentrations, more than four orders of magnitude lower than antiandrogens currently in clinical 
use. Further, antiandrogen gold nanoparticles bound androgen receptor with the highest affinity 
reported to-date (to our knowledge) and selectively agonized a newly discovered G-protein coupled 
receptor involved in prostate carcinogenesis and disease risk. These platforms provide opportunities 
for increasingly potent and selective therapy of treatment-resistant prostate cancers and may exhibit 
further enhanced therapeutic efficacy via drug co-conjugation, image-based treatment 
guidance/monitoring, concurrent laser photothermal ablation therapy, and/or high-Z enhanced 
radiotherapy. 
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MACROPHAGE-MEDIATED DELIVERY OF GOLD NANORODS 
 
5.1 Macrophage-Targeting Nanoparticles for Tissue-Selective Delivery to Solid Tumors 
 Gold nanoparticles have demonstrated tremendous utility and multifunctionality for the 
diagnosis and treatment of cancer.[1-6] Not only can these structures serve as targeted drug delivery 
vehicles,[7] they can also act as contrast agents for near-infrared (NIR) laser photothermal tumor 
ablation [8-12] and as platforms in a range of other biomedical diagnostic [1,13,14] and therapeutic 
[15-18] applications. The uptake and removal of circulating nanoparticles by the mononuclear 
phagocyte system (MPS),[19] represents one of the most significant impediments to the efficient 
delivery of nanoscale structures to solid tumors and to-date, the majority of tumor-targeting strategies 
for nanoparticles attempt to evade the MPS and increase circulation time. Here, we show that 
colloidal gold nanorods (AuNRs) can be actively-targeted towards phagocytic macrophages that 
exhibit high intrinsic accumulation and infiltration into solid tumors. Macrolide-functionalized gold 
nanorods were preferentially delivered to tumor-associated macrophage (TAM) cells and selectively 
induced TAM-dependent cytotoxicity towards breast cancer cells in co-culture. Because TAMs 
migrate freely in circulation, bypass the blood-brain-barrier, and extensively accumulate/infiltrate into 
breast tumors, these data show that macrophage-targeting gold nanoparticles can serve as promising 
candidates for targeted cancer therapy. 
Although the MPS plays an important physiological function in removing foreign material, 
cellular debris, and pathogens from circulation, its cells also play a principal role in anti-tumor 
immunity [20] and as such, TAMs readily accumulate and infiltrate into solid tumors, comprising up 
to 50% of tumor mass in breast carcinomas.[21] A limited number of studies have investigated the 
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ability of macrophages to deliver nanoscale drugs and imaging agents to solid tumors. Badie and 
coworkers have shown that TAMs can serve as efficient carriers of cyclodextrin-based nanoparticles 
(CDPs; fluorescent analogues of IT-101) into glioma tumors.[22] CDPs were found to preferentially 
accumulate in TAMs that subsequently migrated into circulation and localized at distant tumor sites. 
Because TAMs are able to bypass the blood-brain-barrier during pathogenesis,[23] increasingly-
specific delivery of camptothecin (IT-101) to brain tumors is expected from CDPs. Jackson et al. 
found that circulating, PEG-labeled quantum dots are similarly uptaken by TAMs that readily 
infiltrate glial tumors.[24] TAMs have also been actively targeted by nanoparticle ligands to facilitate 
increasingly-specific delivery. Mannan-conjugated lipid nanoparticles have achieved selective gene 
delivery to alveolar macrophages;[25] folate-targeted iron oxide nanoparticles have exhibited TAM-
exclusive accumulation in breast tumors [26] and glutamine-functionalized liposomes have 
demonstrated TAM-dependent translocation into neuroblastoma tumors.[27] Hirschberg and 
coworkers have further exploited TAMs to preferentially deliver photothermal contrast agents to 
tumor cells,[28,29] finding that TAMs efficiently take up PEGylated gold nanoshells and 
subsequently infiltrate glial tumor spheroids to allow selective NIR laser photothermal ablation 
therapy (810 nm, ≥7 W cm-2, 10 min). 
Macrolides are a class of structurally-homologous antibiotics widely administered for more 
than four decades for the treatment of microbial infections in humans, particularly those of the 
respiratory tract and soft tissues. In addition to their broad-spectrum antibiotic activity, one notable 
hallmark of macrolides is their exceptionally high accumulation in phagocytic cells (macrophages) 
that facilitate increasingly specific delivery of these drugs to sites of inflammation (infection).[30,31] 
We hypothesized that macrolide ligands could also facilitate the preferential delivery of gold 
nanoparticles to inflamed tumor tissues via TAMs, allowing for enhanced TAM anti-tumor 
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potential,[32-34] increasingly effective laser photothermal therapy,[8-12] and/or heat shock protein-
induced activation of macrophage-mediated anti-tumor immunity.[35] To this end, gold nanorods 
(AuNRs) were synthesized via seed-mediated growth from chloroauric acid and conjugated with 
PEG-thiol or mixed self-assembled monolayers of (9:1) PEG-thiol and thiol-PEGylated azithromycin 
(Zithromax), clarithromycin (Biaxin), or tricyclic ketolide (TE-802) (Figure 5.1A,B; Figure 5.2). 
Each of the nanorods, abbreviated hereafter as PEG-AuNRs, Azith-AuNRs, Clarith-AuNRs, and 
TriKeto-AuNRs, respectively, were conjugated such that they displayed 1 × 103 macrolide ligands 
and 9 × 103 PEG-thiol molecules per particle, as well as a NIR absorption maximum ca. 818 nm. 




Figure 5.1. A) Schematic representation and (B) physiochemical characteristics of the macrolide-gold 
nanorods used herein. C) Cardioid immersion dark-field scattering microscopy (DFSM) of cell 
cultures (green) illustrating preferential uptake/accumulation of macrolide-gold nanorods (red) into 
tumor-associated macrophage cells (RAW 264.7) relative to squamous cell carcinoma (HSC-3) and 
keratinocyte cells (HaCaT). PEGylated gold nanorods exhibited only nominal cell-surface binding 




Figure 5.2. Transmission electron microscopy (TEM) image of the as-synthesized colloidal gold 
nanorods. Scale bar represents 100 µm. Adapted from Dreaden et al. [36]. 
 
5.1.1 Design and Development of Near-Infrared Absorbing, Macrophage-Targeting Gold 
Nanorods 
Synthesis and Characterization of Macrolide-Gold Nanorods. Thiol PEGylated macrolide 
ligands were synthesized as described in Dreaden et al. (See Section 5.21).[37] Gold nanorods 
(AuNRs) were synthesized as described in Dickerson et al. with slight modifications.[9] Briefly, 
NaBH4 (600 µL, 10 mM; 4 °C) was rapidly added to a stirred 7.5 mL solution containing 0.333 
mM HAuCl4•(H2O)3 (Sigma) and 0.133 M cetyltrimethylammonium bromide (CTAB, Sigma). The 
reaction was allowed to proceed for 5 min, then 320 µL of the as-formed seed solution was rapidly 
injected into a 420 mL growth solution containing 0.479 mM HAuCl4•(H2O)3, 95.7 mM CTAB, 
86.2 µM AgNO3 (Fischer), and 0.528 mM ascorbic acid (Sigma). The seeded growth solution was 
gently mixed and allowed to react overnight. The crude nanorod solution was purified and 
concentrated by centrifugation (30 min, 4185 × g) and stored at 4 ºC until use. All reactions were 
performed at room temperature under aseptic conditions in aqueous solutions (18 MΩ). Particle size 
was analyzed via transmission electron microscopy (TEM, JEOL 100CX II). Hydrodynamic diameter 
(HD) and zeta potential (ζ) measurements were performed using a NanoZS Zetasizer particle 
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analyzer (Malvern, 633 nm). Optical extinction measurements were performed using an Ocean 
Optics HR4000CG-UV-NIR spectrometer. 
Nanoparticle ligand coverages were determined as described in Dreaden et al. with slight 
modifications.[38] Briefly, purified gold nanorod concentrates were rapidly injected into aqueous 
solutions containing PEG-thiol or 9:1 mole ratios of PEG-thiol and macrolide ligands Azith, Clarith, 
or TriKeto (PEG-thiol, hydroxy octa(ethylene glycol)-lipoic amide). Molar excesses of ligands relative 
to AuNRs were adjusted until comparable grafting densities were achieved for each of the macrolide-
AuNR conjugates following centrifugal purification (15 min, 4185 × g; twice). Azith- Clarith- and 
TriKeto-AuNRs contained 1×103 macrolide ligands and 9×103 PEG-thiol ligands per nanorod, 
obtained by incubating with solutions containing 1.3, 1.6, and 3.9 × 105-fold ligand excesses, 
respectively, at 30 ºC, under sonication for 12 h. Adsorbate coverages of Azith, Clarith, TriKeto were 
determined via UV absorption assay (260 nm) of centrifugal supernatants; coverages for PEG-thiol 
were determined via Ellman’s assay (Pierce/Thermo Scientific). Molar extinction cross sections for 
thiol PEGylated Azith, Clarith, and TriKeto [UV-vis (water): ε260 nm] were found to be 1.08 ± 0.03, 
0.841 ± 0.03, and 1.26 ± 0.02 × 104 L mol-1 cm-1, respectively. Molar extinction cross sections of the 
nanorods were interpolated from experimental data in Orendorff and Murphy.[39] Nanoparticle 
supernatants used in coverage assays were centrifuged at 18,000 × g for 1 h to remove any trace 
particles. Gold nanorods used in these studies were ca. 50 ± 8 nm in length and 13 ± 2 nm in width 
(4.0 ± 0.9 aspect ratio) as measured by TEM (Figure 5.2) and were stably dispersed in complete 
growth media over 24 h [UV-vis (water): λmax~818 nm]. 
Cell Culture and Laser Photothermal Therapy. RAW 264.7 alveolar TAMs, MCF7 human 
breast adenocarcinoma cells, HSC-3 human oral squamous cell carcinoma cells, and HaCaT non-
malignant human epithelial keratinocyte cells were subcultured in Dulbecco's modified Eagle’s 
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medium (DMEM) supplanted with 10% v/v fetal bovine serum (FBS), 20 I.U./mL penicillin, 100 
ug/mL streptomycin, and 250 ng/mL amphotericin B at 37 ºC in a 5% CO2 humidified atmosphere. 
RAW 264.7 and MCF7 cells were obtained from ATCC; HSC-3 and HaCaT cells were a gift from 
Dr. Ivan H. El-Sayed (UCSF Otolaryngology). Cells were passaged using 0.25% trypsin containing 
2.21 mM EDTA in Hank's Buffered Salt Solution (HBSS, Mediatech) and pelleted via 
centrifugation (RAW 264.7, 2000 rpm; MCF7, 1750 rpm; HSC-3/HaCaT, 1500 rpm). All 
experiments were performed on cells passaged 12 h prior. Cells were counted via hemacytometry and 
passaged to surface area-equivalent confluences. Spectroscopic and microscopic measurements were 
performed in complete media lacking phenol red. Co-cultures were constructed by passaging RAW 
264.7 TAMs onto 12-well tissue culture plates (BD). Culture media was removed following 
overnight incubation and replaced with complete media containing 10 pM AuNR conjugates. 
Following 24 h incubation with the nanoconjugates, adherent cells were washed with DPBS, 
trypsinized, pelleted, triturated, and seeded onto DPBS-rinsed MCF7 cultures passaged onto 96-well 
tissue culture plates (BD) 12 h prior. TAMs were allowed to adhere for 12 h, after which adherent 
cells in co-culture were washed with DPBS and incubated with 50 µL DPBS (ca. 1.6 mm depth). 
Monolayers were irradiated using a fiber optic-coupled near-infrared (NIR) diode laser (λ=808 nm, 
Power Technologies) for 10 min (646 mW cm-2) and positioned atop a 5 mm copper plate heated to 
37 ºC (n = 3; non-irradiated, n=6). TAM-only photothermal experiments were similarly performed 
in 96-well plates and irradiated after 24 h AuNR incubation and washing with PBS (n=3 non-
irradiated, n=6). Each plate contained an independent set of control cells. Following treatment, 
cultures were allowed to incubate in complete growth media for 24 h and viability was analyzed by 
tetrazolium assay (XTT, Sigma) following the manufacture’s instructions. TAM proliferation assays 
in response to macrolide and macrolide-AuNR exposure were similarly performed (Figure 5.3). 
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Figure 5.3. Effects of macrolide-gold nanorods and macrolide ligands on RAW 264.7 tumor-
associated macrophage (TAM) proliferation. A) Macrolide-gold nanorods and (B) thiol-PEGylated 
macrolide ligands diminished TAM proliferation in a dose-dependent manner (24 h). Values in 
parentheses indicate half maximal inhibitory concentrations. Error bars represent SD. Adapted from 
Dreaden et al. [36]. 
 
Dark-Field Scattering Microscopy. Nanoparticle uptake/accumulation was assessed via dark-
field scattering optical microscopy (DFSM) using an inverted-objective Olympus IX70 microscope 
fitted with a cardioid immersion dark-field optical condenser (U-DCW), 100x/1.35na oil iris 
objective (UPLANAPO), tungsten lamp illumination, and a Nikon D200 digital SLR camera. 
Round glass coverslips (18 mm; Fischer) were sterilized by ethanol immersion and UV exposure (30 
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min), followed by immersion in 0.04 mg/mL rat tail collagen/DPBS (Roche) for 6 h at 37 °C in a 
5% CO2 humidified atmosphere. The collagen-coated coverslips were next rinsed in DPBS and cells 
were passaged onto the coverslips. After 12 h, growth solutions were replaced with media containing 
0.5 nM of the nanoconjugates and the cells were allowed to incubate for 24 h. Cell monolayers were 
rinsed in DPBS and fixed in 4 % paraformaldehyde/DPBS for 15 min at 4 ºC. The fixed coverslips 
were coated in glycerol, mounted and sealed onto glass slides, and imaged immediately. 
Laser Scanning Confocal Microscopy. RAW 264.7 TAMs were passaged onto 12-well tissue 
culture plates. Following overnight incubation, growth media was removed and replaced with 
complete media containing 10 pM AuNR conjugates. Following 24 h incubation with the 
nanoconjugates, adherent cells were washed with DPBS and incubated with 500 µL of 300 nM 4',6-
diamidino-2-phenylindole (DAPI; Molecular Probes; DPBS, 37 ºC), a membrane-permeable 
fluorescent nuclear marker, for 10 min. DAPI-labeled, AuNR-loaded TAMs were rinsed twice with 
DPBS (37 ºC), trypsinized, pelleted, triturated, and seeded onto DPBS-rinsed MCF7 cultures 
passaged onto 12-well tissue culture plates containing sterile 18 mm round glass coverslips at their 
base. TAMs were allowed to adhere for 12 h, after which adherent cells in co-culture were washed 
with DPBS (37 ºC) and incubated with 1 mL of 4 µM ethidium homodimer-1 (EthD-1; Molecular 
Probes, DPBS, 37 ºC), a membrane-impermeable fluorescent nuclear marker for apoptotic/necrotic 
cells, for 45 min. After 12 h, co-culture medium was removed and replaced with fresh growth media. 
Following an additional 24 h of incubation, adherent co-culture cells were mounted and sealed onto 
75 x 25 mm glass slides using 10 µL of 4 µM EthD-1 and 5 µL of Crystal Mount™ mounting 
medium (Sigma). Labeled co-cultures were immediately imaged via confocal fluorescence microscopy 
using an inverted-objective Zeiss Axiovert 200M microscope equipped with a Neofluor 40x/1.3na oil 
objective and Zeiss ZEN 2009 software. 
 162
5.1.2 Macrolide-Gold Nanorods Selectively Target and Induce Macrophage Cytotoxicity 
Towards Breast Cancer Cells 
Preferential uptake/accumulation of the macrolide-AuNRs into TAM cells was assessed via 
cardioid immersion dark-field scattering microscopy (DFSM). TAM cells (RAW 264.7) exhibited 
substantially higher levels of macrolide-AuNR uptake than either squamous cell carcinoma (HSC-3) 
or keratinocyte cells (HaCaT) cells (Figure 5.1C) and showed only nominal cell-surface binding by 
PEG-AuNRs.[37] Based on these findings, phototoxicity from NIR laser exposure (λ=808 nm) was 
assessed using TAMs treated with sub-lethal concentrations of macrolide-AuNRs (10 pm, 24 h; 
Figures 5.3,4). NIR laser exposure of TAM cultures washed/immersed in buffer (1.6 mm) showed 
modest phototoxicity from Azith- and TriKeto-AuNRs, but no significant effects from Clarith-
AuNRs, PEG-AuNRs, or laser treatment alone (10 min, 646 mW cm-2). We then evaluated the 
effects of AuNR-loaded TAMs and NIR laser exposure on cell viability in breast adenocarcinoma co-
cultures. TAM cultures were again loaded with sub-lethal concentrations of macrolide-AuNRs (10 
pm, 24 h), washed with buffer, and seeded onto MCF7 breast cultures at 50% plating densities to 
reflect physiological levels of TAM infiltration into breast carcinomas (Figure 5.5).[21] After 12 h, 
co-cultures were washed and immersed in buffer (1.6 mm), NIR laser-exposed (10 min, 646 mW cm-
2), and allowed to incubate in complete growth media for an additional 24 h. While no statistically 
significant cytotoxic effects from NIR laser exposure were observed, we found substantial cytotoxicity 
in co-cultures containing macrolide-AuNR-treated TAMs and significant, but notably diminished 




Figure 5.4. A) Near-infrared laser photothermal ablation of tumor-associated macrophage (TAM) 
cells loaded with macrolide-gold nanorods (AuNRs). B) Selective cytotoxicity of AuNR-loaded 
TAMs co-cultured with MCF7 breast adenocarcinoma cells. Error bars represent SD. P-values in (A) 
reported relative to non-irradiated RAW 264.7 cells; P-values in (B) reported relative to non-
irradiated, non-AuNR-treated co-cultures. *P<0.05, **P<0.01, ***P<0.001. Adapted from Dreaden 





Figure 5.5. Microscopic image of breast carcinoma:macrophage co-cultures. MCF7 human breast 
adenocarcinoma cells are indicated by solid arrowheads and RAW 264.7 tumor-associated 
macrophage cells (TAMs) are indicated by open arrowheads. Adapted from Dreaden et al. [36]. 
 
In order to delineate which cells contributed to co-culture cell death, AuNR-treated TAMs 
were labeled with 4',6-diamidino-2-phenylindole (DAPI), a membrane-permeable fluorescent nuclear 
marker, prior to passage into co-culture. DAPI-labeled, AuNR-loaded TAM cells were thoroughly 
rinsed with buffer and again seeded at 50% plating densities with MCF7 breast adenocarcinoma cells. 
After 12 h, culture media was removed and replaced with fresh growth media. Following an 
additional 24 h of incubation, adherent co-culture cells were labeled with ethidium homodimer-1 
(EthD-1), a membrane-impermeable fluorescent nuclear marker for apoptotic/necrotic cells. 
Confocal fluorescence microscopy of the co-cultures revealed that MCF7 breast cancer cells 
contributed near exclusively to the observed cell death, with no colocalization of DAPI-labeled TAM 




Figure 5.6. Tumor-associated macrophages (TAMs) treated with macrolide-gold nanorods (AuNRs) 
induce cell death in co-cultured breast adenocarcinoma cells. Macrolide-AuNR-loaded TAM nuclei 
were labeled with 4',6-diamidino-2-phenylindole (DAPI, blue) and seeded onto MCF7 breast cell 
cultures at 50% plating densities. Confocal fluorescence microscopy using the apoptotic/necrotic 
nuclear marker, ethidium homodimer-1 (EthD-1, red), shows cytotoxicity exclusive to breast 
adenocarcinoma cells. Scale bar represents 25 µm. Adapted from Dreaden et al. [36]. 
 
Although macrophage cytokine activation by gold nanoparticles (AuNPs) is well-
documented,[32-34] we believe this to be the first report on the subsequent effects of AuNP-
activated macrophages on nearby cells. Tsai and coworkers observed upregulation of cytotoxic tumor 
necrosis factor (TNF-α) and interlukin (IL) 1/6 in response to the administration of untargeted 
AuNPs.[32] In a study by Puntes and coworkers, enhanced upregulation of cytotoxic TNF-α and IL-
1/6 was also observed in macrophage cells treated with peptide-conjugated gold nanoparticles 
designed to mimic virus-like particles through epitope repetition.[33] Groll and coworkers more 
recently observed that PEGylated AuNRs can likewise increase cytotoxic TNF-α and IL-1/6 protein 
levels in AuNR-treated macrophages.[34] Together, these findings suggest that AuNP-activated 
macrophages may enhance the innate cytotoxic responses of TAMs towards the tumors which they 
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infiltrate. Moreover, macrolide-AuNRs that actively target TAMs may further augment anti-tumor 
response and achieve increasingly preferential delivery due to the size-dependent enhanced 
permeability and retention (EPR) effect.[40] Clinical trials involving the systemic administration of 
therapeutic TNF-α-AuNPs may additionally synergize with tumor-specific cytotoxic effects from 
AuNP-activated TAMs (CYT-6091, CytImmune Sciences, Inc.).[7] 
Unwanted MPS uptake of nanostructures can be mitigated in a variety of ways including 
saturation by “decoy” nanoparticles (e.g. 3.4-8.5 nmol dosages in rats),[24] transient depletion of 
circulating macrophages (e.g. by anti-αCSF1 [26] and/or liposomal clodronate [20]), and surface-
functionalization with protein-repellant polymers (e.g. PEG, POx),[41,42] complement inhibitors 
(e.g. heparin),[43] and/or “markers of self” (e.g. CD47[41] and CD200). In spite of these efforts, 
biodistribution profiles of “stealth” AuNPs typically remain high in MPS organs such as the spleen 
and liver.[2,45] Jeong and coworkers observed that intravenously administered PEG-AuNPs 
sequester in splenic macrophages and neutrophil-infiltrated liver tissues, resulting in tissue-specific 
inflammation (i.e. upregulation of TNF-α, IL-1/6/10/12).[42] While potentially beneficial in tumor 
tissues, the deleterious effects of AuNP-activated TAMs described here could result in significant 
impacts to healthy tissues and warrant further investigation. 
5.1.3 Outlook and Conclusions 
 In conclusion, we have synthesized a novel gold nanoparticle conjugate which targets and 
activates anti-tumor potential in macrophage cells that exhibit high accumulation and infiltration 
into solid tumors. Macrolide-gold nanorods (AuNRs) preferentially accumulated in tumor-associated 
macrophage cells (TAMs) that exhibited selectively-enhanced cytotoxicity towards breast 
adenocarcinoma cells in co-culture. Although modest near-infrared photothermal ablation response 
was observed in monocultures of AuNR-activated TAMs, we observed no additive cytotoxic effects 
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from photothermally-treated TAMs in co-culture over the time course of these experiments – as 
would be expected from heat-shock protein-induced activation or photothermal ablation. Taken 
together, the ability of TAMs to migrate freely in circulation, bypass the blood-brain-barrier, and 
preferentially accumulate and infiltrate into solid tumors make macrolide-functionalized gold 
nanoparticles promising candidates for targeted cancer drug delivery to breast and brain tumors. 
Enhanced anti-tumor potential by tumor-localized, AuNR-activated TAMs may further synergize 
with chemotherapeutic treatment regimens and warrant further investigation. 
5.2 Ligand-Dependent Susceptibility of Macrolide-Gold Nanorods to Multiple Drug 
Resistance 
 Forty percent of all human tumors develop resistance to chemotherapy.[43] This treatment 
resistance can be drug-specific; however, it is often accompanied by wide-ranging drug insensitivity, 
or multiple drug resistance (MDR), which is responsible for treatment failure in more than 90% of 
all metastatic cancer cases.[44] The transmembrane drug efflux pump MDR1 P-glycoprotein (P-gp, 
Figure 5.7A) is considered to be the most prevalent and single most important cause of MDR in 
humans.[48,49] Nanoscale drug carriers can overcome MDR in many cases and are widely believed 
to be less susceptible to drug efflux due to endocytotic uptake/protection.[45-47] The intrinsic 
vulnerability of nanoparticles to P-gp-mediated efflux is, however, poorly understood and it is 
currently unclear whether nanoscale drug carriers, as a whole, are subject to P-gp efflux. We 
hypothesized that nanoparticles covalently conjugated with various substrates of P-gp may be able to 
circumvent P-gp-mediated efflux, thereby increasing their therapeutic potential. We found that the 
cellular accumulation of nanoparticles conjugated with MDR-evasive substrates was unaffected by 
competitive inhibitors for P-gp, but that the accumulation of those conjugated with MDR-
susceptible substrates was significantly enhanced. These findings suggest, for the first time, that 
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nanoscale drug carriers, themselves, can be susceptible to MDR and that P-gp-mediated drug efflux 
depends directly on the extent to which the nanoparticles’ surface ligands are recognized by P-gp and 
other MDR proteins. These data further provide opportunities for the design of increasingly 
efficacious drugs and imaging agents in the future. 
 Polymeric nanoparticles, liposomes, iron oxide nanoparticles, micelles, polysaccharide 
nanoparticles, and diamond nanoparticles have all demonstrated increasing efficacy in treating MDR 
cells in vitro/vivo,[45,48] but differentiating effects attributable to nanoparticle-accelerated delivery 
kinetics from direct interactions with P-gp is difficult. Further, many components of nanoscale drug 
carriers, as well as their excipients/solubilizing agents, can likewise diminish drug:P-gp interactions 
and obfuscate direct comparisons. For example, Kabanov and coworkers have shown that nonionic 
triblock copolymers (Pluronic) that self-assemble to form micellar drug carriers can, themselves, 
transiently deplete ATP, diminishing P-gp-mediated efflux of the drugs that they deliver.[54] 
Mumper and coworkers have shown that polyoxyethylene oleyl ethers (Brij 78) used to produce 
nanoscale drug emulsions can similarly diminish P-gp-mediated drug efflux by transient ATP 
depletion.[49] When non-bonded to a nanocarrier, many common components of nanoscale drug 
carriers such as Cremophor EL, Tween 80, PEG (0.4-20 kDa), TPGS, Myrj 52, sucrose 
monolaurate, and Triton X-100, can also inhibit efflux by P-gp.[50] Neutral phospholipids of 
which many liposomes/micelles are comprised (e.g. phosphatidylcholine [51]) can also act as 
competitive substrates for P-gp. 
Gold nanoparticles are promising candidates for targeted anti-cancer drug delivery and laser 
photothermal therapies. Phase I clinical trials have been successfully completed for the former [7] and 
human pilot studies [52] are currently in progress for the latter, both for the treatment of solid 
tumors in the US. To investigate the hypothesis that nanoparticle ligation may diminish P-gp-
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mediated drug efflux, we synthesized a series of colloidal gold nanorods covalently conjugated with 
structurally homologous substrates of P-gp that exhibit varying degrees of susceptibility to P-gp-
medited efflux, as reported previously.[53-58] Figure 5.7B illustrates the composition of these model 
nanoscale drug carriers, each comprised of a ca. 50 × 13 nm gold nanorod (Figure 5.7C) covalently 
conjugated with PEG or a mixed self-assembled monolayer of PEG stabilizer and one of three PEG-
anchored macrolide antibiotics: azithromycin (Zithromax), clarithromycin (Biaxin), or tricyclic 
ketolide (TE-802). These gold nanorod (AuNR) conjugates are abbreviated hereafter as PEG-
AuNRs, Azith-AuNRs, Clarith-AuNRs, and TriKeto-AuNRs, respectively. Macrolides were used as 
model substrates here due to their known biocompatibility, widespread use as broad-spectrum 
antibiotics, and well-characterized interactions with P-gp and the specific inhibitors and cell lines 
employed in this study.[59-64] Trends in efficacy between these macrolides (TriKeto>Clarith>Azith) 
correspond directly with their reported susceptibility to P-gp-mediated efflux 
(Azith>Clarith>TriKeto),[53-58] with second-generation Azith and Clarith exhibiting diminished 
therapeutic response relative to third-generation TriKeto, due in large part to its decreased 
recognition by P-gp.[58] Nanorods were used here due to their high absorption at tissue-penetrating,  
near-infrared (NIR) frequencies (Figure 5.7D), often useful in adjunctive therapeutic 
applications.[9] Figure 5.7C conceptually illustrates how nanocarrier/drug accumulation could be 
diminished by MDR via P-gp-mediated efflux and/or exocytosis of the gold nanoconjugates through 




Figure 5.7. A) Structure of the multiple drug resistance (MDR) protein, MDR1 P-glycoprotein (P-
gp). B) Illustration of the model nanoscale drug carriers employed herein: colloidal gold nanorods 
(AuNRs) covalently bonded with structurally homologous macrolide antibiotic substrates for P-gp 
that exhibit varying degrees of recognition/efflux (TriKeto<Clarith<Azith). C) Electron microscopy 
and D) extinction spectrum of the gold nanorods. E) Schematic illustrating how the accumulation of 
nanoscale drug carriers could be diminished by MDR via P-gp-mediated (i) efflux and/or (ii) 
exocytosis of the gold nanoconjugates through P-gp flippase activity. Adapted from Dreaden et al. 
[37]. 
 
5.2.1 Design and Development of Nanoscale Substrates for MDR1 P-glycoprotein 
Summary. Thiol PEGylated macrolides were synthesized by Huisgen cycloaddition of azido 
octa(ethylene glycol)-lipoic amide (7) with 3'-ethynylbenzyl derivatized azithromycin (8), 
clarithromycin (10), and tricyclic ketolide TE-802 (12). Gold nanorods were synthesized by seed-
mediated growth [9] and spectrophotometric accumulation assays (24 h) were performed as described 
by Cho and Xia [60] using nanoparticle molar extinction cross sections interpolated from Orendorff 
and Murphy [39] with corrections for optical extinction from P-gp inhibitors (100 µM) and growth 
media, as well as diffuse scattering from cellular debris. Adherent cells were counted manually in 
triplicate from 0.603 mm2 images obtained immediately prior to each assay. Nanorods used in these 
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studies were functionalized with 1×103 macrolide and 9×103 PEG-thiol ligands particle-1 (as 
determined by UV-absorption and Ellman’s assay, respectively) and were purified by centrifugation 
prior to conjugation and twice prior to use in cell culture. Dark-field scattering microscopy (DFSM) 
was performed following 24 h incubation with 0.5 nM nanoparticle-supplanted complete growth 
media. Fluorescence microscopy was performed following 24 h incubation with 0.5 nM nanoparticle-
supplanted complete growth media containing Alexa Fluor 647-dextran (Invitrogen) to lable 
endocytotic vesicles. Nanoconjugates were fluorescently-labeled by substituting 11% of their polymer 
layer with carboxyfluorescein-terminal PEG-SH (5 kDa) during conjugation. Efflux experiments 
were performed using P-gp(+) J774.2 (ATCC) [53] and P-gp(-) COLO 205 (ATCC) [61] cells. 
Tetrazolium assay (Sigma, XTT) found no significant toxicity for the nanoconjugates or P-gp 
inhibitors at these concentrations. Electron microscopy was performed using a JEOL 100CX II 
transmission electron microscope and extinction spectra were obtained using an Ocean Optics, 
HR4000CG-UV-NIR spectrometer. 
Experimental Materials/Methods. All commercially available starting materials were used 
without further purification. Octaethylene glycol (OEG) was purchased from Sigma Aldrich. 
Reaction solvents were either high performance liquid chromatography (HPLC) grade or American 
Chemical Society (ACS) grade and used without further purification. Analtech silica gel plates (60 
F254) were used for analytical thin layer chromatography (TLC), and Analtech preparative TLC plates 
(UV 254, 2000 µm) were used for purification. UV light and anisaldehyde/iodine stain were used to 
visualize the spots. 200-400 Mesh silica gel was used in column chromatography. Nuclear magnetic 
resonance (NMR) spectra were recorded on a Varian-Gemini 400 magnetic resonance spectrometer. 
1H NMR spectra were recorded in parts per million (ppm) relative to the peak of CDCl3, (7.24 
ppm).13C spectra were recorded relative to the central peak of the CDCl3 triplet (77.0 ppm) and were 
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recorded with complete hetero-decoupling. High-resolution mass spectra (HR-MS) were recorded at 
the Georgia Institute of Technology mass spectrometry facility in Atlanta. 3’-
ethynylbenzylazithromycin 8, 3’-ethynylbenzylclarithromycin 10, and 3’-ethynylbenzyltricyclic 
ketolide 12, were synthesized as we previously reported.[62,63] 
Synthesis of Tosyl octa(ethylene glycol) (1). The synthetic procedure was adapted from Sauvé 
and co-workers.[64] Octa(ethylene glycol) (0.50 g, 1.35 mmol) was dissolved in anhydrous 
methylene chloride (7 mL) at 0°C, followed by addition of freshly prepared Ag2O (0.47 g, 2.02 
mmol), KI (0.09 g, 0.50 mmol), and then TsCl (0.26 g, 1.35 mmol). The reaction mixture was left 
to stir at 0°C, under argon for 30 min, after which TLC deemed the reaction complete. Ag2O was 
filtered off over a pad of celite cake washing with 12:1 CH2Cl2/CH3OH. The filtrate was 
concentrated and purified on a silica column using 3:2 CH2Cl2/acetone. Gradually increasing polarity 
to 1:4, yielded the title compound as a colorless oil (0.58 g, 78%). 1H NMR (400 MHz, CDCl3): 
δ=2.44  (3H, s), 2.81 (1H, br), 3.58 – 3.70 (30H, m), 4.15 (2H, t, J = 4.8 Hz), 7.35 (2H, d, J = 8.4 
Hz), 7.80 ppm (2H, d, J = 8.4 Hz); HR-MS (ESI): m/z calcd for [C23H40O11S + H]+: 525.2364; 
found 525.2377. ESI=electrospray ionization. 
Synthesis of Azido octa(ethylene glycol) (2. To a solution of tosyl octa(ethylene glycol) 1 (0.5 g, 
0.95 mmol) in DMF (10 mL), was added sodium azide (0.25 g, 3.81 mmol) and the reaction 
mixture stirred at 85°C under argon gas for 6 h. TLC confirmed completion of reaction. DMF was 
evaporated off and the residue dissolved in ethyl acetate (25 mL). Excess sodium azide was filtered off 
and the product purified on silica plug eluting with 12:1 CH2Cl2/MeOH, affording the title 
compound as colorless oil in 84% (0.44 g) yield. 1H NMR (400 MHz, CDCl3): δ=3.38 (2H, t, J = 
5.2 Hz), 3.58-3.73 ppm (30H, m). DMF=dimethylformamide. 
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Synthesis of Azido monotosyl octa(ethylene glycol) (3). Reaction of azido octa(ethylene glycol) 2 
(0.33 g, 0.82 mmol), Ag2O (0.29 g, 1.23 mmol), KI (0.054 g, 0.33 mmol), TsCl (0.17 g, 0.90 
mmol) in DCM (10 mL) as described for the protocol of compound 1, afforded 0.39 g (87%) of the 
desired product. 1H NMR (400 MHz, CDCl3): δ=2.44 (3H, s), 3.38 (2H, t, J = 4.0 Hz), 3.57-3.70 
(28H, m), 4.15 (2H, t, J = 4.0 Hz), 7.35 (2H, d, J = 8.0 Hz), 7.80 ppm (2H, d, J = 8.0 Hz). 
Ts=tosyl. 
Synthesis of Azido phthalimide octa(ethylene glycol) (4). A solution of compound 3 (0.45 g, 
0.81 mmol) and phthalimide potassium salt (0.15 g, 0.81 mmol) in anhydrous DMF (10 mL) was 
stirred at 50°C for 12 h under argon. DMF was evaporated off, redissolved the crude mixture in ethyl 
acetate (40 mL), and filtered off excess salt. Purification by silica preparative TLC eluting with 20:1 
CH2Cl2/MeOH yielded 79% (0.34 g) of the title compound. 1H NMR (400 MHz, CDCl3): δ=3.37 
(2H, t, J = 4.8 Hz), 3.57-3.74 (28H, m), 3.88 (2H, t, J = 6.0 Hz), 7.70 (2H, m), 7.83 ppm (2H,m); 
HR-MS (FAB): m/z calcd for C24H36N4O9 [M+H]+: 525.2560; found 525.2609. FAB=fast atom 
bombardment. 
Synthesis of Amino azido octa(ethylene glycol) (5). A mixture of compound 4 (0.28 g, 0.53 
mmol) and methylamine solution (40 wt% in water, 3.2 mL, 40.6 mol) was stirred at room 
temperature for 64 h. Excess methylamine was evaporated off. The crude product was dissolved in 1 
N HCl (10 mL) and extracted with CH2Cl2 (4 x 5 mL). The aqueous layer was basified with 1 M 
NaOH and then extracted with 10% MeOH/CH2Cl2 (4 x 5 mL), dried over anhydrous sodium 
sulfate and evaporated to dryness to give 0.14 g (68%) of the title compound as oil. 1H NMR (400 
MHz, CDCl3): δ=2.87 (2H, m), 3.38 (2H, t, J = 4.8 Hz), 3.50 (2H, t, J = 4.8 Hz), 3.62-3.68 ppm 
(26H, m); HR-MS (FAB): m/z calcd for C16H34N4O7 [M+H]+: 395.2506; found 395.2522. 
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Synthesis of Azido octa(ethylene glycol)-Lipoic Amide (7, Figure 5.8). To a solution of 
compound 5 (0.20 g, 0.50 mmol) and lipoic acid 6 (0.11 g, 0.50 mmol) in dry CH2Cl2 (7 mL) were 
added EDCI (0.095 g, 0.50 mmol) and DMAP (0.003 g, 0.023 mmol). The reaction was allowed to 
stir under argon for 4.5 h at room temperature. The solvent was concentrated under reduced pressure 
and the residue was purified by silica preparative TLC eluting with 12:1 CH2Cl2/MeOH to afford 7 
as yellow oil (0.27 g, 91%). 1H NMR (400 MHz, CDCl3): δ=1.38-1.52 (2H, m), 1.58-1.72 (4H, 
m), 1.87-1.93 (1H, m), 2.19 (2h, t, J = 7.6 Hz), 2.41-2.5 (1H, m), 3.07-3.22 (2H, m), 3.37 (2H, t,  
J = 4.8 Hz), 3.45 (2H, m), 3.55 (2H, t, J = 5.2 Hz), 3.57-3.69 ppm (28H, m); HR-MS (FAB): m/z 
calcd for C24H46N4O8S2 [M+H]+: 583.2835; found 583.2858. EDCI=1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide, DMAP=4-Dimethylaminopyridine, ME=methyl. 
 
 
Figure 5.8. Synthesis of Azido octa(ethylene glycol)-Lipoic Amide (7). Adapted from Dreaden et al. 
[37]. 
 
Synthesis of Azithromycin-PEG Thiol (9, Figure 5.9). 3’-Ethynylbenzylazithromycin 8 (0.057 
g, 0.059 mmol) and compound 7 (0.045 g, 0.059 mmol) were dissolved in anhydrous THF (5 mL) 
and stirred under argon at room temperature. Copper (I) iodide (0.008 g, 0.042 mmol) and Hunig’s 
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base (0.6 mL) were then added to the reaction mixture with continued stirring for 26 h.  A solution 
of 4:1 saturated NH4Cl/NH4OH (30 mL) was added to the reaction mixture and extracted with 20% 
MeOH/CH2Cl2 (3 x 30 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. 
The crude product was purified by preparative TLC (silica, 12:1:0.05 CH2Cl2/MeOH/Et3N) to give 
80 mg  (83%) of compound 9 as yellow foam. 1H NMR (400 MHz, CDCl3): δ=0.84-1.01 (9H, m), 
1.07-2.00 (37H, m), 2.07-2.66 (16H, m), 2.83-3.25 (8H, m), 3.34-3.65 (32H, m), 3.73-3.97 (3H, 
m), 4.19 (1H, m), 4.40 (1H , d, J = 7.2 Hz), 4.56 (2H, t, J = 4.0 Hz), 4.75 (1H, m), 5.04 (1H, m), 
6.38 (1H, br), 7.35 (2H, br), 7.78 (2H, d, J = 8.0 Hz), 7.97 ppm (1H, s); 13C NMR (100 MHz, 
CDCl3): δ=8.9, 9.3, 11.5, 12.3, 15.0, 16.6, 18.4, 21.6, 21.7, 22.3, 25.6, 26.8, 27.4, 29.1, 29.9, 
34.9, 36.5, 36.6, 37.1, 38.7, 39.3, 40.4, 42.2, 42.4, 45.8, 46.1, 49.5, 50.6, 53.7, 53.9, 56.6, 58.1, 
64.6, 65.7, 68.9, 69.7, 70.1, 70.4, 70.7, 70.8, 73.0, 74.2, 74.5, 78.0, 78.3, 83.4, 95.0, 102.6, 121.1, 
125.9, 129.5, 130.3, 139.4, 147.5, 173.0, ppm 178.7; HR-MS (MALDI): m/z calcd for 
C70H122N6O20S2 [M+H]+: 1431.8228;  found 1431.8233. THF=tetrahydrofuran, Hunig’s 
















































Figure 5.9. Synthesis of Azithromycin-PEG Thiol (9). Adapted from Dreaden et al. [37]. 
 
Synthesis of Clarithromycin-PEG Thiol (11, Figure 5.10). Reaction of 3’-
ethynylbenzylclarithromycin 10 (0.050 g, 0.021 mmol) and compound 7 (0.034 g, 0.021 mmol) 
according to the protocol described for the synthesis of compound 9, followed by similar preparative 
TLC conditions gave 58 mg (69%) of 11 as yellow foam. 1H NMR (400 MHz, CDCl3): δ=0.83 
(6H, m), 1.03-1.90 (33H, m), 2.10-2.60 (12H, m), 2.81-3.16 (14H, m), 3.40-3.72 (35H, m), 3.89-
3.93 (4H, m), 4.43 (1H, d, J = 6.8 Hz), 4.58 (2H, m), 4.86 (1H, m), 5.03 (1H , d, J = 9.6 Hz), 6.50 
(1H, br), 7.60 (2H, br), 7.85 (2H, m), 8.03 ppm (1H, s); 13C NMR (100 MHz, CDCl3): δ=9.3, 
10.6, 12.0, 12.3, 14.1, 15.9, 16.0, 17.4, 18.0, 18.6, 19.8, 21.0, 22.6, 25.4, 28.9, 29.3, 29.4, 29.6, 
30.1, 31.9, 34.6, 34.8, 36.2, 37.3, 38.4, 38.9, 39.1, 40.2, 42.0, 44.9, 45.1, 49.3, 50.4, 50.5, 53.7, 
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56.4, 65.8, 69.1, 69.5, 69.9, 70.1, 70.4, 70.5, 70.6, 72.6, 74.2, 76.6, 76.8, 77.7, 78.2, 81.1, 95.9, 
105.0, 121.4, 126.1, 130.0, 146.8, 172.9, 175.6, 220.9 ppm; HR-MS (MALDI): m/z calcd for 





















































Figure 5.10. Synthesis of Clarithromycin-PEG Thiol (11). Adapted from Dreaden et al. [37]. 
 
Synthesis of Tricyclic Ketolide-PEG Thiol (13, Figure 5.11). Reaction of 3’-
ethynylbenzyltricyclic ketolide 12 (0.052 g, 0.07 mmol) and compound 7 (0.047 g, 0.08 mmol) 
according to the protocol described for the synthesis of compound 9, followed by similar preparative 
TLC conditions gave 65 mg (71%) of 13 as yellow foam. 1H NMR (400 MHz, CDCl3): δ=0.82 
(3H, t, J = 7.2 Hz), 1.03 (3H, d, J = 6.4 Hz), 1.17-1.90 (35H, m), 2.10-2.44 (5H, m), 2.57-2.98 
(5H, m), 3.11-3.97 (42H, m), 4.20 (1H, d, J = 8.0 Hz), 4.28 (1H, d, J = 8.0 Hz), 4.56 (2H, t, J = 
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4.0 Hz), 4.92 (1H, d, J = 8.0 Hz), 6.64 (1H, br), 7.30 (2H, d, J = 8.0 Hz), 7.77 (2H, d, J = 7.6 Hz), 
7.98 ppm (1H, s); 13C NMR (100 MHz, CDCl3): δ=10.6, 11.3, 13.1, 14.3, 14.6, 16.5, 19.3, 19.8, 
21.4, 22.3, 25.6, 29.1, 29.6, 29.9, 31.8, 34.9, 36.4, 36.6, 37.0, 38.7, 38.8, 39.4, 40.4, 42.5, 42.7, 
48.2, 56.7, 65.7, 69.7, 70.2, 70.3, 70.5, 70.7, 76.7, 78.7, 79.2, 81.8, 104.0, 121.2, 126.0, 129.4, 
130.1, 138.8, 147.5, 156.2, 169.8, 173.2, 204.4 ppm; HR-MS (MALDI): m/z calcd for 












































Figure 5.11. Synthesis of Tricyclic Ketolide-PEG Thiol (13). Adapted from Dreaden et al. [37]. 
 
Synthesis and Characterization of Macrolide-Gold Nanorods. Colloidal gold nanorods were 
synthesized by seed-mediated growth as described previously.[9] Briefly, 600 µL of ice-cold 10 mM 
NaBH4 was rapidly injected into a stirred 7.5 mL aqueous solution of 0.333 mM HAuCl4 and 0.133 
M cetyltrimethylammonium bromide (CTAB). The mixture was allowed to react for 5 min, after 
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which 320 µL was aliquoted into a 420 mL aqueous solution of 0.479 mM HAuCl4, 95.7 mM 
CTAB, 86.2 µM AgNO3, and 0.528 mM ascorbic acid. The seeded growth solution was gently 
mixed and allowed to react overnight. The crude nanorod product was purified by centrifugation (30 
min, 4185 × g) and stored at 4 ºC until use. All reactions were performed at room temperature under 
aseptic conditions. Particle sizing was performed by transmission electron microscopy (TEM, JEOL 
100CX II). Hydrodynamic diameter (HD) and zeta potential (ζ) was measured using a NanoZS 
Zetasizer particle analyzer (Malvern, 633 nm). Gold nanorods used in these studies were 50 ± 8 nm 
in length and 13 ± 2 nm in width (4.0 ± 0.9 aspect ratio;  λmax~818 nm; HD = 110 ± 10 nm, ζ = 
+46.6 mV). Azith-, Clarith-, TriKeto-, and PEG-AuNRs exhibited HD values of 130 ± 10, 162 ± 4, 
151 ± 2, and 210 ± 9 nm, respectively, and ζ values of +31.9, +35.4, +23.4, and +37.7 mV, 
respectively. 
Nanoparticle ligand coverages were determined as described in Dreaden et al. with slight 
modifications.[38] Briefly, purified gold nanorod concentrates were rapidly injected into aqueous 
solutions containing PEG-thiol or PEG-thiol and macrolide ligands 9, 11, or 13 (PEG-thiol, 
hydroxy octa(ethylene glycol)-lipoic amide). Nanorod/ligand solutions were incubated at 30 ºC, 
under sonication for 12 h, and purified via centrifugation (15 min, 4185 × g; twice). Adsorbate 
coverages of 9, 11, 13, and PEG-thiol were quantified by UV absorption assay (260 nm) and 
Ellman’s assay (Pierce/Thermo Scientific), respectively, using experimentally derived molar extinction 
cross sections for the thiol PEGylated macrolides: ε260 nm = 1.08 ± 0.03 × 104 L mol-1 cm-1 
(azithromycin, 9), 0.841 ± 0.03 × 104 L mol-1 cm-1 (clarithromycin, 11), 1.26 ± 0.02 × 104 L mol-1 
cm-1 (tricyclic ketolide, 13). Molar extinction cross sections of the nanorods were interpolated from 
experimental data in Orendorff and Murphy.[39] Nanoparticles used in coverage assays were 
centrifuged at 18,000 × g for 1 h to remove any trace particles present in the supernatant. Optical 
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extinction measurements were obtained using an Ocean Optics HR4000CG-UV-NIR spectrometer. 
Nanoconjugates used in these studies were functionalized with 1×103 macrolide ligands and 9×103 
PEG-thiol ligands per nanorod, each obtained by incubating with solutions containing 1.3, 1.6, and 
3.9 × 105-fold ligand excesses (9, 11, 13, respectively) (Figure 5.12). Functionalized nanoparticles 
were stably dispersed in growth media over the time course of the experiments (Figure 5.13). 
 
 
Figure 5.12. Extinction spectra of the purified macrolide-gold nanorod conjugates. The near-





Figure 5.13. Spectral stability of macrolide-gold nanorod conjugates dispersed in complete cell 
growth media (24 h, Dulbecco's modified eagle's medium supplanted with 10% v/v fetal bovine 
serum, 20 I.U./mL penicillin, 100 ug/mL streptomycin, and 250 ng/mL amphotericin B). Adapted 
from Dreaden et al. [37]. 
 
Cell Culture. RAW264.7 (ATCC) and J774.2 (Sigma) cells were subcultured in Dulbecco's 
modified eagle's medium supplanted with 10% v/v fetal bovine serum (FBS), 20 I.U./mL penicillin, 
100 ug/mL streptomycin, and 250 ng/mL amphotericin B at 37 ºC in a 5% CO2 humidified 
atmosphere. COLO 205 (ATCC) cells were subcultured in Roswell Park Memorial Institute-1640 
medium with similar supplements and under similar conditions. Spectroscopic assays were performed 
in media lacking phenol red. All experiments were performed on cells passaged 12 h prior. P-gp 
inhibitors were co-incubated with nanoparticle-supplanted media for 24 h.  
Nanoparticle Uptake and Localization. Nanoparticle accumulation was assessed using an 
inverted-objective dark-field scattering microscope (DFSM) and an inverted-objective laser-scanning 
confocal microscope. In dark-field imaging experiments, collagen-coated coverslips were prepared by 
incubating 0.04 mg/mL rat tail collagen/DPBS with glass coverslips (18 mm dia) for 6 h at 37 °C in 
a 5% CO2 humidified atmosphere. The coated substrates were rinsed in DPBS and cells were 
passaged onto the coverslips. After 12 h, growth solutions were replaced with media containing 0.5 
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nM of the nanoconjugates and the cells were allowed to incubate for 24 h. Cell monolayers were then 
rinsed in DPBS and fixed in 4 % paraformaldehyde/DPBS for 15 min at 4 ºC. The fixed coverslips 
were coated in glycerol, and mounted and sealed onto glass slides. Dark-field microscopy was 
performed using an inverted objective Olympus IX70 microscope fitted with a dark-field condenser 
(U-DCW), 100x/1.35 oil Iris objective (UPLANAPO), tungsten lamp, and a Nikon D200 digital 
SLR camera. In confocal fluorescence colocalization experiments, macrolide-AuNR conjugates were 
labeled with a carboxyfluorescein-terminal PEG-SH and cellular endosomes were labeled with a 
fluorescent dextran conjugate. Carboxyfluorescein-PEG-SH was obtained by reacting NH2-PEG-SH 
(5 kDa, Laysan Bio) with 5-(and-6)-carboxyfluorescein succinimidyl ester (Molecular Probes) in a 10 
mM HEPES buffered aqueous solution containing 30% v/v ethanol (pH 7.4) for 24 h at room 
temperature in dark. Fluorescently-labeled PEG-SH was dialyzed twice (500 MWCO, Spectra/Por), 
each time at a 103 volume excess for 24 h with three solvent exchanges. Purified gold nanorod 
concentrates were rapidly injected into aqueous solutions containing PEG-thiol and fluorescently-
labeled PEG-SH or PEG-thiol, fluorescently-labeled PEG-SH, and macrolide ligands 9, 11, or 13 in 
dark, under sonication, at 30 ºC for 12 h. Molar excesses of polymers and ligands were identical to 
those used to prepare unlabeled nanoconjugates, with 11 mol% of the polymer component 
substituted for fluorescently-labeled PEG-SH. Fluorescent macrolide-AuNRs were dialyzed for two 
days (12-14 kDa MWCO) in dark, then centrifuged twice at 4185 × g for 5 min and redispersed in 
deionized water. RAW264.7 cells were incubated in dark with 6 µM Alexa Fluor 647-dextran (10 
kDa, Invitrogen) and 0.5 nM macrolide-AuNR conjugates for 24 h under growth conditions. The 
labeled cells were washed in PBS buffer and fixed in 4% paraformaldehyde/DPBS for 30 min at 4 ºC 
and imaged using an inverted-objective laser-scanning confocal microscope (FluoView 1000; 
Olympus, 60x/1.42). 
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5.2.2 Evidence for the Susceptibility of Nanoscale Drug Carriers to Multiple Drug Resistance: 
Ligand-Dependent P-glycoprotein Efflux and Inhibition 
Targeted cellular uptake of the model nanoscale drug carriers was assessed using a lung 
macrophage cell line, commonly employed in conjunction with studies involving macrolides due to 
their high in vivo accumulation in tumor-associated macrophages and in lung tissues.[30,31] Figure 
5.14A shows that macrolide-AuNRs preferentially accumulate in macrophage cells relative to 
PEGylated control nanoparticles and do so in a dose-dependent manner (t=24 h). As expected, trends 
in accumulation observed here correlate directly with reported trends in efficacy for these drugs in 
treating MDR cell lines.[55] Confocal imaging of fluorescently-labeled nanoparticles (Figure 5.14B) 
further show that uptake and intracellular colocalization of the nanoparticles occurs in a manner 
consistent with that previously reported for macrolide accumulation in phagocytic cells.[65] Dark-
field scattering microscopy (DFSM) also found that uptake of the nanoconjugates occurred in a 
macrolide-competitive manner (Figure 5.15). Together, these data support that intracellular 
transport of the nanocarriers is directed by their macrolide substrate ligands and that endosomal 




Figure 5.14. A) Targeted cellular delivery of macrolide-gold nanorods (AuNRs) to macrophage cells 
illustrating preferential accumulation relative to untargeted control nanoparticles (PEG-AuNRs). B) 
Confocal microscopy of fluorescently-labeled AuNRs (green) illustrating colocalization patterns 
(yellow) similar to that of free macrolides which localize within endocytic organelles (red). Error bars 
represent SD. Adapted from Dreaden et al. [37]. 
 
 
Figure 5.15. Dark-field scattering microscopy (DFSM) of lung macrophage cells illustrating ligand-
competitive cellular accumulation of macrolide-AuNRs. RAW264.7 cells were incubated with 0.5 
nM nanoparticle-supplanted media in the presence and absence of 0.5 µM of their corresponding 
free, non-thiol PEGylated macrolide compounds (24 h). Accumulation was significantly diminished 
in the presence of the free macrolides, corroborating previous finding of macrolide-dependent 
trafficking observed in spectrophotometric assay and intracellular co-localization studies. Adapted 
from Dreaden et al. [37]. 
 
Cellular accumulation of the macrolide-AuNRs was assessed in the presence and absence of 
specific inhibitors [53] for P-gp to determine the effect of P-gp-mediated efflux on retention of the 
nanoparticle constructs. No significant changes in cellular accumulation were observed with P-gp(-) 
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COLO 205 cells [61] in response to P-gp inhibition by either cyclosporine A or verapamil HCl 
(Figure 5.16A). Surprisingly, we observed significantly increased accumulation of Azith- and 
Clarith-AuNRs with P-gp(+) J774.2 cells [53] in response to both inhibitors, with no significant 
changes in TriKeto-AuNR accumulation (Figure 5.16B). These findings agree well with previous 
reports indicating i) macrolide-competitive P-gp binding by verapamil and cyclosporine,[66,67] ii) 
diminished recognition of TriKeto (TE-802) by P-gp,[58] iii) enhanced activity by third-generation 
tricyclic ketolides towards MDR cell lines,[56,57] and iv) P-gp-dependent accumulation/cytotoxicity 
by the free macrolide ligands (Figure 5.17). These data show that P-gp-mediated drug efflux can 
play a significant role in the cellular trafficking and retention of nanoscale drug carriers to which P-gp 
substrates (e.g. chemotherapeutics, imaging agents, etc.) are appended. Concurrent DFSM of 
nanoparticle- and P-gp inhibitor-treated cells (Figure 5.18) further corroborate the findings in 
Figure 5.16, showing augmented cellular accumulation of Azith- and Clarith-AuNRs in the presence 




Figure 5.16. Changes in the cellular accumulation of macrolide-gold nanorods in response to 
competitive inhibition of P-glycoprotein (P-gp) in (A) P-gp null COLO 205 cells and (B) P-gp-
expressing J774.2 cells. P-gp(-) cells exhibit nanoparticle accumulation independent of P-gp 
inhibition by both verapamil and cyclosporine, while P-gp(+) cells exhibit augmented accumulation 
of nanoparticles covalently conjugated with the highly-susceptible P-gp substrates azithromycin 
(Azith-) and clarithromycin (Clarith-). Error bars represent SD. P≤ *0.05, **0.01, ***0.001. Adapted 
from Dreaden et al. [37]. 
 
 
Figure 5.17. Enhanced cytotoxicity of the macrolide ligands (0.5 µM, 24 h) towards P-gp(+) J774.2 
cells in response to competitive P-gp inhibition by cyclosporine A and verapamil HCl. Although the 
macrolide ligands were not toxic up to 10 µM (24 h), cell viability was significantly decreased relative 
to inhibitor-treated control cells following P-gp inhibition and associated [53] increases in 
intracellular macrolide accumulation. Cell viability was assessed by tetrazolium assay (Sigma, XTT). 
Error bars represent SD. P≤ *0.05, **0.01, ***0.001. Adapted from Dreaden et al. [37]. 
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Figure 5.18. Dark-field scattering microscopy (DFSM) showing augmented cellular accumulation of 
Azith- and Clarith-AuNRs in the presence of both P-gp inhibitors and no significant change in the 
accumulation of TriKeto-AuNRs (24 h). P-gp(+) RAW264.7 cells were incubated with 0.5 nM 
nanoparticle-supplanted media for 24 h in the presence of ligand-competitive inhibitors for the drug 
efflux pump P-gp. Images are false color with scattering (orange) overlaid with bright-field 
micrographs (green) for contrast. Adapted from Dreaden et al. [37]. 
 
5.2.3 Outlook and Conclusions 
In summary, we have demonstrated that the transmembrane drug efflux pump MDR1 P-
glycoprotein (P-gp) can significantly decrease the accumulation of nanoscale drug carriers bearing 
ligands recognized by multiple drug resistance (MDR) protein 1. Specifically, we found that the 
cellular accumulation of gold nanorods conjugated with MDR-evasive substrate ligands was 
unaffected by competitive inhibitors for P-gp, while the accumulation of those conjugated with 
MDR-susceptible substrates was significantly enhanced. Although the exocytosis of gold 
nanoparticles [68] and other nanoscale drug carriers is commonly observed, we believe this to be the 
first report of P-gp-mediated drug efflux of a biomedical nanoparticle and suggests that these 
constructs, as a whole, are susceptible to both acquired and intrinsic multiple drug resistance. Because 
P-gp-mediated efflux was found to be ligand-dependent, the use of non-substrate ligands, semi-labile 
or cleavable anchoring groups, or the co-administration of blocking antibodies for P-gp [61] may 
serve to increase the efficacy of these and other therapeutic nanotechnologies in the future. While 
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detailed studies are currently underway to determine the precise mechanism(s) by which P-gp 
facilitates nanocarrier efflux, recent crystallographic studies by Higgins [69] and Chang [44] indicate 
that P-gp’s binding sites are accessible via both the cytoplasm and the inner membrane leaflet, 
suggesting that protection of nanocarriers by the endosomal bilayer may be less effective in MDR 
evasion than previously hypothesized. Further, because of the large size of these particles relative to 
the central pore diameter of P-gp (ca. 5 nm), these findings suggest that the so-called “pore model” is 
less dominant here and that efflux likely proceeds via partitioning of the macrolide ligands into the 
inner membrane leaflet, followed by lateral diffusion and recognition/efflux. P-gp recognizes 
approximately 50% of all chemotherapeutics (e.g. doxorubicin, vinblastine, taxol, etoposide, 
topotecan) and a variety of other compounds (0.3-4 kDa) which bind at multiple and partially 
overlapping sites with a high degree of structural diversity and stereoselectivity.[44,70] Nanoscale 
drug carriers that incorporate P-gp substrate compounds may benefit from minimizing surface 
presentation of efflux-susceptible ligands. 
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CHARGE CARRIER DYNAMICS IN SEMICONDUCTOR-GOLD CORE-SHELL 
NANOROD ARRAYS 
 
6.1 Plasmon-Enhanced Optical and Electronic Processes in Molecules and Materials 
The resonant interaction of electromagnetic waves with electron oscillations at the surfaces of 
nanoscale metals is known as localized surface plasmon resonance (LSPR). LSPR is determined by the 
nanoparticle’s material, as well as its size, shape, and dielectric environment and results in intense 
absorption/scattering and the generation of highly polarized near-fields which dephase on the 
femtosecond time scale.[1-4] Absorbed energy can be dissipated through electron collisions,[5] lattice 
vibrations,[2,6] or resonant coupling to neighboring electronic systems. LSPR coupling interactions 
have been shown to enhance the absorption cross sections of molecules[7] and semiconductor 
nanoparticles[8] in their vicinity, as well as to enhance the optical activity of surface adsorbates.[9] 
Their interactions with radiative electronic systems have been shown to enhance molecular 
fluorescence intensity,[10] Raman scattering,[11-13] second- and third- harmonic generation (SHG 
and THG),[14,15] hyper-Rayleigh scattering,[16] and hyper-Raman scattering.[17] The rational 
design of photovoltaic and photodiode devices incorporating plasmonic elements has also resulted in 
improved performance[18,19] and recently allowed for ultrafast electron spin manipulation in 
colloidal core-shell nanoparticles.[20] 
LSPR coupling with excitonic systems exhibiting well-defined band structure involves 
increasingly complex and varied interactions and has been shown to enhance Förster Resonance 
Energy Transfer (FRET) efficiency between semiconductor quantum dots (QDs),[21] as well as 
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resonant energy transfer between metallic and semiconducting nanoparticles.[22,23] In general, 
plasmon-exciton interactions in solid-state excitonic systems are characterized by i) enhanced 
quantum efficiency,[8,24,25] ii) exciton energy shift,[26,27] iii) increased radiative decay 
rate,[26,28,29] and iv) emission polarized parallel with resonantly coupled LSPR modes.[24,30] 
These phenomena require that the exciton energy overlap with that of the LSPR,[25,31] and that the 
transition dipole moment of the exciton lie collinear with the dipole moment of the LSPR.[24,32] 
Although numerous reports have individually studied the aforementioned phenomena, few 
have performed systematic studies of distance-, energy-, and polarization- dependence. Kotov and 
coworkers have studied CdTe nanowire/Au nanoparticle assemblies in solution and shown a 5-fold 
enhancement in luminescence intensity and a ca. 1/3 reduction in photoluminescence (PL) 
lifetime.[29] Later, using a chemically-responsive molecular linker, they showed that a model based 
on the Förster relation can be used to describe the observed changes in exciton lifetime and emission 
energy due to distance-dependent effects of the LSPR on exciton mobility.[27] In a more recent 
report, Ginger and coworkers performed systematic studies of close-packed monolayers of CdSe 
quantum dots (QDs) upon which Ag nanoprisms with varying LSPRs were deposited.[31] They 
observed maximum enhancement of QD emission intensity, radiative decay rate, and non-radiative 
decay rate when the LSPR wavelength of the prisms coincided with the bandgap energy of the QDs. 
Atwater and Polman have fabricated horizontally aligned arrays of Ag nanorods on substrates 
containing immobilized Si QDs which photoluminesce over the wavelength range of the transverse 
and longitudinal LSPR modes of the nanorods.[24] They observed QD emission enhancement at 
each of the two orthogonally-polarized LSPR wavelengths which polarized parallel to the dipole 
moment of their resonantly coupled plasmon mode. 
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While radiative effects associated with plasmon-exciton coupling in the solid-state is actively 
studied, non-radiative effects[26,33] are less well characterized. In prior publications, we have studied 
plasmon-exciton coupling and non-radiative exciton relaxation in vertically aligned CdTe-Au core-
shell nanorod arrays and found that Au shells supporting LSPRs resonant with the bandgap energy of 
the CdTe core resulted in increased non-radiative exciton relaxation rates which were highly sensitive 
to the incident polarization and the orientation of the longitudinal axis of the rod.[34-36] In low 
aspect ratio nanorod cores, we also observed that by increasing the thickness of the Au shell to 
maximize LSPR extinction, non-radiative excitonic relaxation was enhanced, but no longer exhibited 
tilt-anisotropy. Here, we analyze spectroscopic, computational, and theoretical results obtained from 
extinction-optimized, high aspect ratio nanorod arrays in the context of prior studies and present our 
overall conclusions of how plasmon-exciton coupling in this novel system results in differing 
mechanisms of enhanced non-radiative relaxation. 
6.2 Design, Fabrication, and Modeling of a Nanoscale Electronic System to Study 
Polarization-, Wavelength-, and Field-Dependent Plasmon-Exciton Coupling 
CdTe-Au core-shell nanorod arrays were fabricated as previously described.[34,37,38] 
Briefly, a layer of Bi2Te3 was deposited onto a polyvinyl alcohol surface-corrupted (0001) sapphire 
substrate by pulsed laser deposition (PLD, λexcimer = 248 nm). Heating of the Bi2Te3 layer to 370 ºC 
caused the film to dewet and coalesce into isolated seeds which served as nucleation sites for the 
subsequent vapor-liquid-solid (VLS) growth of the CdTe nanorods. Varying thicknesses of Au were 
then sputtered onto half of each substrate at room temperature. CdTe core and Au shell dimensions 
were experimentally determined by scanning electron microscopy (SEM) and tapping-mode atomic 
force microscopy (AFM), respectively. 
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The experimental configuration of the ultrafast pump-probe measurements has also been 
described in detail elsewhere.[34] Briefly, the core-shell nanorod arrays were optically pumped (λpump 
=  400 nm) by a Ti-sapphire laser (Clark MXR) and absorption at the CdTe bandedge energy (λprobe 
=  770 nm) was subsequently probed as a function of time delay. All experiments were performed at 
low pump fluence to exclude contributions from multiple carrier generation. Transient bleach 
intensity (∆T(t)/T(∞)) was recorded for each array as a function of tilt angle and shell thickness where 
∆T(t)/T(∞) = |T(∞) - T(t)|/T(∞) and T(t) and T(∞)  are transient and steady-state transmission, respectively. 
The array samples were rotated in the kE -plane of the linear-polarized pump and probe beams such 
that θ = 0º corresponds to polarization along the transverse axes of the nanorods and θ = 90º 
corresponds to polarization along the longitudinal axes of the nanorods for propagation vector k
r
 and 
electric field polarization E
r
. 
Optical spectra, electric field distribution, and particle polarization were calculated by 
Discrete Dipole Approximation (DDA). The method approximates a particle as an array of 
polarizable points in a cubic lattice which acquire dipole moments in response to an incident 
electromagnetic field. Each of these dipoles is assigned a position in the array, a relative volume, and a 
complex dielectric function for the particle and its surrounding environment. The method has been 
successfully employed to model the optical properties of plasmonic nanoparticles of complex 
geometry and their arrays for more than 15 years.[3,39,40] 
Optical extinction, absorption, and scattering spectra were calculated using DDSCAT 
6.1.[41] Electric field and polarization plots were calculated using modified Fortran codes of the 
program kindly provided by G.C. Schatz (Northwestern University). Calculations were performed 
using linearly polarized incident excitation for 184 x 74 nm and 283 x 72 nm hemispherically-
capped, cylindrical wurtzite CdTe cores with homogenous Au shells of varying thickness covering all 
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sides but the flat base (~105 total dipoles per particle). Experimentally determined complex refractive 
indices for Au[42] and CdTe[43] were applied in vacuo. Briefly, the polarization P of each point in 
the (i = 1,…,N) dipole array is described in terms of its polarizability αi and response to the local 
electromagnetic field Eloc at position ri 
)( ilocii rEP •= α ,     (1) 
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for amplitude E0 and wavevector k=ω/c of the incident electromagnetic field. The collective 
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Substitution and rearrangement of Equations (2) and (3) into Equation (1) gives 
EPA =•' ,      (4) 
where A’ is a 3N×3N interaction matrix for the system and E and P are 3N-dimensional vectors. 
Solution of these 3N complex linear equations yields wavelength-dependent polarization vectors for 
each dipole, from which electric field intensities, as well as extinction, absorption and scattering cross 
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for Cext = Cabs + Csca. 
6.3 Plasmon-Enhanced Nonradiative Charge Carrier Relaxation in Nanoscale Semiconductor 
Photovoltaic Materials 
Figures 6.1A,B show the SEM images of the of the fabricated low and high aspect ratio 
CdTe-Au core-shell nanorod arrays, respectively. As shown previously,[38] these nanorods appear 
structurally isolated from one another and exhibit a high degree of size and shape uniformity. Because 
the low and high aspect ratio nanorod arrays were grown from the same diameter seeds, their widths 
are likewise similar. X-ray diffraction indicates the CdTe cores to be wurtzite single crystal with 
alternating Cd2+ and Te2- layers stacked along the growth direction of the rod (i.e. the c-axis). Note 
that the ground-state absorption transition moment µr Eg of the nanorod therefore lies parallel to its 
longitudinal axis. Following previous reports,[24,32,35] plasmon-exciton coupling is expected to be 
strongest when the surface plasmon field E
r
SPR is oriented parallel to the ground-state absorption 
moment µr Eg. Quantum confinement effects are not expected here (rBohr = 7.5 nm). Figure 6.1C 
shows a schematic of the experimental configuration used for the ultrafast transient absorption 
measurements. Nanorod arrays were tilted from θ = 0 - 75 º, in the kE -plane where θ is the angle 
between the longitudinal axis of the nanorod and the incident field propagation vector k
r
 with linear 
polarization E
r
of the laser. The arrays are optically pumped at 400 nm by a Ti-sapphire laser and 
absorption (770 nm) is probed at varying delay times. The pump wavelength was chosen to coincide 




Figure 6.1. SEM images of (A) low and (B) high aspect ratio CdTe-Au core-shell nanorod arrays and 
(C) a schematic of the experimental configuration used for transient absorption measurements. The 
arrays were tilted from θ = 0 - 75 º in the kE -plane, where θ is the angle between the longitudinal 
axis of the nanorod and the incident field propagation vector k
r
 with linear polarization E
r
. The 
arrays are optically pumped at 400 nm by a Ti-sapphire laser and absorption (770 nm) is probed at a 
varying time delay. Low and high aspect CdTe nanorod cores are ca. 74 nm in width with 184 nm 
and 285 nm length, respectively. Adapted from Dreaden et al. [46]. 
 
In order to maximize plasmonic field effects of the Au nanoshell on the CdTe nanorod cores, 
optical response at the ground-state absorption bandedge energy (770 nm) of the core was modeled 
as a function of Au shell thickness. Figure 6.2A,B show the calculated angle- and wavelength- 
dependent extinction cross sections of low and high aspect ratio CdTe cores, respectively, with thin, 
15 nm Au shells. As depicted in the inset of Figure 6.2A, transverse and longitudinal pump laser 
polarizations are denoted 0° and 90°, respectively. Figures 6.2C,D illustrate similar plots for Au 
shell thicknesses theoretically predicted to maximize relative plasmon extinction anisotropy at the 770 
nm probe wavelength. In both the low and high aspect ratio CdTe cores, thickening of the Au shell 
was found to result in a spectral blue-shift of the longitudinal ( θ = 90º) plasmon resonance, thereby 
increasing its overlap with the 770 nm CdTe ground-state absorption wavelength. These spectral 
shifts are consistent with experimentally observed thickness-dependent optical responses from 
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spherical core-shell nanoparticles.[4,20,47] We observed 4.3- and 2.6- fold LSPR extinction 
anisotropy in low and high aspect ratio core-shell nanorods, respectively, with 15 nm Au shells, while 
9.4- and 4.3- fold anisotropy was observed with optimized shell thicknesses. 
 
 
Figure 6.2. Calculated wavelength- and angle- dependent LSPR extinction cross section for CdTe-
Au core-shell nanorods with varying shell thicknesses. Low aspect ratio nanostructures were 
approximated as 184 x 74 nm hemispherically-capped, cylindrical wurtzite CdTe cores with 
homogeneous (A) 15 nm and (C) 26 nm outer Au shells covering all sides but the rod base. High 
aspect ratio (283 x 72 nm) CdTe cores with (B) 15 nm and (D) 39 nm outer Au shells were similarly 
calculated in vacuo. The 770 nm CdTe absorption bandedge (probe wavelength) is denoted by 
dashed white lines. Adapted from Dreaden et al. [46]. 
 
Carrier dynamics in the nanorod cores were monitored at the CdTe bandgap energy so that 
the observed decay kinetics excluded contributions from rapid intraband relaxation.[48] Figure 6.3 
illustrates tilt-dependent transient absorption kinetics of the probe excitation (770 nm) in low and 
high aspect ratio CdTe-Au core-shell nanorod arrays with thin (15 nm) and thick (extinction-
optimized) shell thicknesses. In all cases, enhanced relaxation rates were observed relative to bare 
CdTe nanorod arrays (4.5 ps). Both low and high aspect ratio CdTe nanorod cores with 15 nm outer 
Au shells exhibited enhanced non-radiative relaxation with increasing tilt angle, showing 60% and 
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50% reductions in decay lifetime, respectively. In contrast, both CdTe nanorod cores with outer Au 
shell thicknesses optimized for tilt-dependent LSPR extinction anisotropy exhibited orientationally 
isotropic decay kinetics. We note here dramatic differences in the order of the observed decay rate 
kinetics, indicating mechanisms with different dependencies on carrier concentration. Transient 
absorption kinetics of both CdTe nanorod cores with thin Au shells (at low angle) and those from the 
cores with thicker Au shells (at all angles) exhibit (semi-linear) second-order decay kinetics which we 
attribute to Auger recombination.[49] In contrast, decay kinetics of both CdTe nanorod cores with 
thin Au shells (at high angle) displayed increasingly rapid first-order (exponential) decay kinetics 
expected in the case of excited-state absorption. Contributions from electron-phonon coupling in the 
gold shell are not anticipated here due to the fact that such decay rates are insensitive to both size and 
shape and are much slower than those observed here.[2,50] Further, the decrease in decay lifetime 
relative to bare CdTe nanorod cores (4.5 ps) observed for all in the transverse configuration is 
believed to be associated charge-transfer interactions between the CdTe conduction band and the 
gold Fermi band.[34] We should also note that our analyses here are concerned with mechanisms of 
non-radiative relaxation in the absence of surface and/or defect contributions. In cases where surface 
and/or trap recombination become increasingly significant (i.e. higher surface:volume, lower aspect 




Figure 6.3. Transient bleach of CdTe absorption (770 nm) as a function of tilt angle (º) for 
vertically aligned arrays of low and high aspect ratio CdTe-Au core-shell nanorods with optimal and 
sub-optimal Au shell thicknesses. CdTe nanorod cores of aspect ratio (A) ca. 2 and (B) 3 coated with 
15 nm outer Au shells exhibit tilt-dependent non-radiative relaxation of the probe excitation while 
CdTe nanorod cores of aspect ratio (C) ca. 2 and (D) 3 coated with Au shell thicknesses optimized 
for tilt-dependent LSPR extinction anisotropy exhibit orientationally isotropic non-radiative carrier 
relaxation. CdTe aspect ratio, Au shell thickness, incident field polarization, and decay lifetimes are as 
indicated. λpump = 400 nm, λprobe = 770 nm. Adapted from Dreaden et al. [46]. 
 
Increased non-radiative exciton relaxation rates in the CdTe-Au nanorods are proposed to 
result from enhanced ground- and/or excited-state absorption processes.[36] Recall that the c-axis of 
the single crystal, wurtzite CdTe nanorod core lies along its longitudinal axis. Absorption from its 
ground electronic state therefore occurs with a transition moment µr Eg parallel to the long axis of the 
nanorod core, with enhanced rates observed for perturbations (e.g. surface plasmon fields) having 
significant dipolar contribution parallel to this moment. This ground-state absorption process, 
depicted in Figure 6.4A, increases exciton density and Coulomb coupling between charge carriers, in 
turn resulting in energy transfer from one exciton to another. This transfer (Auger recombination) 
occurs on the sub-nanosecond scale, competing with radiative relaxation and resulting in a net 
ionization of the nanorod core and second-order (semi-linear) relaxation kinetics.[51] Because the 
decay of excited-state electrons is equal to the decay rate of excited-state electrons times the 
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concentration of excited-state electrons, one can see that rearrangement and integration of the rate 
expression will yield an exponential decay function. In contrast, absorption from the excited-state 
(Figure 6.4B) may result in intraband electronic transitions into the CdTe conduction band, into 
the Au shell, or stimulated emission. Here, the excited-state decay rate is equal to the Auger 
recombination rate times the concentration of excitons squared, yielding a decay with linear 
dependency after integration. Because the decay rate involving excited-state absorption is first-order 
with respect to exciton concentration and Auger recombination (ground-state absorption) is second-
order, we expect to observe exponential decay kinetics when excited-state absorption dominates and 





Figure 6.4.  Proposed plasmon-enhanced exciton interactions in CdTe-Au core shell nanorod arrays. 
A) Enhanced ground-state absorption by resonantly-coupled plasmon fields ESPR parallel to the 
bandgap absorption transition moment µ
r
Eg results in increased carrier density and less rapid Auger 
recombination. B) Enhanced excited-state absorption by resonantly-coupled plasmon fields E
r
SPR 
non-parallel to the bandgap absorption transition moment µ
r
Eg results in increasingly rapid 
ionization processes. The decay rate in (A) is second-order whereas in (B) it is first-order with respect 
to exciton concentration.[36] Semi-linear and semi-exponential decay kinetics are therefore expected 
when (A) and (B) dominate plasmon-enhanced relaxation, respectively. Adapted from Dreaden et al. 
[46]. 
 
Computational modeling of the plasmon field strength and induced polarization in the 
nanorod arrays further corroborates LSPR effects on ground- and excited-state absorption and 
subsequent tilt-dependent non-radiative decay kinetics. Figure 6.5 illustrates the calculated electric 
field enhancement distribution (at λ = 770  nm) for CdTe-Au core-shell nanorods of varying aspect 
ratio, shell thickness, and tilt angle. The distribution of polarization induced parallel to the CdTe 
ground-state absorption transition moment µr Eg is also shown for these configurations. Significant 
plasmonic field enhancement was observed in all cases with apparent dipolar character for all in the 
transverse (0º) configuration, regardless of aspect ratio or shell thickness. Because this transverse 




Eg, it is thus expected to enhance 
ground-state absorption of the probe excitation and lead to second-order decay kinetics in all cases. 
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As in Figure 6.4A, the predominant contributor to second-order non-radiative decay kinetics 
observed for all in the transverse configuration is attributed to enhanced ground-state absorption and 
Auger recombination. In the longitudinal (90º) configuration, both nanorod cores with thin Au 
shells exhibit plasmon fields with diminished dipolar contributions along the ground-state absorption 
transition moment µr Eg of the core (Figures 6.5A,B). In this orientation, we expect, and indeed 
observe, increasingly rapid first-order non-radiative relaxation kinetics which we attribute to 
predominant excited-state absorption (Figure 6.4B). In contrast, when coated with LSPR extinction-
optimized Au shell thicknesses, the longitudinal plasmon modes appear dipolar with respect to µr Eg 
(Figuress 6.5C,D) and we expect probe absorption decay similar to the second-order kinetics 
observed in the transverse configuration. Here, experimentally observed decay kinetics agree well with 




Figure 6.5. Calculated plasmonic field enhancement (color) and normalized polarization distribution 
induced parallel to the CdTe ground-state absorption transition moment µ
r
Eg (grayscale) for 770 nm 
probe excitation in CdTe-Au core-shell nanorods of varying aspect ratio, shell thicknesses, and 
orientation. Transverse and longitudinal excitation of structures with 15 nm Au shells is shown for 
(A) low and (B) high aspect ratio CdTe nanorod cores. Transverse and longitudinal excitation of 
structures with extinction optimized Au shells is shown for (C) low and (D) high aspect ratio CdTe 
nanorod cores. Adapted from Dreaden et al. [46]. 
 
6.4 Outlook and Conclusions 
In conclusion, plasmonic field enhancement of non-radiative exciton relaxation rates was 
investigated in vertically-aligned arrays of high aspect ratio CdTe-Au core-shell nanorods. Increasing 
shell thickness in the high aspect ratio nanorods was found to result in dramatic differences in the 
polarization-dependent non-radiative relaxation kinetics of charge carriers in the CdTe cores. Based 
on computational modeling and kinetics analyses, we attribute these differences to varying 
mechanisms of plasmonic field enhancement which result in either predominant ground- or excited- 
state absorption processes. Our results were compared with previous investigations of low aspect ratio 
CdTe-Au core-shell nanorods to provide overall conclusions regarding plasmonic field effects on non-
radiative exciton relaxation rates in this system. We propose that when the dipolar component of the 
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resonantly-coupled plasmon field of the shell is polarized parallel to the ground-state absorption 
transition moment of the CdTe core that exciton-exciton annihilation (Auger recombination) 
dominates carrier relaxation kinetics and slower second-order decay rates are observed. When 
contributions of the resonantly-coupled plasmon field are non-dipolar or orthogonal to the ground-
state absorption transition moment of the CdTe core, excited state absorption processes are believed 
to dominate and increasingly rapid first-order decay kinetics are observed. These processes were 
found to vary greatly depending on the thickness of the Au shell and the orientation of the array, but 
were insensitive to aspect ratio of the nanorods. These findings have significant implications in the 
optimal design of photovoltaic and optoelectronic devices incorporating anisotropic active layers 
and/or plasmonic elements. 
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PLASMON HYBRIDIZATION IN SURFACE ENHANCED RAMAN 
SCATTERING 
 
7.1 Raman Spectroscopy and Electromagnetic Contributions to Surface Enhanced Raman 
Scattering 
 Since its first observation in the mid-1970’s,[1-3] significant progress in the fundamental 
understanding of processes associated with surface-enhanced Raman scattering (SERS) – namely, 
electromagnetic[3-8] (EM) and chemical[2,9-12] enhancement – has been achieved. Although only 
one in 106 photons incident upon a sample typically are Raman scattered,[13] proximity to a 
nanostructured metal surface has been shown increase Raman signal intensity by factors as much as 
106 to 1014.[14-19] EM enhancements arise in nanostructured metals, noble metals in particular, due 
to their large surface-to-volume ratio. While noble metals support bulk plasmons which oscillate at 
mid- to far- UV wavelengths, their surface plasmons do so at near-UV, visible, and near-IR 
wavelengths, resonantly coupling with light in the energetic range  of commonly used laser excitation 
sources and their Raman scattered photons. Resonant excitation of surface plasmons (absorption) 
serves to focus and confine photons at sub-diffraction limited volumes, resulting in highly intense 
local electric fields which amplify both the incident and Raman-scattered photons (i.e.E2×E2). 
Electric field enhancements (E4) can be as high as 105 at the surfaces of single nanoparticles[20] 
and as high as 1010 to 1014 in nanoparticle dimers,[21] arrays,[22] and aggregates.[23] EM 
enhancement by such multiparticle systems has allowed for the sensitive detection of SERS from 
single-molecules.[15,17,24-27] Surface plasmon resonance has also been shown to enhance 
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spectroscopically relevant non-linear optical processes such as second-harmonic generation,[28-30] 
hyper-Rayleigh scattering,[31-34] and hyper-Raman scattering.[35] 
7.2 Hot Spots, Plasmon Resonance, and Symmetry 
Coupled nanoparticles (e.g. dimers, arrays, and aggregates) supporting optical surface 
plasmons have been shown to generate highly intense local electric fields at their junctions – so called 
“hot spots”[15,17,25,26] – which allow the small fraction of molecules therein to contribute to the 
majority of the observed SERS signal.[23] Recently, plasmonic nanoparticles of triangular 
geometry[36-38] have been shown to generate large EM fields due to their sharp surface features and 
associated “lightning rod” effect.[39,40] Accordingly, coupled triangular nanoprisms,[41,42] or 
bowtie antennas,[43-46] have been shown by Van Duyne and Moerner to generate tremendous EM 
enhancement at their junctions due to near-field coupling between surface plasmon modes of the 
same parity (i.e. mode, order, symmetry, angular momentum, ℓ) on adjacent nanoprisms. 
Studies of EM SERS enhancement, in particular, have spurred great interest in the 
plasmonic properties of nanoscale materials and the coupling interactions of their near-fields. 
Advances in lithographic,[36,44,46,47] spectroscopic,[48-51] computational,[21,38,52-54] and 
synthetic[55-57] methods have improved our fundamental understanding of how near-fields of 
surface plasmon modes can couple and enhance one another with decreasing distance. Schatz, Halas, 
and Nordlander have contributed greatly to our understanding of these processes, illustrating the 
complex, distance-dependent relationships between surface plasmon resonance mode, frequency, 
coupling strength, and field localization/intensity.[21,50,52] More recently, “forbidden” (∆ℓ>0) 
coupling between surface plasmon modes of dissimilar order has been shown theoretically and 
experimentally to increase at small interparticle distances due to reduced symmetry.[50,52,53,58-60] 
This broken symmetry allows so-called “dark” plasmons – modes which lack a net moment in the 
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isolated (primitive) particle – to become optically excitable. More importantly, symmetry reduction 
also creates admixtures of these primitive plasmon modes, rendering them dipole-active. Because EM 
SERS enhancements are most often greatest at short interparticle distances, multimodal plasmon 
coupling interactions become increasingly important in interpreting observed Raman enhancements 
from multiparticle assemblies, particularly at the single-molecule level. 
7.3 Design and Fabrication of Nanoparticle Arrays to Study Distance-Dependent Multipolar 
Plasmon Coupling 
The work herein investigates the effect of reduced symmetry and multimodal plasmon 
coupling on SERS enhancements from Au nanoprism pair arrays separated at varying distances. We 
show that at short interparticle distances, intraparticle coupling of the primitive dipole plasmon 
modes with primitive higher order plasmon modes can increase SERS intensity by imparting dipolar 
character to the latter. Gold nanoprism pair arrays were fabricated by electron-beam lithography and 
distance-dependent SERS enhancement of substrate phonon vibrations excited in the vicinity of the 
prism pair’s primitive quadrupolar surface plasmon resonance was investigated. In contrast to that 
expected for single-mode coupling interactions alone, we found that SERS intensity increased 
significantly when the particles approached one another. Theoretical modeling found this effect to 
result from a further reduction in symmetry and increased dipolar character of the plasmon resonance 
at the Raman excitation/scattering wavelength. These results reiterate the importance of considering 
changes in both plasmon field intensity and mode in the interpretation of Raman enhancement from 
multiparticle assemblies and roughened surfaces, particularly at the single-molecule level. 
Au nanoprism arrays were fabricated using a JEOL JBX-9300FS 100 kV electron beam 
lithography (EBL) system. Silicon nitride substrates were pre-fabricated as described elsewhere.[61] 
Briefly, a layer of Si3N4 was deposited onto a prime grade double-side polished silicon wafer, followed 
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by selective etching of the Si wafer to produce an array of freely supported silicon nitride membrane 
windows ca. 150 x 150 µm2 in area. Each window was covered in its entirety by a single 200 x 200 
 µm2 design pattern comprising several thousand particle pairs spaced >800 nm from one another to 
reduce far-field coupling. Tip-to-tip separation of the nanoprism pairs was varied from 9-220 nm. 
The Si3N4 membrane was spin-coated with an 80 nm poly methyl methacrylate (PMMA) resist and 
patterned with electron beam doses 2500-3500 µC/cm2 with a 2 nA beam current.  Following 
exposure, the wafer was developed in a solution of isopropyl alcohol and methyl isobutyl ketone (3:1, 
IPA:MIBK) for 10 sec, rinsed in IPA for >60 sec, and dried in N2. A CVC electron beam evaporator 
was then used to deposit a 0.5 nm Cr adhesion layer (0.1 Å/sec), followed by 19 nm of Au (0.5 
Å/sec). After deposition, the remaining PMMA was removed by imersion in 1165 remover 
(MicroChem), leaving the gold nanoprism arrays. Samples were imaged by scanning electron 
microscopy (SEM, Zeiss Ultra 60 FE-SEM) at 10 kV accelerating voltage using a secondary electron 
detector. Topographical analyses of the deposits were performed using a Dimension 3000 (Digital 
Instruments) atomic force microscope in tapping mode. All nanoprism arrays were deposited on the 
same Si3N4 membrane array.  
Electric field distribution, particle polarization, and optical spectra were calculated by the 
Discrete Dipole Approximation (DDA), a finite-element computational method used to model the 
electromagnetic properties of sub-wavelength particles. DDA approximates a nanoparticle as a 3-
dimensional array of points in a cubic lattice which acquire dipole moments upon excitation by an 
incident electromagnetic field. Each dipole possesses a unique position in the array, a volume, and a 
complex dielectric function for the material and its surroundings. DDA has been used to model the 
electromagnetic responses of plamonic nanoparticles with high precision for more than a 
decade.[38,54,62-66] 
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Optical spectra (extinction, absorption, and scattering) were calculated using DDSCAT 
6.1.[67-71] Electric field enhancement and particle polarization plots were calculated using Fortran 
codes of the program modified by G.C. Schatz (Northwestern University). All calculations were 
performed for triangular plates 18 nm in height with 59 nm base length and 70 nm bisector length 
(ca. 3.7 × 104 dipoles per particle) for incident field polarization parallel with the prism’s bisector. 
Particle pairs were coupled coplanar with tip-to-tip orientation. Electric field and polarization plots 
were taken in the plane of the particle’s center of mass. Complex dielectric functions for Au [72] and 
the Si3N4 [73] support were applied using effective medium theory.[47,74-76] Note that herein we 
model the optical response of nanoparticle pairs down to 9 nm edge-to-edge separation and therefore 
neglect quantum mechanical contributions which impart a spatially non-local dielectric function at 
gaps ca. 2 nm and below.[77-79] 
Dipole-dipole coupling of prism pairs was approximated using a derivation[49] of the 
quasistatic interaction of coupled dipoles model by Kreibig and Volmer [80,81] where Claussius-
Missoti dipole polarizabilities, near-linearity of the Au dielectric function over the wavelength shift 
region, effective medium,[47,74-76] and “head-to-tail” orientation of dipoles is assumed. The 
function was solved by deriving the prism shape factor (γ) which is equal to the negative of the ratio 
of the metal:medium dielectric functions at the dipolar surface plasmon resonance wavelength. 
Volume polarizability ( Λ=6) was adjusted until reasonable fit was observed. In agreement with 
previous reports of shape factors derived for colloidal Ag prismsatic plates,[82] the shape factor ( γ) 
for this prism was found to be 12.5 (or L=0.0739). The sensitivity factor (S), which describes the 
change in a particle’s surface plasmon resonance wavelength as a function of its medium’s refractive 
index (∂λ/∂RIU), was found to be 209 nm/RIU, remarkably, within 2% of that experimentally 
determined by Mirkin, Schatz, and Van Duyne (205 nm/RIU, Figure 7.1).[83] 
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Figure 7.1. Calculated change in Au nanoparism extinction (solid) and absorption (dashed) cross 
section in varying medium refractive index. Adapted from Dreaden et al. [84]. 
 
Steady-state optical extinction spectra were obtained using a SEE110 microspectrometer 
fitted with a pinhole aperture, fiber optic-coupled CCD array detector, 20× objective (ca. 64 µm2 
detection area), and tungsten lamp. Spectra were averaged over 500 scans to minimize noise. The 
incident beam propagated perpendicular to the plane of the nanoparism array was polarized parallel 
to their interparticle axis. 
Raman spectroscopy was performed using a JOBIN YVON Ramanor HG2S spectrometer 
equipped with a µ-Raman attachment and argon ion laser excitation (514.5 nm, 390 s int, 10 accum, 
14 mW input). Stokes-shifted spectra were collected in a backscattering configuration. The incident 
beam propagated perpendicular to the plane of the nanoprism array and was polarized parallel to the 
interparticle axis. 
7.4 Contributions from Plasmon Hybridization to Off-Resonance SERS in Nanoparticle 
Assemblies 
Figure 7.2A,B illustrate SEM images of the fabricated Au nanoprism pair arrays showing 
well-defined shape and homogenous separation. The nanoprisms were found by scanning electron 
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microscopy (SEM) and atomic force microscopy (AFM) to be 19±1 nm in height with a 59±4 nm 
base length and 70±5 nm bisector length. Optical extinction spectra of the arrays (Figure 7.2C) 
exhibit spectral red-shift in surface plasmon resonance when polarized along the interparticle axis of 
the prisms, a characteristic indicative of near-field plasmon coupling.[21,42 ,50-53,85] 
Computational electromagnetics calculations (Figure 7.2D) show excellent agreement with 
experimental results (Figure 7.3). 
 
 
Figure 7.2. SEM images of Au nanoprism pair arrays fabricated by electron beam lithography (EBL) 
with (A) 28.9 nm and (B) 219.6 nm tip-to-tip separation. C) Selected experimental and (D) 
calculated polarized optical extinction spectra of Au nanoprism pairs illustrating spectral red-shift 
from distance-dependent plasmon coupling. Scale bars in (A,B) and their insets represent 200 nm 
and 30 nm, respectively. The incident field in (C) and (D) propagate into the plane of the prism 




Figure 7.3. Normalized observed (left) and calculated (right) extinction spectra of Au nanoprism 
pairs oriented tip-to-tip at and polarized along the interparticle axis at varying separation distances. 
Experimental spectra required normalization due to signal intensity fluctuations. Observed prisms are 
19±1 nm in height with 59±4 nm base length and 70±5 nm bisector length. Calculations were 
performed for prisms 18 nm in height with 59 nm base length and 70 nm in bisector length. 
Adapted from Dreaden et al. [84]. 
 
Calculations of the electric field distribution, induced polarization, and near-field coupling 
were performed to correlate the SERS responses from the Au nanoprism pair arrays with changes in 
their respective plasmon modes and field enhancements as a function of distance. Figure 7.4 
illustrates wavelength-dependent electric field intensity distributions (top panel) and induced particle 
polarizations (bottom panel) for a single (i.e. unpaired) Au nanoprism polarized along its bisector (see 
Figure 7.2A inset). The strong extinction band observed at 827 nm in Figure 7.2C,D and Figure 
7.3 is attributed to the dipolar surface plasmon resonance (Figure 7.4). Consistent with reports by 
Schatz and coworkers,[21,38] this resonant mode exhibits maximum field intensity at the prism tips 
with opposing poles observed along the bisector at the particle-medium interface. The weak, blue-
shifted band at 558 nm is assigned to the quadrupolar surface plasmon mode of the prism. In 
contrast to the dipolar mode, this resonance exhibits maximum field intensity along its sides with like 
poles observed both along the bisector and its orthogonal axis (Figure 7.4).[21,38]  The peak 
shoulders at 623 and 514.5 nm exhibit mixed modes of surface plasmon resonance with field 
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intensity and polarization distributions characteristic of admixtures of dipolar and quadrupolar 
modes. In both cases, field intensity is neither fully localized at the prism tips, nor its sides. Particle 
polarization at both wavelengths (623 and 514.5 nm) appears as the superposition of those observed 
in the dipolar and quadrupolar modes with the shoulder at 623 nm exhibiting a stronger dipolar 
contribution (Figure 7.5). Note that the aforementioned conclusions are true only for incident 




Figure 7.4. Wavelength-dependent electric field intensity distributions (top panel) and particle 
polarization plots (bottom panel) for a single, unpaired, Au nanoprism. Dipolar and quadrupolar 
surface plasmon modes correspond to 827 and 558 nm, respectively, with mixed modes at 623 and 
514.5 nm. Wavelengths, incident field polarization, and color intensity scale are as indicated. Solid 
and open poles indicate strong and weak directionality, respectively, and have been qualitatively 
added to facilitate interpretation. Maximum color intensity of the 827 nm dipole resonance is scaled 
to 10% and magnitudes of the displacement vectors are scaled as indicated to aid in comparison. 
Asymmetry in some particle polarization plots is due to a random 75% reduction in illustrated dipole 




Figure 7.5. Calculated extinction spectrum of a single Au nanoprism with peak assignments and 
wavelengths of interest noted. The dipolar surface plasmon resonance (red, ℓ=1), quadrupolar surface 
plasmon resonance (green, ℓ=2), 623 nm shoulder resonance (yellow), and shoulder resonance at the 
514.4 nm SERS excitation wavelength (blue) are illustrated for a prism 18 nm in height with 59 nm 
base length and 70 nm bisector length. Adapted from Dreaden et al. [84]. 
 
Having determined the surface plasmon contributions at our Raman excitation wavelength 
(514.5 nm) for single Au nanoprism particles, we now consider distance-dependent electromagnetic 
properties of pairs coupled tip-to-tip. As can be seen in Figure 7.2C,D and Figure 7.3, the 
polarized dipolar surface plasmon resonance of individual Au nanoprisms (ca. 827 nm) red-shifts 
considerably as their near-fields couple with decreasing distance. Fractional wavelength shifts 
observed from this mode (Figure 7.6), show excellent agreement with both computational and 
classical electromagnetic calculations for dipole-dipole coupling (i.e. 1/distance3 dependence as 
1/dℓ+ℓ’+1 for ℓ=1 for dipoles and ℓ=2 for quadrupoles, etc.). Moreover, we note a significant increase in 
peak broadening and asymmetry, as well as a decrease peak intensity, of the coupled dipolar mode as 
the prisms approach (Figure 7.3). These effects indicate redistribution of the primitive dipolar 
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plasmon’s oscillator strength by coupling to higher order plasmon modes on the adjacent prism as 
symmetry is reduced with distance.[87] In agreement with the plasmon hybridization model, a small 
increase in oscillator strength of the quadrupolar surface plasmon resonance at 558 nm is indeed 
observed (Figure 7.7).  
 
Figure 7.6. Experimental and calculated fractional wavelength shift of the dipolar surface plasmon 
resonance mode of Au nanoprism pairs oriented tip-to-tip as a function of separation:bisector ratio 
indicating strong near-field coupling characteristic of dipole-dipole interactions. Au nanoprism pairs 
are polarized along their interparticle axis. Adapted from Dreaden et al. [84]. 
 
 
Figure 7.7. Calculated extinction spectrum of Au nanoprism pairs oriented tip-to-tip at varying 
separation distances in the region of 514.5 nm SERS excitation (dotted black line). Each prism is 18 




As discussed previously,[50,52,53,58-60] coupling interactions between surface plasmon 
modes of unequal parity become allowed at short distances due to reduced symmetry, increasing the 
relative dipolar character of higher order plasmon modes. Calculations presented in Figure 7.8 
further support this behavior in the Au nanoprism pairs. Change (%) in field intensity distribution at 
the Raman excitation wavelength was plotted for a fixed Au nanoprism as another prism interacts 
with it from 164 nm to 9 nm tip-to-tip separation. Redistribution of the electric field intensity clearly 
shows increased dipolar character and further indicates mixing of the adjacent particle’s primitive 
dipolar plasmon mode with that of the resonance at 514.5 nm. This mixing reflects a further 
reduction in symmetry of the charge distribution about the prism due to field perturbation by 
adjacent particle. Because of this, the plasmon mode at the Raman scattering wavelength becomes 
increasingly dipole-active as the prisms approach, increasing their ability to enhance the incident and 




Figure 7.8. A) Calculated percent change in electric field intensity distribution for a fixed Au 
nanoprism (λ=514.5 nm) as another approaches from 164 to 9 nm tip-to-tip separation. B) Increased 
dipolar (ℓ =1) character at small distances indicates mixing of the prism’s 514.5 nm mode with the 
primitive dipolar surface plasmon mode of the adjacent particle due to reduced symmetry and allows 
for increased coupling to the incident and Raman scattered photons. Wavelength, incident field 
polarization, and color intensity scale are as indicated. Adapted from Dreaden et al. [84]. 
 
Distance-dependent EM enhancement was further examined and is shown in Figure 7.9,10. 
Maximum and integrated SERS enhancement E4 was calculated for Au nanoprism pairs at the 
514.5 nm Raman scattering wavelength and at their coupled dipolar surface plasmon mode as a 
function of distance (Figure 7.10). It assumed here that field enhancement at the incident and 
Stokes-shifted wavelengths are effectively equivalent. Almost no change in the maximum and 
integrated E4 is observed at our Raman scattering wavelength, while that of the coupled dipolar 
mode noticeably increases with decreasing distance.[46] This data indicates that distance-dependent 




Figure 7.9. Raman spectrum of the first-order optical phonon resonance of silicon (520 cm-1) at 
varying Au nanoprism pair separations. The incident field (λex=514.5 nm) was polarized along the 




Figure 7.10. A) Calculated maximum SERS enhancement E4 and (B) integrated E4 of the 
dipolar surface plasmon modes and that at the 514.5 nm Raman laser wavelength as a function of Au 
nanoprism separation for interparticle coupling interactions alone. Note the sensitivity to distance by 
the dipolar mode and lack thereof by the mode at the 514.5 nm Raman scattering wavelength. 
Maximum E4 was observed at the central plane bisecting the Au nanoprism pairs and 
integratedE4 was taken across a 0.12 µm2 × 0.001 µm plane bisecting the prism pair. Adapted 
from Dreaden et al. [84]. 
 
Results from finite-element calculations can be summarized as such: i) distance-dependent 
redistribution of the primitive dipole plasmon’s oscillator strength to higher order plasmon modes ( 
specifically to that at the Raman excitation wavelength) was observed; ii) net electric field intensity at 
the Raman excitation wavelength was found to be insensitive to interparticle distance; iii) dipolar 
redistribution of the electric field intensity  at the Raman excitation wavelength was found at short 
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interparticle distances. Based on these results, we expect distance-dependent optical coupling and 
polarized SERS enhancement to occur only at short interparticle distances. 
Raman spectroscopy is often used in microelectronics processing to characterize 
semiconductor materials and their associated electronics states, phonon interactions, charge carriers, 
purity, crystal structure, etc.[88-91] The first order (q=0) optical phonon resonance of silicon[92] 
(520 cm-1) is particularly useful and can be used to probe stress/strain,[89,93,94] temperature,[95,96] 
crystallinity,[90] and charge carrier concentrations,[97] in silicon chip devices. Enhancement of the 
first-order optical phonon resonance of silicon (520 cm-1), commonly observed in Si3N4 thin 
films,[98-100] was probed by polarized Raman spectroscopy (λex=514.5 nm). Figure 7.11 compares 
observed and calculated enhancement of integrated Raman intensity at decreasing Au nanoprism 
distances. Although EM calculations predict negligible distance-dependent changes in E4, SERS 
enhancement is indeed observed as Au nanoprism pairs approach. Moreover, the observed 
enhancement is found to occur with a distance-dependence similar with that predicted for dipole-
dipole interactions. Note that these factors do not reflect so called “SERS enhancement factors” as 




Figure 7.11. Observed distance-dependent enhancement of polarized Raman scattering intensity 
(520 cm-1) for the Au nanoprism array (black squares) and that calculated based on maximum field 
intensity alone (red circles). Distance-dependent enhancement calculated for dipole-dipole coupling 
between Au nanoprism pairs is shown for reference. Calculated enhancement is reported as fractional 
E4 relative to 164 nm separation, as shown in Figure 4, left panel. Error bars represent standard 
deviation. Adapted from Dreaden et al. [84]. 
 
7.5 Outlook and Conclusions 
In conclusion, we have studied distance-dependent SERS enhancement from electron-beam 
fabricated Au nanoprism pair arrays in the vicinity of their quadrupolar surface plasmon resonance. 
In agreement with the results of Halas and Nordlander, we find that at short interparticle distances, 
reduced symmetry and associated mixed-mode plasmon coupling results in increased dipolar 
character of the plasmon mode resonant with our Raman excitation. Theoretical modeling finds that 
this increased dipolar character does not result in increased field intensity, but instead, dipolar spatial 
redistribution of the field. As a result, we observed enhanced optical coupling and SERS with 
decreasing distance. These findings show that multimodal surface plasmon interactions can 
significantly contribute to SERS enhancement from coupled nanoparticle systems and that changes 
in both field intensity and mode should be thoughtfully considered when interpreting contributions 
to Raman scattering from such systems. 
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